CA2428739C - Complementing cell lines - Google Patents

Complementing cell lines Download PDF

Info

Publication number
CA2428739C
CA2428739C CA2428739A CA2428739A CA2428739C CA 2428739 C CA2428739 C CA 2428739C CA 2428739 A CA2428739 A CA 2428739A CA 2428739 A CA2428739 A CA 2428739A CA 2428739 C CA2428739 C CA 2428739C
Authority
CA
Canada
Prior art keywords
adenovirus
cells
cell line
sequences
subgroup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2428739A
Other languages
French (fr)
Other versions
CA2428739A1 (en
Inventor
Ronald Vogels
Menzo Jans Emco Havenga
Majid Mehtali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of CA2428739A1 publication Critical patent/CA2428739A1/en
Application granted granted Critical
Publication of CA2428739C publication Critical patent/CA2428739C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • C12N7/025Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, measles virus.

Description

COMPLEMENTING CELL LINES

Technical field: The invention relates to the field of biotechnology generally, and more specifically to adenoviral-based complementing cell lines.
Back rg ound: Typically, vector and packaging cells have to be adapted to one another so that they have all the necessary elements, but they do not have overlapping elements which lead to replication competent virus by recombination. Therefore, the sequences necessary for proper transcription of the packaging construct may be heterologous regulatory sequences derived from, for example, other human adenovirus (Ad) serotypes, non-human adenoviruses, other viruses like, but not limited to, SV40, hepatitis B virus (HBV), Rous Sarcoma Virus (RSV), cytomegalovirus (CMV), etc. or from higher eukaryotes such as mammals. In general, these sequences include a promoter, enhancer and poly-adenylation sequences.
PER.C6 (ECACC deposit number 96022940, deposited on February 29, 1996) is an example of a cell line devoid of sequence overlap between the packaging construct and the adenoviral vector (Fallaux et al., 1998). Recombinant viruses based on subgroup 'C adenoviruses such as Ad5 and Ad2 can be propagated efficiently on these packaging cells. Generation and propagation of adenoviruses from other serotypes, like subgroup B viruses, has proven to be more difficult on PER.C6 cells. However, as described in European patent application 00201738.2, recombinant viruses based on subgroup B virus Ad35 can be made by co-transfection of an expression construct containing the Ad35 early region-1 sequences (Ad35-El). Furthermore, Ad35-based viruses that are deleted for E1A sequences were shown to replicate efficiently on PER.C6 cells. Thus, the E1A proteins of Ads complement Ad35-E1A fimctions, whereas at least part of the E1B functions of Ad35 are necessary. This serotype specificity in E1B functions was recently also described for Adz recombinant viruses. In an attempt to generate recombinant adenoviruses derived from subgroup B virus Adz, Abrahamsen et at. (1997) were not able to generate El-deleted viruses on 293 cells without contamination of wild-type (wt) Adz. Viruses that were picked after plaque purification on 293-ORF6 cells (Brough et al., 1996) were shown to have incorporated Adz E1B sequences by non-homologous recombination. Thus, efficient propagation of Adz recombinant viruses proved possible only in the presence of Ad7-E1B expression and Ad5-B40RF6 expression. The E1B proteins are known to interact with cellular as well as viral proteins (Bridge et al., 1993; White, 1995).
Possibly, the complex formed between the E1B 55K protein and E4-ORF6 which is necessary to increase mRNA export of viral proteins and to inhibit export of most cellular mRNAs, is critical and in some way serotype specific.

Description of the Invention The present invention provides new packaging cell lines capable of complementing recombinant adenoviruses based on serotypes other than subgroup C viruses, such as serotypes from subgroup B, like adenovirus type 35.
In one aspect the invention provides packaging cell lines capable of complementing recombinant adenovirus based on a serotype of subgroup B, preferably of serotype 35.
With the terms "based on or derived from an adenovirus" is meant that it utilizes nucleic acid corresponding to nucleic acid found in said serotype. The utilized nucleic acid may be derived by PCR cloning or other methods known in the art.
In one aspect of the invention, the new packaging cells are derived from primary, diploid human cells such as, but not limited to, primary human retinoblasts, primary human embryonic kidney cells or primary human amniocytes. Transfection of primary cells or derivatives thereof with the adenovirus EIA gene alone can induce unlimited proliferation (immortalisation), but does not result in complete transformation. However, expression of EIA in most cases results in induction of programmed cell death (apoptosis), and occasionally immortalisation is obtained (Jochemsen et al., 1987). Co-expression of the E I B gene is required to prevent induction of apoptosis and for complete morphological transformation to occur (reviewed in White, 1995). Therefore, in one aspect of the invention, primary human cells or derivatives thereof are transformed by expression of adenovirus El proteins of a subgroup other than subgroup C, preferably subgroup B, more preferably adenovirus type 35. The combined activity of the E1A and E1B proteins establishes indefinite growth of the cells and enables complementation of recombinant adenoviruses.
The complete morphological transformation of primary cells by adenovirus E 1 genes is the result of the combined activities of the proteins encoded by the E I A and E I B
regions. The roles of the different E 1 proteins in lytic infection and in transformation have been studied extensively (reviewed in Zantema and van der Eb, 1995;
White, 1995, 1996). The adenovirus E1A proteins are essential for transformation of primary cells.
The E1A proteins exert this effect through direct interaction with a number of cellular proteins that are involved in regulation of transcription. These include the pRB family of proteins, p300/CBP and TATA binding protein. In addition to this E1A increases the level of p53 protein in the cells. In the absence of adenovirus E1B activity the rise in p53 levels leads to the induction of apoptosis. Both proteins encoded by the E1B
region counteract the induction of apoptosis although by different mechanisms. EIB-21K seems to counteract apoptosis in a manner similar to Bcl-2 via interaction with the effector proteins downstream in the apoptosis pathway (Han et al., 1996), whereas E1B-functions through direct interaction with p53. Importantly, the molecular mechanism by which the E1B-55K proteins of Ad2 and 5 (subgroup C) and Ad12 (subgroup A) function in the ability to neutralise p53 may differ. Whereas Ad5 E1B-55K binds p53 strongly and the complex localises to the cytoplasm, Ad12 E1B-55K binds p53 weakly and both proteins are localised in the nucleus (Zantema et al., 1985; Grand et al., 1999). Both proteins, however, inhibit the transactivation of other genes by p53 (Yew and Berk, 1992).
In rodent cells, the activity of E1A together with either E1B-21K or 55K is sufficient for full transformation although expression of both E1B proteins together is twice as efficient (Rao et al., 1992; ). In human cells however, the activity of the E1B-55K protein seems to be more important given the observation that E1B-55K is indispensible for the establishment of transformed cells (Gallimore, 1986).
Example 6 hereof describes the generation of pIG270. In this construct the Ad35-E1 genes are expressed from the hPGK promoter and transcription is terminated by the HBVpA. The hPGK promoter constitutes a Hincll-EcoRl fragment of the promoter sequence described by Singer-Sam et al. (1984). The HBVpA is located in a BamHI-Bg1II fragment of the Hepatitis B virus genome (Simonsen and Levinson, 1983;
see also Genbank HBV-AF090841). As mentioned before, the promoter and polyadenylation sequences of the E1 expression constructs described in this invention may be derived from other sources whithout departing from the invention. Also, other functional fragments of the hPGK and HBVpA sequences mentioned above may be used.
The functionality of pIG270 was shown by transformation of primary Baby Rat Kidney cells (BRK). Comparison with an equivalent Ad5-E1 expression construct learned that Ad35-E1 genes were less efficient in transforming these cells.
The same has been found for the El genes of Adl2 (Bernards et al., 1982).
It is unclear which E1 protein(s) determine(s) the difference in transformation efficiency of El sequences observed for adenoviruses from different subgroups.
In the case of Adl2, transfection studies with chimeric ElA/EIB genes suggested that the efficiency of transformation of BRK cells was determined by the E1A proteins (Bernards et al., 1982). The ElB-55K protein is shown infra to contain serotype-specific functions necessary for complementation of El-deleted adenoviruses. If these functions are related to the regulation of mRNA distribution or another late viral function, it is unlikely that these are involved in the transformation efficiency.
Analysis of functional domains in the Ad2 or Ad5 E1B-55K proteins using insertion mutants have revealed that functions related to viral replication, late protein synthesis and host protein shut-off are not confined to specific domains but are distributed along the protein (Yew et al., 1990). Using the same set of mutants, the domains important for interaction with p53 and E4-Orf6 were found to be more restricted. In addition to one common binding region (amino acids 262 to 326), p53 binding was affected by mutations at as 180 and E4-Orf6 binding was affected by mutations at as 143 (Yew and Berk, 1992; Rubenwolf et al., 1997).
Altogether these results indicate that it is difficult to separate the E1B-55K
functions related to transformation (p53 binding) and late protein synthesis (Orf6 binding).
The invention discloses new El constructs that combine the high efficiency of transformation of one serotype with the serotype-specific complementation function of another serotype. These new constructs are used to transform primary human embryonic retinoblast cells and human amniocytes.
In another aspect of the invention, the transforming E1 sequences are derived from different serotypes. As disclosed in European Patent application 00201738.2, Ad35 El sequences are capable of transforming Baby Rat Kidney (BRK) cells, albeit with a lower efficiency than that seen with Ad5 El sequences. This was also observed for El sequences from Adl2 (Bernards et al., 1982). Therefore, in this aspect of the invention, primary diploid human cells or derivatives thereof are transformed with chimeric El construct that consists of part of the El sequences of a serotype that enables efficient transformation of primary human cells or derivatives thereof and part of the E1 sequences of another serotype which El sequences provide the serotype-specific E1B
function(s) that enable(s) efficient propagation of E1-deleted viruses of that serotype.
In a preferred embodiment of this aspect of the invention, the E I A region is derived from a subgroup C
adenovirus, like, but not limited to, Ad5, and the E I B coding sequences are derived from an alternative adenovirus more particularly from an adenovirus of subgroup B, more particularly from adenovirus type 35. E1B-21K coding sequences may also be chimeric comprising both subgroup C and subgroup B coding sequences. Preferably, all or most of E1B-21K comprises subgroup C coding sequences. In a more preferred embodiment, the E1A coding sequences and the E1B-21K coding sequences are derived from a subgroup C adenovirus, like, but not limited to, Ad5. In one embodiment the cell further comprises EIB-55k coding sequences that are, preferably, as far as not overlapping with the 21K
coding sequences-derived from an adenovirus of subgroup B, more particular from adenovirus type 35. In an even more preferred embodiment, all El coding sequences are derived from a subgroup C adenovirus, like but not limited to Ad5, except for at least the part of the E1B-55K coding sequences that are necessary for serotype-specific complementation of an alternative adenovirus subgroup, more particular adenovirus subgroup B, more particular adenovirus type 35. The invention also provides a packaging 5 cell line wherein the primary, diploid human cells or derivatives thereof have been transformed with a chimeric adenovirus E 1 construct comprising part of a first adenovirus El coding sequence of a first adenovirus serotype that enables efficient transformation of primary human cells and derivatives thereof; and part of a second adenovirus El coding sequence of a second adenovirus serotype, wherein said second adenovirus E1 coding sequence provides the serotype-specific adenovirus E1B
function(s) that enable(s) efficient propagation of recombinant adenovirus E1-deleted viruses of said second adenovirus serotype. Preferably, said first adenovirus serotype is a subgroup C adenovirus and said second adenovirus serotype is a subgroup B
adenovirus, more particular adenovirus type 35. In one embodiment the packing cell line of the invention comprises bovine adenovirus E1B-55k. Such a bovine E1B-55k expressing cell line is particularly suited for obtaining high yields of a complemented bovine recombinant adenovirus.

The primary diploid human cells or derivatives thereof are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules. In the latter case, one DNA molecule carries at least part of the E1 sequences of the serotype enabling efficient transformation and the second DNA
molecule carries at least part of the sequences necessary for serotype-specific complementation. Provided is also a hybrid construct comprising E1-sequences of the serotype enabling efficient transformation and E1 sequences of another serotype necessary for serotype-specific complementation. The sequences providing serotype specific complementation may ofcourse also contain further activities contributing to transformation. Preferably, said sequences enabling efficient transformation comprise ElA. Preferably said sequences and said sequences necessary for serotype specific complementation preferably comprise E1B sequences. More preferably said sequences enabling efficient transforming comprise E1A and E1B-21K sequences and said sequences necessary for serotype specific complementation comprise E1B-55K
sequences. Provided also are cells transformed by such hybrid construct. Such cells can favorably be used for the propagation of recombinant El deleted adenovirus of said another serotype. Of course it is also possible to provide both functions of E
1 sequences on separate constructs. In all aspects, the sequences are operatively linked to regulatory sequences enabling transcription and translation of the encoded proteins.
Preferably a packaging cell of the invention further comprises a DNA encoding at least E4-orf6 of an adenovirus of subgroup B, preferably adenovirus serotype 35. Preferably, said E4-orf6 is derived from said another serotype. Preferably said cell comprises E113-55K
and E4-orf6 of the same serotype as the recombinant vector to be propagated/complemented or otherwise produced.
In another aspect of the invention, new packaging cells are described that are derived from PER.C6 (ECACC deposit number 96022940; Fallaux et at., 1998) and contain Ad35-E1 sequences integrated into their genome. These Ad35-El sequences are present in a functional expression cassette, but preferably do not contain sequences overlapping with sequences present in the recombinant viral vector. Preferably, the functional expression cassette consists of a heterologous promoter and poly-adenylation signal functionally linked to Ad35-E1 sequences. More specifically, the Ad35-E1 coding sequences are functionally linked to the human phosphoglycerate gene promoter (hPGK) and hepatitus B virus poly-adenylation signal (HBV-pA). Preferably, Ad35-E1 coding sequences comprise the coding regions of the E1A proteins and the E1B promoter sequences linked to E1B coding sequences up to and including the stop codon of the E1B
55K protein. More preferably, the Ad35-El sequences comprise nucleotide 468 to nucleotide 3400 of the Ad35 wt sequence. To be able to select for transfected cells, a dominant selection marker like, but not limited to, the neon gene has to be incorporated on the expression vector or the Ad35 expression vector is co-transfected with a separate expression vector mediating expression of the selection marker. In both cases, the selection marker becomes integrated in the cellular genome. Other Ad5-E1 transformed cell lines like 293 (Graham et al., 1977) and 911 (Fallaux et al., 1996) or established human cell lines like A549 cells may be used without departing from the present invention.
In another aspect of the invention, PER.C6-derived cells are described that express functional Ad35 E I B sequences. In one embodiment, the Ad35-EIB
coding sequences are driven by the EIB promoter and terminated by a heterologous poly-3o adenylation signal like, but not limited to, the HBVpA. In a preferred embodiment, the Ad35-E1B coding sequences are driven by a heterologous promoter like, but not limited to, the hPGK promoter or Elongation Factor-1 a (E F-1 a) promoter and terminated by a heterologous pA signal like, but not limited to, the HBVpA. These Ad35-E1B
sequences preferably comprise the coding regions of the E1B 21K and the E1B

proteins located between nucleotides 1611 and 3400 of the wild-type (wt) Ad35 sequence. More preferably, the Ad35-ElB sequences comprise nucleotides 1550 to of the wt Ad35 sequence. In an even more preferred embodiment, the E1B
sequences comprise the coding sequences of the E1B-55K gene located between nucleotides and 3400 of the wt Ad35 sequence. In an even more preferred embodiment a packaging cell line or a cell line of the invention lacks a functional coding sequence for ElB 21k.
Such cell lines in general produce significantly more recombinant adenovirus than ElB
21 K positive cell lines.

The invention further provides a method for complementing a recombinant adenovirus comprising providing a packaging cell line or a cell line according to the invention, with said recombinant adenovirus and culturing said cell to allow for complementation. In a preferred embodiment said method further comprises harvesting complemented recombinant adenovirus. Preferably said recombinant adenovirus is derived from adenovirus subgroup B. More preferably said recombinant adenovirus is derived from adenovirus serotype 35.
In another aspect the invention provides a recombinant adenovirus obtained by a method of the invention or with a packaging cell of the invention. Such adenovirus can be obtained essentially free from contaminating wild type adenovirus, or replication competent adenovirus. Such recombinant adenovirus preparations are very suited for administration of therapeutic sequences to somatic tissues in vivo in for instance a gene therapeutic setting. Preferred are recombinant adenoviruses comprising a deletion of nucleic acid encoding at least one E1-region protein. Preferably, such adenovirus further comprises a deletion of nucleic acid encoding at least one E3-region protein.
Preferably, such adenovirus further comprises a deletion of nucleic acid encoding at least one E4-region protein. Preferably, such adenovirus further comprises a deletion of nucleic acid encoding at least E4-Orf6 protein. For this reason the invention also provides the use of a recombinant adenovirus of the invention for the preparation of a medicament.

With the term E1B-55K protein as used herein, is meant the protein encoded by the E1B-region in an adenovirus serotype having a similar function in said serotype as provided by the E 1 B-5 5K protein Ads.
With the term E113-21K protein as used herein, is meant the protein enclosed by the E1B-region in an adenovirus serotype having a similar function in said serotype as provided by the E1B-19K protein of Ad5. The same terminology applies for the sequences encoding these proteins. When referring to Ad35-E1 sequences from a specified nucleotide to nucleotide 3400 is meant'up to and including nucleotide 3400'.
Cell lines subject of this invention are useful for, among other things, the production of recombinant adenoviruses designed for gene therapy and vaccination. The cell lines, being derived from cells of human origin, are also useful for the production of human recombinant therapeutic proteins like, but not limited to human growth factors, human antibodies. In addition the cell lines are useful for the production of human viruses other than adenovirus like, but not limited to, influenza virus, herpes simplex virus, rotavirus, measles virus.
A preferred derivative of primary, diploid human cells is the PER.C6 cell line (ECACC
deposit number 960022940).

It is within the skills of the artisan to provide for proteins having a similar function in kind as the adenovirus El protein referred to in this document. For instance a functional part may be provided and/or a derivative may be provided with a similar function in kind, not necessarily in amount.
Such parts and derivatives are considered to be part of the invention, in as far as similar transforming/complementing and/or serotype specificity function is provided in kind, not necessarily in amount.

Brief Description of the Figures FIG. 1: Bar graph showing the percentage of serum samples positive for neutralization for each human wt adenovirus tested (see, Examplel for description of the neutralization assay).
FIG. 2: Graph showing absence of correlation between the VP/CCID50 ratio and the percentage of neutralization.
FIG. 3: Bar graph presenting the percentage sera samples that show neutralizing activity to a selection of adenovirus serotypes. Sera were derived from healthy volunteers from Belgium and the UK.
FIG. 4: Bar graph presenting the percentage sera samples that show neutralizing activity to adenovirus serotypes 5, 11, 26, 34, 35, 48 and 49. Sera were derived from five different locations in Europe and the United States.
FIG. 5: Sequence of human adenovirus type 35.
FIG. 6: Map of pAdApt3 5IP 1.
FIG. 7: Schematic representation of the steps undertaken to construct pWE.Ad35.pIX-rITR.
FIG. 8: Map of pWE.Ad35.pIX-rITR.
FIG. 9: Map of pRSV.Ad3 5-El .
FIG. 10: Map of PGKneopA.
FIG. 11: Map of pRSVpNeo.
FIG. 12: Map of pRSVhbvNeo.
FIG. 13: Map ofpIG.E1A.E1B.
FIG. 14: Map of pIGl35.
FIG. 15: Map of pIG270.
FIG. 16: Map of pBr.Ad35.leftITR-pIX.
FIG. 17: Map of pBr.Ad35.1eftlTR-pIXiE1A
FIG. 18: Map of pBr.Ad35.O21K
FIG. 19: Map of pBr.Ad35.A55K1 FIG. 20: Map of pBrAd35OSM
FIG. 21: Schematic representation of Ad35-BlA/E1B deletion constructs.
FIG. 22: Map of pIG.35BL.
FIG. 23: Map of pRSVneo4.
FIG. 24: Map of pIG35Bneo.
FIG. 25: Map of pIG35.55K
FIG. 26: Map of pIG535 FIG. 27: Map of pIG635 FIG. 28: Map of pIG735 FIG 29: Map of pCC271 FIG 30: Map of pCC535s FIG 31: Map of pCR535E1B
FIG 32: Map of pCC2155s FIG 33: Map of pCC536s FIG 34: Map of pIG536 FIG 35: Map of pBr.Ad35.PRn FIG 36: Map of pBr.Ad35.PRni\E3 FIG 37: Map of pWE.Ad35.pIX-rITRL\EE3 FIG 38: Alignment of E113-21K (A) and E1B-55K (B) amino acid sequences in pCC536s with wtAd5 and wtAd35 sequences.

Detailed Description of The Invention The invention is further explained by the use of the following illustrative examples.

Example 1 A high throughput assay for the detection of neutralizing activity in human serum To enable screening of a large amount of human sera for the presence of neutralizing 10 antibodies against all adenovirus serotypes, an automated 96-wells assay was developed.
Human sera A panel of 100 individuals was selected. Volunteers (50% male, 50% female) were healthy individuals between ages 20 and 60 years old with no restriction for race.
All volunteers signed an informed consent form. People professionally involved in adenovirus research were excluded.
Approximately 60 ml blood was drawn in dry tubes. Within two hours after sampling, the blood was centrifuged at 2500 rpm for 10 minutes. Approximately 30 ml serum was transferred to polypropylene tubes and stored frozen at -20 C until further use.
Serum was thawed and heat-inactivated at 56 C for 10 minutes and then aliquoted to prevent repeated cycles of freeze/thawing. Part was used to make five steps of twofold dilutions in medium (DMEM, Gibco BRL) in a quantity enough to fill out approximately 70 96-well plates. Aliquots of undiluted and diluted sera were pipetted in deep well plates (96-well format) and using a programmed platemate dispensed in 100 1 aliquots into 96-well plates. This way the plates were loaded with eight different sera in duplo (100 gl/well) according to the scheme below:
Where S1/2 to S8/2 in columns 1 and 6 represent 1 X diluted sera and Sx/4, Sx/8, Sx/16 and Sx/32 the twofold serial dilutions. The last plates also contained four wells filled with 100 1 fetal calf serum as a negative control. Plates were kept at -20 C until further use.
Preparation of human adenovirus stocks Prototypes of all known human adenoviruses were inoculated on T25 flasks seeded with PER.C6 cells (Fallaux et al., 1998) and harvested upon full CPE.
After freeze/thawing 1-2 ml of the crude lysates was used to inoculate a T80 flask with PER.C6 and virus was harvested at full CPE. The timeframe between inoculation and occurrence of CPE as well as the amount of virus needed to re-infect a new culture, differed between serotypes. Adenovirus stocks were prepared by freeze/thawing and used to inoculate 3-4 T175 cm2 three-layer flasks with PER.C6 cells. Upon occurrence of CPE, cells were harvested by tapping the flask, pelleted and virus was isolated and purified by a two-step CsCl gradient as follows. Cell pellets were dissolved in 50 ml 10 mM NaPO4 buffer (pH
7.2) and frozen at -20 C. After thawing at 37 C, 5.6 ml sodium deoxycholate (5% w/v) was added. The solution was mixed gently and incubated for 5-15 minutes at 37 C to completely lyse the cells. After homogenizing the solution, 1875 gl 1M MgCl2 was added. After the addition of 375 pl DNAse (10 mg/ml) the solution was incubated for 30 minutes at 37 C. Cell debris was removed by centrifugation at 1880xg for 30 minutes at RT without brake. The supernatant was subsequently purified from proteins by extraction with FREON (3x). The cleared supernatant was loaded on a 1M Tris/HCl buffered cesium chloride block gradient (range: 1.2/1.4 g/ml) and centrifuged at 21000 rpm for 2.5 hours at 10 C. The virus band is isolated after which a second purification using a 1M
Tris/HCI buffered continues gradient of 1.33 g/ml of cesium chloride was performed. The virus was then centrifuged for 17 hours at 55000 rpm at 10 C. The virus band is isolated and sucrose (50 % w/v) is added to a final concentration of 1%. Excess cesium chloride is removed by dialysis (three times 1 hr at RT) in dialysis slides (Slide-a-lizer, cut off 10000 kDa, Pierce, USA) against 1.5 liter PBS supplemented with CaC12 (0.9 mM), MgCl2 (0.5mM) and an increasing concentration of sucrose (1, 2, 5%). After dialysis, the virus is removed from the slide-a-lizer after which it is aliquoted in portions of 25 and 100 l upon which the virus is stored at -85 C.
To determine the number of virus particles per milliliter, 50 l of the virus batch is run on a high-pressure liquid chromatograph (HPLC) as described by Shabram et al (1997). Viruses were eluted using a NaC1 gradient ranging from 0 to 600 mM. As depicted in table I, the NaCl concentration by which the viruses were eluted differed significantly among serotypes.
Most human adenoviruses replicated well on PER.C6 cells with a few exceptions.
Adenovirus type 8 and 40 were grown on 911-E4 cells (He et al., 1998).
Purified stocks contained between 5x1010 and 5x1012 virus particles/ml (VP/ml; see table I).

Titration of purified human adenovirus stocks Adenoviruses were titrated on PER.C6 cells to determine the amount of virus necessary to obtain full CPE in five days, the length of the neutralization assay. Hereto, l00 1 medium was dispensed into each well of 96-well plates. 25 l of adenovirus stocks pre-diluted 104, 105, 106 or 107 times were added to column 2 of a 96-well plate and mixed by pipetting up and down 10 times. Then 25 l was brought from column 2 to column 3 and again mixed. This was repeated until column 11 after which 25 l from column 11 was discarded. This way, serial dilutions in steps of 5 were obtained starting off from a pre-diluted stock. Then 3x104 PER.C6 cells (ECACC deposit number 96022940) were added in a 100 gl volume and the plates were incubated at 37 C, 5%
CO2 for five or six days. CPE was monitored microscopically. The method of Reed and Muensch was used to calculate the cell culture-inhibiting dose 50% (CCID50).
In parallel, identical plates were set up that were analyzed using the MTT
assay (Promega). In this assay, living cells are quantified by colorimetric staining. Hereto, 20 l MTT (7.5 mgr/ml in PBS) was added to the wells and incubated at 37 C, 5% CO2 for two hours. The supernatant was removed and 100 gl of a 20:1 isopropanol/triton-solution was added to the wells. The plates were put on a 96-well shaker for 3-5 minutes to solubilize the precipitated staining. Absorbance was measured at 540 nm and at 690 nm (background). By this assay, wells with proceeding CPE or full CPE can be distinguished.

Neutralization assay 96-well plates with diluted human serum samples were thawed at 37 C, 5% CO2.
Adenovirus stocks diluted to 200 CCID50 per 50 1 were prepared and 50 l aliquots were added to columns 1-11 of the plates with serum. Plates were incubated for 1 hour at 37 C, 5% CO2. Then 50 gl PER.C6 cells at 6x105/ml were dispensed in all wells and incubated for 1 day at 37 C, 5% CO2. Supernatant was removed using fresh pipette tips for each row and 200 1 fresh medium was added to all wells to avoid toxic effects of the serum. Plates were incubated for another 4 days at 37 C, 5% CO2. In addition, parallel control plates were set up in duplo with diluted positive control sera generated in rabbits and specific for each serotype to be tested in rows A and B and with negative control serum (FCS) in rows C and D. Also, in each of the rows E-H a titration was performed as described above with steps of five times dilutions starting with 200 CCID50 of each virus to be tested. On day 5, one of the control plates was analyzed microscopically and with the MTT assay. The experimental titer was calculated from the control titration plate observed microscopically. If CPE was found to be complete, i.e. the first dilution in the control titration experiment analyzed by MTT shows clear cell death, all assay plates were processed. If not, the assay was allowed to proceed for one or more days until full CPE was apparent after which all plates were processed. In most cases, the assay was terminated at day 5. For Adl, 5, 33, 39, 42 and 43 the assay was left for six days and for Ad2 for eight days.
A serum sample is regarded as "non-neutralizing" when, at the highest serum concentration, a maximum protection of 40% is seen compared to controls without serum.
The results of the analysis of 44 prototype adenoviruses against serum from healthy volunteers are shown in FIG. 1. As expected, the percentage of serum samples that contained neutralizing antibodies to Ad2 and Ad5 was very high. This was also true for most of the lower numbered adenoviruses. Surprisingly, none of the serum samples contained neutralizing antibodies to Ad35. Also, the number of individuals with neutralizing antibody titers to the serotypes 26, 34 and 48 was very low.
Therefore, recombinant El-deleted adenoviruses based on Ad35 or one of the other above mentioned serotypes have an important advantage compared to recombinant vectors based on Ad5 with respect to clearance of the viruses by neutralizing antibodies.
Also, Ad5-based vectors that have (parts of) the capsid proteins involved in immunogenic response of the host replaced by the corresponding (parts of) the capsid proteins of Ad35 or one of the other serotypes will be less, or even not, neutralized by the vast majority of human sera.
As can be seen in Table I, the VP/CCID50 ratio calculated from the virus particles per ml and the CCID50 obtained for each virus in the experiments was highly variable, and ranged from 0.4 to 5 log. This is probably caused by different infection efficiencies of PER.C6 cells and by differences in replication efficiency of the viruses.
Furthermore, differences in batch qualities may play a role. A high VP/CCID50 ratio means that more viruses were put in the wells to obtain CPE in 5 days. As a consequence, the outcome of the neutralization study might be biased since more (inactive) virus particles could shield the antibodies. To check whether this phenomenon had taken place, the VP/CCID50 ratio was plotted against the percentage of serum samples found positive in the assay (FIG. 2).
The graph clearly shows that there is no negative correlation between the amount of viruses in the assay and neutralization in serum.
Example 2 The prevalence of neutralizing activity (NA) to Ad35 is low in human sera from different geographic locations In Example 1 the analysis of neutralizing activity ("NA") in human sera from one location in Belgium was described. Strikingly, of a panel of 44 adenovirus serotypes tested, one serotype, Ad3 5, was not neutralized in any of the 100 sera assayed. In addition, a few serotypes, Ad26, Ad34 and Ad48 were found to be neutralized in 8%, or less, of the sera tested. This analysis was further extended to other serotypes of adenovirus not previously tested and, using a selection of serotypes from the first screen, was also extended to sera from different geographic locations.
Hereto, adenoviruses were propagated, purified and tested for neutralization in the CPE-inhibition assay as described in Example 1. Using the sera from the same batch as in Example 1, adenovirus serotypes 7B, 11, 14, 18 and 44/1876 were tested for neutralization. These viruses were found to be neutralized in, respectively, 59, 13, 30, 98 and 54 % of the sera. Thus, of this series, Adl l is neutralized with a relatively low frequency.
Since it is known that the frequency of isolation of adenovirus serotypes from human tissue as well as the prevalence of NA to adenovirus serotypes may differ on different geographic locations, we further tested a selection of the adenovirus serotypes against sera from different places. Human sera were obtained from two additional places in Europe (Bristol, UK and Leiden, NL) and from two places in the United States (Stanford, CA and Great Neck, NY). Adenoviruses that were found to be neutralized in 20% or less of the sera in the first screen, as well as Ad2, Ad5, Ad27, Ad30, Ad38, Ad43, were tested for neutralization in sera from the UK. The results of these experiments are 5 presented in FIG. 3. Adenovirus serotypes 2 and 5 were again neutralized in a high percentage of human sera. Furthermore, some of the serotypes that were neutralized in a low percentage of sera in the first screen are neutralized in a higher percentage of sera from the UK, for example, Ad26 (7% vs. 30%), Ad28 (13% vs. 50%), Ad34 (5% vs.
27%) and Ad48 (8% vs. 32%). Neutralizing activity against Adl 1 and Ad49 that were 1 o found in a relatively low percentage of sera in the first screen, are found in an even lower percentage of sera in this second screen (13% vs. 5% and 20% vs. 11%
respectively).
Serotype Ad35 that was not neutralized in any of the sera in the first screen, was now found to be neutralized in a low percentage (8%) of sera from the UK. The prevalence of NA in human sera from the UK is the lowest to serotypes Ad11 and Ad35.
15 For further analysis, sera obtained from two locations in the US (Stanford, CA
and Great Neck, NY) and from The Netherlands (Leiden). FIG. 4 presents an overview of data-obtained with these sera and the previous data. Not all viruses were tested in all sera, except for Ad5, Adl I and Ad35. The overall conclusion from this comprehensive screen of human sera is that the prevalence of neutralizing activity to Ad35 is the lowest of all serotypes throughout the western countries: on average 7% of the human sera contain neutralizing activity (5 different locations). Another B-group adenovirus, Adl 1 is also neutralized in a low percentage of human sera (average 11 % in sera from 5 different locations). Adenovirus type 5 is neutralized in 56% of the human sera obtained from 5 different locations. Although not tested in all sera, D-group serotype 49 is also neutralized with relatively low frequency in samples from Europe and from one location of the US (average 14%).
In the herein described neutralization experiments, a serum is judged non-neutralizing when, in the well with the highest serum concentration, the maximum protection of CPE is 40% compared to the controls without serum. The protection is calculated as follows:

I% protection = OD corresponding well - OD virus control x 100 %
OD non-infected control - OD virus control As described in Example 1, the serum is plated in five different dilutions ranging from 4x to 64x diluted. Therefore, it is possible to distinguish between low titers (i.e., neutralization only in the highest serum concentrations) and high titers of NA
(i.e., also neutralization in wells with the lowest serum concentration). Of the human sera used in our screen that were found to contain neutralizing activity to Ad5, 70% turned out to have high titers whereas of the sera that contained NA to Ad35, only 15% had high titers. Of the sera that were positive for NA to Adl I only 8% had high titers. For Ad49, this was 5%. Therefore, not only is the frequency of NA to Ad35, Adl I and Ad49 much lower as compared to Ad5, but of the sera that do contain NA to these viruses, the vast majority has low titers. Adenoviral vectors based on Adl 1, Ad35 or Ad49 have therefore a clear advantage over Ad5 based vectors when used as gene therapy vehicles or vaccination io vectors in vivo or in any application where infection efficiency is hampered by neutralizing activity.
In the following examples, the construction of a vector system for the generation of safe, RCA-free Ad35-based vectors is described.

Example 3 Sequence of the human adenovirus type 35 Ad35 viruses were propagated on PER.C6 cells and DNA was isolated as follows:
To 100 l of virus stock (Ad35: 3.26x1012 VP/m1),10 1 lOX DNAse buffer (130 MM
Tris-HC1 pH7.5; 1,2 M CaC12; 50mM MgC12) was added. After addition of 10 gl 10mgr/ml DNAse I (Roche Diagnostics), the mixture was incubated for 1 hr. at 37'C.
Following addition of 2.5 10.5M EDTA, 3.21l 20% SDS and l.5 1 ProteinaseK*(Roche Diagnostics; 20mgr/ml), samples were incubated at 50 C for 1 hr. Next, the viral DNA
was isolated using the GENECLEAN spin kit (Biol01 Inc.) according to the manufacturer's instructions. DNA was eluted from the spin column with 25 l sterile MilliQ water. The total sequence was generated by Qiagen Sequence Services (Qiagen GmbH, Germany). Total viral DNA was sheared by sonification and the ends of the DNA
were made blunt by T4 DNA polymerase. Sheared blunt fragments were size fractionated on agarose gels and gel slices corresponding to DNA fragments of 1.8 to 2.2kb were obtained. DNA was purified from the gel slices by the QlAquick gel extraction protocol and subcloned into a shotgun library of pUC19 plasmid cloning vectors. An array of clones in 96-well plates covering the target DNA 8 (+/- 2) times was used to generate the total sequence. Sequencing was performed on Perkin-Elmer 9700 thermocyclers using Big Dye Terminator chemistry and AmpliTaq FS DNA polymerase followed by purification of sequencing reactions using QIAGEN DyeE& 96 technology.
Sequencing reaction products were then subjected to automated separation and detection of fragments on ABI 377 XL 96 lane sequencers. Initial sequence results were used to generate a * trade-mark contiguous sequence and gaps were filled in by primer walking reads on the target DNA
or by direct sequencing of PCR products. The ends of the virus turned out to be absent in the shotgun library, most probably due to cloning difficulties resulting from the amino acids of pTP that remain bound to the ITR sequences after proteinase K
digestion of the viral DNA. Additional sequence runs on viral DNA solved most of the sequence in those regions, however it was difficult to obtain a clear sequence of the most terminal nucleotides. At the 5' and the sequence portion obtained was 5'-CCAATAATATACCT-3' (SEQ. I.D. NO. 1 ) while at the 3' end, the obtained sequence portion was 5'-AGGTATATTATTGATGATGGG-3' (SEQ. I.D. NO. 2 ). Most human adenoviruses have a terminal sequence 5'-CATCATCAATAATATACC-3' (SEQ. I.D. NO. 3 ). In addition, a clone representing the 3' end of the Ad35 DNA obtained after cloning the terminal 7 kb Ad35 EcoRI fragment into pBr322 also turned out to have the typical CATCATCAATAAT... sequence. Therefore, Ad35 may have the typical end sequence and the differences obtained in sequencing directly on the viral DNA are due to artefacts correlated with run-off sequence runs and the presence of residual amino acids of pTP.
The total sequence of Ad35 with corrected terminal sequences is given in FIG.
5.
Based sequence homology with Ad5 (Genbank # M72360) and Adz (partial sequence Genbank # X03000) and on the location of open reading frames, the organization of the virus is identical to the general organization of most human adenoviruses, especially the subgroup B viruses. The total length of the genome is 34,794 basepairs.
Example 4 Construction of a plasmid-based vector system to generate recombinant Ad35-based viruses.
A fimctional plasmid-based vector system to generate recombinant adenoviral vectors comprises the following components:
1. An adapter plasmid comprising a left ITR and packaging sequences derived from Ad35 and at least one restriction site for insertion of an heterologous expression cassette and lacking E1 sequences. Furthermore, the adapter plasmid contains Ad35 sequences 3' from the E1B coding region including the pIX promoter and coding sequences enough to mediate homologous recombination of the adapter plasmid with a second nucleic acid molecule.
2. A second nucleic acid molecule, comprising sequences homologous to the adapter plasmid, and Ad35 sequences necessary for the replication and packaging of the recombinant virus, that is early, intermediate and late genes that are not present in the packaging cell.
3. A packaging cell providing at least functional El proteins capable of complementing the E1 function of Ad35.
Other methods for generating recombinant adenoviruses on complementing packaging cells are known in the art, and may be applied to Ad35 viruses without departing from the invention. As an example, the construction of a plasmid-based system, as outlined above, is described in detail below.

ll Construction of Ad35 adapter plasmids.
The adapter plasmid pAdApt (described in International Patent Application W099/55132) was first modified to obtain adapter plasmids that contain extended polylinkers and that have convenient unique restriction sites flanking the left ITR and the adenovirus sequence at the 3' end to enable liberation of the adenovirus insert from plasmid vector sequences. Construction of these plasmids is described below in detail:
Adapter plasmid pAdApt was digested with Sall and treated with Shrimp Alkaline Phosphatase to reduce religation. A linker, composed of the following two phosphorylated and annealed oligos: ExSalPacF 5'- TCG ATG GCA AAC AGC TAT
TAT GGG TAT TAT GOO TTC GAA TTA ATT AA- 3' (SEQ. I.D. NO. 4) and ExSalPacR 5' - TCG ATT AAT TAA TTC GAA CCC ATA ATA CCC ATA ATA OCT
GTT TGC CA- 3' (SEQ. I.D. NO.. 5) was directly ligated into the digested construct, thereby replacing the Sall restriction site by Pi-PspI, Swal and Pacl. This construct was designated pADAPT+ExSalPac linker. Furthermore, part of the left ITR of pAdApt was amplified by PCR using the following primers: PCLIPMSF: 5'- CCC CAA TTG GTC
GAC CAT CAT CAA TAA TAT ACC TTA TTT TGG -3' (SEQ. I.D. NO. 6) and pCLIPBSRGI: 5'- GCG AAA ATT GTC ACT TCC TOT G - 3' (SEQ. I.D. NO.7 ). The amplified fragment was digested with MunI and BsrGI and cloned into pAdS/Clip (described in International Patent Application WO99/55132), which was partially digested with EcoRI and after purification digested with BsrG1 thereby re-inserting the left ITR and packaging signal. After restriction enzyme analysis, the construct was digested with Scal and SgrAI and an 800 bp fragment was isolated from gel and ligated into Scal/SgrAI digested pADAPT+ExSalPac linker. The resulting construct, designated plPspSalAdapt, was digested with SaII, dephosphorylated, and ligated to the phosphorylated ExSalPacF/ExSalPacR double-stranded linker previously mentioned. A
clone in which the PacI site was closest to the 1TR was identified by restriction analysis and sequences were confirmed by sequence analysis. This novel pAdApt construct, termed plPspAdapt thus harbours two ExSalPac linkers containing recognition sequences for Pacl, PI-PspI and BstBI, which surround the adenoviral part of the adenoviral adapter construct, and which can be used to linearize the plasmid DNA prior to cotransfection with adenoviral helper fragments.
In order to further increase transgene cloning permutations, a number of polylinker variants were constructed based on plPspAdapt. For this purpose, pIPspAdapt was first digested with EcoRI and dephosphorylated. A linker composed of the following two phosphorylated and annealed oligos: Ecolinker+: 5' -AAT TCG GCG CGC CGT
CGA CGA TAT CGA TAG CGG CCG C -3' (SEQ. I.D. NO. 8 ) and Ecolinker-: 5' -AAT TGC GGC CGC TAT CGA TAT CGT CGA CGG CGC GCC G -3' (SEQ. I.D.
NO. 9 ) was ligated into this construct, thereby creating restriction sites for Ascl, Sall, EcoRV, Cia! and Not!. Both orientations of this linker were obtained, and sequences were confirmed by restriction analysis and sequence analysis. The plasmid containing the polylinker in the order 5' Hindu, Kpnl, Age!, EcoRI, AscI, Sall, EcoRV, CM, Not!, NheI, Hpal, BamHI and Xbal was termed plPspAdaptl while the plasmid containing the polylinker in the order HindU!, KpnI, Agel, NotI, CIaI, EcoRV, SaII, Ascl, EcoRI, Nhel, HpaI, BamHI and Xbal was termed plPspAdapt2.
To facilitate the cloning of other sense or antisense constructs, a linker composed of the following two oligonucleotides was designed, to reverse the polylinker of p1PspAdapt: HindXba+ 5'-AGC TCT AGA GGA TCC OTT AAC GCT AGC GAA TTC
ACC GGT ACC AAG CTT A-3' (SEQ. I.D. NO. 10); HindXba- 5'-CTA GTA AGC
TTG GTA CCG GTG AAT TCG CTA GCG TTA ACG GAT CCT CTA G-3' (SEQ. I.D.
NO.11). This linker was ligated into HindIU/XbaI digested plPspAdapt and the correct construct was isolated. Confirmation was done by restriction enzyme analysis and sequencing. This new construct, plPspAdaptA, was digested with EcoRI and the previously mentioned Ecolinker was ligated into this construct. Both orientations of this linker were obtained, resulting in plPspAdapt3, which contains the polylinker in the order Mal, Ban-II, Hpal, NheI, EcoRI, AscI, SaII, EcoRV, Clal, Not!, Age!, KpnI and HindIII. All sequences were confirmed by restriction enzyme analysis and sequencing.
Adapter plasmids based on Ad35 were then constructed as follows:
The left ITR and packaging sequence corresponding to Ad35 wt sequences nucleotides 1 to 464 (FIG. 5) were amplified by PCR on wtAd35 DNA using the following primers:
1Primer 35F1:
25'-CGG AAT TCT TAA TTA ATC GAC ATC ATC AAT AAT ATA CCT TAT AG-3' (SEQ. I.D. NO.12 ) Primer 35R2:
5'-GGT GGT CCT AGG CTG ACA CCT ACG TAA AAA CAG-3' (SEQ. I.D. NO. 13) Amplification introduces a Pact site at the 5' end and an AvrII site at the 3' end of the sequence.
For the amplification, Platinum Pfx DNA polymerase enzyme (LTI) was used according to manufacturer's instructions, but with primers at 0.6 M and with DMSO
5 added to a final concentration of 3%. Amplification program was as follows:
2 min. at 94 C, (30 sec. 94 C, 30 sec. at 56 C, 1 min. at 68 C) for 30 cycles, followed by 10 min. at 68 C.
The PCR product was purified using a PCR purification kit (LTI) according to the manufacturer's instructions, and digested with Pacl and AvrU. The digested fragment was.
10 then purified from gel using the GENECLEAN kit (Bio 101, Inc.). The Ad5-based adapter plasmid plPspAdApt-3 was digested with AvrII and then partially with Pacl and the 5762 bp fragment was isolated in an LMP agarose gel slice and ligated with the abovementioned PCR fragment digested with the same enzymes and transformed into electrocompetent DH10B cells (LTI). The resulting clone is designated plPspAdApt3-15 Ad351ITR
In parallel, a second piece of Ad35 DNA was amplified using the following primers:
335F3: 5'- TGG TGG AGA TCT GGT GAG TAT TGG GAA AAC-3' (SEQ. I.D. NO.
14) 20 435R4:5'- CGG AAT TCT TAA TTA AGG GAA ATG CAA ATC TGT GAG G-3' (SEQ. I.D. NO. 15) The sequence of this fragment corresponds to nucleotides 3401 to 4669 of wtAd35 (FIG. 5) and contains 1.3kb of sequences starting directly 3' from the E1B 55k coding sequence. Amplification and purification were done as previously described herein for the fragment containing the left ITR and packaging sequence. The PCR
fragment was then digested with Pact and subcloned into pNEB 193 vector (New England Biolabs) digested with Sinai and Pacl. The integrity of the sequence of the resulting clone was checked by sequence analysis. pNEB/Ad35pF3R4 was then digested with BgM
and Pact and the AM insert was isolated from gel using the QIAExJ kit (Qiagen).
plPspAdApt3-Ad351TTR was digested with BgIII and then partially with PacI. The bp fragment (containing vector sequences, the Ad35 ITR and packaging sequences as well as the CMV promoter, multiple cloning region and polyA signal) was also isolated using the QIAExII kit (Qiagen). Both fragments were ligated and transformed into competent DHIOB cells (LTI). The resulting clone, pAdApt35IP3, has the expression cassette from plPspAdApt3 but contains the AM left ITR and packaging sequences and a second fragment corresponding to nucleotides 3401 to 4669 from Ad35. A
second version of the Ad35 adapter plasmid having the multiple cloning site in the opposite orientation was made as follows:
plPspAdaptl was digested with NdeI and Bg11I and the 0.7 kbp band containing part of the CMV promoter, the MCS and SV40 polyA was isolated and inserted in the corresponding sites of pAdApt35IP3 generating pAdApt35IP1 (Fig. 6).
pAdApt35.LacZ and pAdApt35.Luc adapter plasmids were then generated by inserting the transgenes from pcDNA.LacZ (digested with KpnI and BamHI) and pAdApt.Luc (digested with Hindu and BamHl) into the corresponding sites in pAdApt35IPl. The generation of pcDNA.LacZ and pAdApt.Luc is described in i o international Patent Application W099155132.

2) Construction of cosmid pWE.Ad35.pIX-r1TR
FIG. 7 presents the various steps undertaken to construct the cosmid clone containing Ad35 sequences from bp 3401 to 34794 (end of the right ITR) that are described in detail below.
A first PCR fragment (pIX-Ndel) was generated using the following primer set:
535F5: 5'-CGG AAT TCG CGG CCG CGG TGA GTA TTG GGA AAA C -3' (SEQ.
I.D. NO.16 ) 635R6: 5'-CGC CAG ATC GTC TAC AGA ACA G-3' (SEQ. I.D. NO. 17) DNA polymerase Pwo (Roche) was used according to manufacturer's instructions, however, with an end concentration of 0.6 gM of both primers and using 50 ngr wt Ad35 DNA as template. Amplification was done as follows: 2 min. at 94 C, 30 cycles of 30 sec. at 94 C, 30 sec. at 65 C and 1 min. 45 sec. at 72 C, followed by 8 at 68 T. To enable cloning in the TA cloning vector PCR2.1, a last incubation with I unit superTaq polymerase (HT Biotechnology LTD) for 10 min. at 72 C was performed.
The 3370 bp amplified fragment contains Ad35 sequences from bp 3401 to 6772 with a Notl site added to the 5' end. Fragments were purified using the PCR
purification kit (LTI).
A second PCR fragment (NdeI-rITR) was generated using the following primers:
735F7: 5'-GAA TGC TGG CTT CAG TTG TAA TC -3' (SEQ. LD. NO.18 ) 835R8: 5'- CGG AAT TCG CGG CCG CAT TTA AAT CAT CAT CAA TAA TAT
ACC-3' (SEQ. I.D. NO. 19) Amplification was done with pfx DNA polymerase (LTI) according to manufacturer's instructions but with 0.6 M of both primers and 3% DMSO using ngr. of wtAd35 DNA as template. The program was as follows: 3 min. at 94 C
and 5 cycles of 30 sec. at 94 C, 45 sec. at 40 C, 2 min.45 sec. at 68 C followed by 25 cycles of 30 sec, at 94 C, 30 sec. at 60 C, 2 min.45 sec. at 68 C. To enable cloning in the TA-cloning vector PCR2. 1, a last incubation with 1 unit superTaq polymerase for 10 min. at 72 C was performed. The 1.6 kb amplified fragment ranging from nucleotides 33178 to the end of the right ITR of Ad35, was purified using the PCR purification kit ( LTI).
Both purified PCR fragments were ligated into the PCR2.1 vector of the TA-cloning kit (Invitrogen) and transformed into STBL-2 competent cells (LTI).
Clones containing the expected insert were sequenced to confirm correct amplification. Next, both fragments were excised from the vector by digestion with Notl and NdeI
and purified from gel using the GENECLEAN kit (BIO 101, Inc.). Cosmid vector pWEl5 (Clontech) was digested with Notl, dephosphorylated and also purified from gel. These three fragments were ligated and transformed into STBL2 competent cells (LTI).
One of the correct clones that contained both PCR fragments was then digested with NdeI, and the linear fragment was purified from gel using the GENECLEAN kit. Ad35 wt DNA
was digested with Ndel and the 26.6 kb fragment was purified from LMP gel using agarase enzyme (Roche) according to the manufacturer's instructions. These fragments were ligated together and packaged using %l phage packaging extracts (Stratagene) according to the manufacturer's protocol. After infection into STBL-2 cells, colonies were grown on plates and analysed for presence of the complete insert. One clone with the large fragment inserted in the correct orientation and having the correct restriction patterns after independent digestions with three enzymes (Ncol, PvuII and Scal) was selected. This clone is designated pWE.Ad35.pIX-rITR. It contains the Ad35 sequences from bp 3401 to the end and is flanked by Notl sites (FIG. 8).

3) Generation of Ad35 based recombinant viruses on PER.C6.
Wild type Ad35 virus can be grown on PER.C6 packaging cells to very high titers. However, whether the Ad5-El region that is present in PER.C6 is able to complement E1-deleted Ad3 5 recombinant viruses is unknown. To test this, PER.
C6 cells were cotransfected with the above described adapter plasmid pAdApt35.LacZ and the large backbone fragment pWE.Ad35.pIX-rITR. First, pAdApt35.LacZ was digested with PacI and pWE.Ad35.pIX-rITR was digested with NotI. Without further purification, 4 gr of each construct was mixed with DMEM (LTI) and transfected into PER.C6 cells, seeded at a density of 5x106 cells in a T25 flask the day before, using Lipofectamin (LTI) according to the manufacturer's instructions. As a positive control, 6ggr of PacI digested pWE.Ad35.pIX-rITR DNA was cotransfected with a 6.7 kb Nhel fragment isolated from Ad35 wt DNA containing the left end of the viral genome including the E1 region. The next day, medium (DMEM with 10% FBS and 1 0mM MgCl2) was refreshed and cells were further incubated. At day 2 following the transfection, cells were trypsinized and transferred to T80 flasks. The positive control flask showed CPE at five days following transfection, showing that the pWE.Ad35.pIX-rITR construct is functional at least in the presence of Ad35-E1 proteins. The transfection with the Ad3 5 LacZ adapter plasmid and pWE.Ad35.pIX-rITR did not give rise to CPE. These cells were harvested in the medium at day 10 and freeze/thawed once to release virus from the cells. 4 ml of the harvested material was added to a T80 flask with PER.C6 cells (at 80% confluency) and incubated for another five days. This harvest/re-infection was repeated for two times but there was no evidence for virus associated CPE.
From this experiment, it seems that the Ad5-El proteins are not, or not well enough, capable of complementing Ad35 recombinant viruses, however, it may be that the sequence overlap of the adapter plasmid and the pWE.Ad35.pIX-rITR backbone plasmid is not large enough to efficiently recombine and give rise to a recombinant virus genome. The positive control transfection was done with a 6.7kb left end fragment and therefore the sequence overlap was about 3.5kb. The adapter plasmid and the pWE.Ad35.pIX-rITR fragment have a sequence overlap of 1.3kb. To check whether the sequence overlap of 1.3 kb is too small for efficient homologous recombination, a cotransfection was done with Pacl digested pWE.Ad35.pIX-rITR and a PCR
fragment of Ad35 wt DNA generated with the above mentioned 35F1 and 35R4 using the same 'procedures as previously described herein. The PCR fragment thus contains left end sequences up to bp 4669 and, therefore, has the same overlap sequences with pWE.Ad35.pIX-rITR as the adapter plasmid pAdApt35.LacZ, but has Ad35 E1 sequences. Following PCR column purification, the DNA was digested with Sall to remove possible intact template sequences. A transfection with the digested PCR product alone served as a negative control. Four days after the transfection, CPE
occurred in the cells transfected with the PCR product and the Ad35 pIX-rITR fragment, and not in the negative control. This result shows that a 1.3kb overlapping sequence is sufficient to generate viruses in the presence of Ad35 El proteins. From these experiments, we conclude that the presence of at least one of the Ad35.E1 proteins is necessary to generate recombinant Ad35 based vectors from plasmid DNA on Ad5 complementing cell lines.
Example 5 1) Construction of Ad35.E1 expression plasmids Since Ad5-E1 proteins in PERC6 are incapable of complementing Ad35 recombinant viruses efficiently, Ad35 E1 proteins have to be expressed in Ad5 complementing cells (e.g., PER.C6). Alternatively, a new packaging cell line expressing Ad35 El proteins has to be made, starting from either diploid primary human cells or established cell lines not expressing adenovirus E1 proteins. To address the first possibility, the Ad35 E 1 region was cloned in expression plasmids as described below.
First, the Ad35 El region from bp 468 to bp 3400 was amplified from wtAd35 DNA using the following primer set:
135F1I- {'-GGG GTA CCG AAT TCT CGC TAG GOT ATT TAT ACC-3' (SEQ. I.D.
NO.20 ) 235F10: 5'-GCT CTA GAC CTG CAG OTT AGT CAG TTT CTT CTC CAC TG-3' (SEQ. I.D. NO.21) This PCR introduces a KpnI and EcoRI site at the 5' end and an SbfI and Xbal site at the 3' end.
Amplification on 5 ngr. template DNA was done with Pwo DNA polymerase (Roche) using the manufacturer's instructions, however, with both primers at a final 5 concentration of 0.6 M. The program was as follows: 2 min. at 94 C, 5 cycles of 30 sec.
at 94 C, 30 sec. at 56 C and 2 min. at 72 C, followed by 25 cycles of 30 sec. at 94 C, 30 sec. at 60 C and 2 min. at 72 C, followed by 10 min. at 72 T. PCR product was purified by a PCR purification kit (LTI) and digested with KpnI and XbaI. The digested PCR
fragment was then ligated to the expression vector pRSVhbvNeo (see below) also 10 digested with KpnI and XbaI. Ligations were transformed into competent STBL-2 cells (LTI) according to manufacturer's instructions and colonies were analysed for the correct insertion of Ad35El sequences into the polylinker in between the RSV promoter and HBV polyA.
The resulting clone was designated pRSV.Ad35-El (FIG. 9). The Ad35 sequences 15 in pRSV.Ad35-El were checked by sequence analysis.
pRSVhbvNeo was generated as follows: pRc-RSV (Invitrogen) was digested with PvuU, dephosphorylated with TSAP enzyme (LTI), and the 3kb vector fragment was isolated in low melting point agarose (LMP). Plasmid pPGKneopA (FIG. 10;
described in International Patent Application W096/35798) was digested with SspI completely to 20 linearize the plasmid and facilitate partial digestion with Pvul. Following the partial digestion with PvuII, the resulting fragments were separated on a LMP agarose gel and the 2245 bp Pvuf fragment, containing the PGK promoter, neomycin-resistance gene and HBVpolyA, was isolated. Both isolated fragments were ligated to give the expression vector pRSV-pNeo that now has the original SV40prom neo-SV40polyA expression 25 cassette replaced by a PGKprom-neo-HBVpolyA cassette (FIG. 11). This plasmid was further modified to replace the BGHpA with the HBVpA as follows: pRSVpNeo was linearised with Scal and further digested with XbaI. The 1145 bp fragment, containing part of the Amp gene and the RSV promoter sequences and polylinker sequence, was isolated from gel using the GeneClean kit (Bio Inc. 101). Next, pRSVpNeo was linearised with Scal and further digested with EcoRl partially and the 3704 bp fragment containing the PGKneo cassette and the vector sequences were isolated from gel as above. A third fragment, containing the HBV polyA sequence flanked by Xbal and EcoRI at the 5' and 3' end respectively, was then generated by PCR
amplification on pRSVpNeo using the following primer set:
3HBV-F: 5'- GGC TCT AGA GAT CCT TCG CGG GAC GTC -3' (SEQ. I.D. NO.22) and 4HBV-R: 5'- GGC GAA TTC ACT GCC TTC CAC CAA GC -3' (SEQ. I.D. NO. 23).
Amplification was done with Elongase enzyme (LTI) according to the manufacturer's instructions with the following conditions: 30 seconds at 94 C, then 5 cycles of 45 seconds at 94 C, 1 minute at 42 C and 1 minute 68 C, followed by 30 cycles of 45 seconds at 94 C, 1 minute at 65 C and 1 minute at 68 C, followed by 10 minutes at 68 T. The 625 bp PCR fragment was then purified using the Qiaquick PCR
purification kit, digested with EcoRI and XbaJ and purified from gel using the GENECLEAN kit. The three isolated fragments were ligated and transformed into DH5a competent cells (LTI) to give the construct pRSVhbvNeo (FIG. 12). In this construct, the transcription regulatory regions of the RSV expression cassette and the neomycin selection marker are modified to reduce overlap with adenoviral vectors that often contain CMV and SV40 transcription regulatory sequences.

2) Generation of Ad35 recombinant viruses on MR. C6 cells cotransfected with an Ad35-El expression consct PER.C6 cells were seeded at a density of 5 x 106 cells in a T25 flask and, the next day, transferted with a DNA mixture containing:
1 g pAdApt35.LacZ digested with Pacl 5 gpRSV.Ad35B1 undigested 2 jig pWE.Ad35.pIX-rITR digested with NotI
Transfection was done using Lipofectamine according to the manufacturer's instructions. Five hours after addition of the transfection mixture to the cells, medium was removed and replaced by fresh medium. After two days, cells were transferred to T80 flasks and further cultured. One week post-transfection, 1 ml of the medium was added to A549 cells and, the following day, cells were stained for LacZ
expression. Blue cells were clearly visible after two hours of staining indicating that recombinant LacZ
expressing viruses were produced. The cells were further cultured, but no clear appearance of CPE was noted. However, after 12 days, clumps of cells appeared in the monolayer and 18 days following transfection, cells were detached. Cells and medium were then harvested, freeze-thawed once, and 1 ml of the crude lysate was used to infect PER.C6 cells in a 6-well plate. Two days after infection, cells were stained for LacZ
activity. After two hours, 15% of the cells were stained blue. To test for the presence of wt and / or replicating competent viruses, A549 cells were infected with these viruses and further cultured. No signs of CPE were found indicating the absence of replication competent viruses. These experiments show that recombinant AdApt35.LacZ
viruses were made on PER.C6 cells cotransfected with an Ad35-El expression construct.

* trade-mark Ad35 recombinant viruses escape neutralization in human serum containing neutralizing activity to Ad5 viruses.
The AdApt35.LacZ viruses were then used to investigate infection in the presence of serum that contains neutralizing activity to Ad5 viruses. Purified Ad5-based LacZ
virus served as a positive control for NA. Hereto, PER.C6 cells were seeded in a 24-wells plate at a density of 2x105 cells/well. The next day, a human serum sample with high neutralizing activity to Ad5 was diluted in culture medium in five steps of five times dilutions. 0.5 ml of diluted serum was then mixed with 4x 106 virus particles AdApt5.LacZ virus in 0.5 nil medium and after 30 minutes of incubation at 37 C, 0.5 ml of the mixture was added to PER.C6 cells in duplicate. For the AdApt35.LacZ
viruses, 0.5 ml of the diluted serum samples were mixed with 0.5 ml crude lysate containing AdApt35.LacZ virus and after incubation 0.5 ml of this mixture was added to PER.C6 cells in duplo. Virus samples incubated in medium without serum were used as positive controls for infection. After two hours of infection at 37 C, medium was added to reach a final volume of 1 ml and cells were further incubated. Two days after infection, cells were stained for LacZ activity. The results are shown in Table II. From these results, it is clear that whereas AdApt5.LacZ viruses are efficiently neutralized, AdApt35.LacZ
viruses remain infectious irrespective of the presence of human serum. This proves that recombinant Ad35-based viruses escape neutralization in human sera that contain NA to Ad5-based viruses.

Example 6 Generation of cell lines capable of complementing El-deleted Ad35 viruses Generation of pIG135 and pIG270 Construct pIG.E I A.E 1 B (FIG. 13) contains E1 region sequences ofAdS
corresponding to nucleotides 459 to 3510 of the wt Ad5 sequence (Genbank accession number M72360) operatively linked to the human phosphoglycerate kinase promoter ("PGK") and the Hepatitis B Virus polyA sequences. The generation of this construct is described in International Patent Application No. W097/00326. The El sequences of Ad5 were replaced by corresponding sequences of Ad35 as follows. pRSV.Ad35-E1 (described in Example 5) was digested with EcoRl and Sse83871 and the 3 kb fragment corresponding to the Ad35 El sequences was isolated from gel. Construct pIG.E1A.E1B
was digested with Sse8387I completely and partially with EcoRI. The 4.2 kb fragment corresponding to vector sequences without the Ad5 El region but retaining the PGK
promoter were separated from other fragments on LMP agarose gel and the correct band was excised from gel. Both obtained fragments were ligated resulting in pIG.Ad35-El.
This vector was further modified to remove the LacZ sequences present in the pUC 119 vector backbone. Hereto, the vector was digested with BsaAI and BstXI
and the large fragment was isolated from gel. A double stranded oligo was prepared by annealing the following two oligos:
IBB1: 5'-GTG CCT AGG CCA CGG GG-3' (SEQ. I.D. NO. 24) and 2BB2: 5'-GTG GCC TAG GCA C-3' (SEQ. I.D. NO, 25).
Ligation of the oligo and the vector fragment resulted in construct pIG 135 (FIG.
14). Correct insertion of the oligo restores the BsaA1 and BstXI sites and introduces a unique AvrII site. Next, we introduced a unique site at the 3' end of the Ad35-El expression cassette in pIG135. Hereto, the construct was digested with SapI
and the 3' protruding ends were made blunt by treatment with T4 DNA polymerase. The thus treated linear plasmid was further digested with BsrGI and the large vector-containing fragment was isolated from gel. To restore the 3' end of the HBVpoIyA sequence and to introduce a unique site, a PCR fragment was generated using the following primers:
3270F: 5'- CAC CTC TGC CTA ATC ATC TC -3' (SEQ. I.D. NO.26) and 4270R: 5'- GCT CTA GAA ATT CCA CTG CCT TCC ACC -3' (SEQ. I.D. NO 27).
The PCR was performed on pIG.Ad35.E1 DNA using Pwo polymerase (Roche) according to the manufacturer's instructions. The obtained PCR product was digested with BsrGI and dephosphorylated using Tsap enzyme (LTI), the latter to prevent insert dimerization on the BsrGI site. The PCR fragment and the vector fragment were ligated to yield construct pIG270 (FIG. 15).

Ad35 El sequences are capable of transforming rat primary cells New born WAG/RU rats were sacrificed at 1 week of gestation and kidneys were isolated. After careful removal of the capsule, kidneys were disintegrated into a single cell suspension by multiple rounds of incubation in trypsin/EDTA (LTI) at 37 C and collection of floating cells in cold PBS containing 1% FBS. When most of the kidney was trypsinized all cells were re-suspended in DMEM supplemented with 10% FBS and filtered through a sterile cheesecloth. Baby Rat Kidney (BRIO cells obtained from one kidney were plated in 5 dishes (Greiner, 6 cm). When a confluency of 70-80%
was reached, the cells were transfected with 1 or 5 ggr DNA/dish using the CaPO4 precipitation kit (LTI) according to the manufacturer's instructions. The following constructs were used in separate transfections: pIG.E1A.E1B (expressing the Ad5-El region), pRSV.Ad35-El, pIG.Ad35-E1 and pIG270 (expressing the Ad35-E1 region).
Cells were incubated at 37 C, 5% CO2 until foci of transformed cells appeared. Table III
shows the number of foci that resulted from several transfection experiments using circular or linear DNA. As expected, the Ad5-E1 region efficiently transformed BRK
cells. Foci also appeared in the Ad35-El transfeced cell layer although with lower efficiency. The Ad35 transformed foci appeared at a later time point: -2 weeks post transfection compared with 7-10 days for Ad5-El. These experiments clearly show that the E1 genes of the B group virus Ad35 are capable of transforming primary rodent cells.
This proves the functionality of the Ad35-E1 expression constructs and confirms earlier findings of the transforming capacity of the B-group viruses Ad3 and Adz (Dijkema, 1979). To test whether the cells in the foci were really transformed a few foci were picked and expanded. From the 7 picked foci at least 5 turned out to grow as established cell lines.

Generation of new packaging cells derived from primary human amniocytes Amniotic fluid obtained after amniocentesis was centrifuged and cells were re-suspended in AmnioMax medium (LTD and cultured in tissue culture flasks at 37 C and 10 % CO2. When cells were growing nicely (approximately one cell division/24 brs.), the medium was replaced with a 1:1 mixture of AmnioMax oompleteniedium and DMEM
low glucose medium (LTI) supplemented with Glutamax I (end concentration 4mM, LTI) and glucose (end concentration 4.5 gr/L, LTD and 10% FBS (LTD. For transfection 5x105 cells were plated in 10 cm tissue culture dishes. The day after, cells were transfected with 20 gr of circular pIG270/dish using the CaPO4 transfection kit (LTI) according to manufacturer's instructions and cells were incubated overnight with the DNA precipitate. The following day, cells were washed 4 times with PBS to remove the precipitate and further incubated for over three weeks until foci of transformed cells appeared. Once a week the medium was replaced by fresh medium. Other transfection agents like, but not limited to, LipofectAmine (LTD or PEI (Polyethylenimine, high molecular weight, water-free, Aldrich) were used. Of these three agents PEI
reached the best transfection efficiency on primary human amniocytes: -1% blue cells 48 hrs.
Following transfection of pAdApt35. LacZ.
Foci are isolated as follows. The medium is removed and replaced by PBS after which foci are isolated by gently scraping the cells using a 50-200 1 Gilson pipette with a disposable filter tip. Cells contained in -10 m1 PBS were brought in a 96 well plate containing 15 l trypsin/BDTA (LTI) and a single cell suspension was obtained by pipetting up and down and a short incubation at room temperature. After addition of 200 l of the above described 1:1 mixture of AmnioMax complete medium and DMEM with supplements and 10% FBS, cells were further incubated. Clones that continued to grow were expanded and analysed their ability to complement growth of El-deleted adenoviral * trade-mark vectors of different sub-groups, specifically ones derived from B-group viruses specifically from Ad35 or Adl 1.

Generation of new packaging cell lines from HER cells 5 HER cells are isolated and cultured in DMEM medium supplemented with 10%
FBS (LTI). The day before transfection, 5x105 cells are plated in 6 cm dishes and cultured overnight at 37 C and 10% CO2. Transfection is done using the CaPO4 precipitation kit (LTI) according to the manufacturer's instructions. Each dish is transfected with 8-10 mgr p1 G2 7 0 DNA, either as a circular plasmid or as a purified 1o fragment. To obtain the purified fragment, pIG270 was digested with AvrII
and Xbal and the 4 kb fragment corresponding to the Ad35 El expression cassette was isolated from gel by agarase treatment (Roche). The following day, the precipitate is washed away carefully by four washes with sterile PBS. Then fresh medium is added and transfected cells are further cultured until foci of transformed cells appear. When large enough (> 100 15 cells) foci are picked and brought into 96-wells as described above. Clones of transformed HER cells that continue to grow, are expanded and tested for their ability to complement growth of E1-deleted adenoviral vectors of different sub-groups specifically ones derived from B-group viruses specifically from Ad35 or Ad 11.

20 New packaging cell lines derived from PER. C6 As described in Example 5, it is possible to generate and grow Ad35 El-deleted viruses on PER.C6 cells with cotransfection of an Ad35-E1 expression construct, e.g.
pRSV.Ad35.El. However, large-scale production of recombinant adenoviruses using this method is cumbersome because, for each amplification step, a transfection of the Ad35-25 El construct is needed. In addition, this method increases the risk of non-homologous recombination between the plasmid and the virus genome with high chances of generation of recombinant viruses that incorporate El sequences resulting in replication competent viruses. To avoid this, the expression of Ad35-E 1 proteins in PER.C6 has to be mediated by integrated copies of the expression plasmid in the genome.
Since PER.C6 30 cells are already transformed and express Ad5-El proteins, addition of extra Ad35-E1 expression may be toxic for the cells, however, it is not impossible to stably transfect transformed cells with El proteins since Ad5-E1 expressing A549 cells have been generated.
In an attempt to generate recombinant adenoviruses derived from subgroup B
virus Adz, Abrahamsen et al. (1997) were not able to generate El-deleted viruses on 293 cells without contamination of wt Adz. Viruses that were picked after plaque purification on 293-ORF6 cells (Brough eta!., 1996) were shown to have incorporated Adz E1B
sequences by non-homologous recombination. Thus, efficient propagation of Adz recombinant viruses proved possible only in the presence of Ad7-E1B expression and Ad5-E4-ORF6 expression. The BIB proteins are known to interact with cellular as well as viral proteins (Bridge et al., 1993; White, 1995). Possibly, the complex formed between the BIB 55K protein and E4-ORF6 which is necessary to increase mRNA
export of viral proteins and to inhibit export of most cellular mRNAs, is critical and in some way serotype specific. The above experiments suggest that the E1A proteins of Ad5 are capable of complementing an Adz-EIA deletion and that Ad7-EIB expression in adenovirus packaging cells on itself is not enough to generate a stable complementing cell line. To test whether one or both of the Ad35-E1B proteins is/are the limiting factor in efficient Ad35 vector propagation on PER.C6 cells, we have generated an Ad35 adapter plasmid that does contain the BIB promoter and E1B sequences but lacks the promoter and the coding region for EIA. Hereto, the left end of wtAd35 DNA was amplified using the primers 35F1 and 35R4 (both described in Example 4) with Pwo DNA polymerase (Roche) according to the manufacturer's instructions. The 4.6 kb PCR
product was purified using the PCR purification kit (LTI) and digested with SnaBI and Apal enzymes. The resulting 4.2 kb fragment was then purified from gel using the QIABxII kilt (Qiagen). Next, pAdApt351P1 (Example 4) was digested with SnaBI
and Apal and the 2.6 kb vector-containing fragment was isolated from gel using the GeneClean it (BIO 101, Inc). Both isolated fragments were ligated to give pBr/Ad35.leftTTR pIX (FIG. 16). Correct amplification during PCR was verified by a functionality test as follows: The DNA was digested with BstBI to liberate the Ad35 insert from vector sequences and 4 g of this DNA was co-transfected with 4 g of NotI digested pWE/Ad35.plX-rITR (Example 4) into PER.C6 cells. The transfected cells were passaged to T80 flasks at day 2 and again two days later CPE had formed showing that the new pBr/Ad35.leftITR pIX construct contains functional El sequences.
The pBr/Ad35.1eftITR-plX construct was then further modified as follows. The DNA
was digested with SnaBI and HindM and the 5' Hindu overhang was filled in using Klenow enzyme. Religation of the digested DNA and transformation into competent cells (LTI) gave construct pBr/Ad351eft1TRp1XADE 1A (FIG. 17). This latter construct contains the left end 4.6 kb of Ad35 except for E1A sequences between bp 450 and 1341 (numbering according to wtAd35, FIG. 5) and thus lacks the E1A promoter and most of the coding sequences. pBr/Ad35.lefIfR-pIXADE1A was then digested with BstBI and 2 g of this construct.was co-transfectedwith 6 pmgr of NotI digested * trade-mark pWE /Ad35. pIX-rITR (Example 4) into PER.C6 cells. One week following transfection full CPE had formed in the transfected flasks.
This experiment shows that the Ad35-ElA proteins are functionally complemented by Ad5-E1A expression in PER.C6 cells and that at least one of the Ad35-E1B proteins cannot be complemented by Ad5-E1 expression in PER.C6. It further shows that it is possible to make a complementing cell line for Ad35 El-deleted viruses by expressing Ad35-E1B proteins in PER.C6. Stable expression of Ad35-E1B
sequences from integrated copies in the genome of PER. C6 cells maybe driven by the E1B
promoter and terminated by a heterologous poly-adenylation signal like, but not limited to, the HBVpA. The heterologous pA signal is necessary to avoid overlap between the E I B insert and the recombinant vector, since the natural E I B termination is located in the pIX transcription unit that has to be present on the adenoviral vector.
Alternatively, the E1B sequences may be driven by a heterologous promoter like, but not limited to the human PGK promoter or by an inducible promoter like, but not limited to the 7xtetO
promoter (Gossen and Bujard, 1992). Also in these cases the transcription termination is mediated by a heterologous pA sequence, e.g. the HBV pA. The Ad35-E1B
sequences at least comprise one of the coding regions of the E1B 21K and the E1B 55K
proteins located between nucleotides 1611 and 3400 of the wt Ad35 sequence. The insert may also include (part of the) Ad35-E1B sequences between nucleotides 1550 and 1611 of the wt Ad35 sequence.

Example 7 Ad35-based viruses deleted for EIA and E1 B-21 K genes efficiently propagate on Ad5 complementing cell lines.
The generation of Ad35-based viruses that are deleted for E1A and retain the full E1B region is described in Example 6 of this application. Such viruses can be generated and propagated on the Ad5 complementing cell line PER.C6. The E1B region comprises partially overlapping coding sequences for the two major proteins 21K and 55K
(Bos et al., 1981). Whereas during productive wt adenoviral infection both 21K and 55K
are involved in counteracting the apoptose-inducing effects of E1A proteins, the ElB 55K
protein has been suggested to have additional functions during the late phase of virus infection. These include the accumulation of viral mRNAs, the control of late viral gene expression and the shutoff of most host mRNAs at the level of mRNA transport (Babiss et al., 1984, 1985; Pilder et al., 1986). A complex formed between E1B-55K and the ORF6 protein encoded by the adenovirus early region 4 (Leppard and Shenk, 1989;
Bridge and Ketner, 1990) exerts at least part of these functions.
To analyze which of the E1B proteins is required for propagation of Ad35-E1A
deleted recombinant viruses on PERC6 packaging cells, the EiB region in construct pBr.Ad35.leftJTR pIXAE1A (see Example 6 and FIG. 17) was further deleted. A
first construct, pBr.Ad35A21K, retains the full E1B-55K sequence and is deleted for and E1B-21K. Hereto, pBr.A.d35.leftITR-pIXAE1A was digested with Ncol and BspEl and the 5 KB vector fragment was isolated from agarose gel using the geneclean kit (BIO
101, Inc.) according to the manufacturer's instructions. Then a PCR fragment was generated with pBr.Ad35.leftITR-pIXAE lA as template DNA using the following primers:
135D21: 5'- TTA GAT CCA TGG ATC CCG CAG ACT C-3' (SEQ. I.D. NO.28) and 235B3: 5'- CCT CAG CCC CAT TTC CAG-3' (SEQ. I.D. NO.29).
3Amplification was done using Pwo DNA polymerase (Roche) according to manufacturer's recommendations with the addition of DMSO (final concentration 3%) in the reaction mixture. The PCR program was as follows: 94 C for 2, then 30 cycles of 94 C for 30", 58 C for 30" and 72 C for 45" and a final step at 68 C for 8' to ensure blunt ends.
This PCR amplifies Ad35-E1B sequences from nucl. 1908 to 2528 (sequence Ad35, FIG. 5) and introduces an Ncol site at the start codon of the E1B-55K
coding sequence (bold in primer 35D21). The 620 bp PCR fragment was purified using the PCR
purification kit (Qiagen) and then digested with NcoI and BspEI, purified from agarose gel as above and ligated to the above described NcoI/BspEl digested vector fragment to give pBr.Ad35A21K (FIG. 18).
Since the coding regions of the 21 K and 55K proteins overlap, it is only possible delete part of the 55K coding sequences while retaining 21K. Hereto, pBr.Ad35.leftTTR-pIXAE1A was digested with Bg1II and the vector fragment was religated to give pBr.Ad35A5SKi (FIG. 19). This deletion removes E1B coding sequences from nucl.
2261 to 3330 (Ad35 sequence in FIG. 5). In this construct the N-terminal 115 amino acids are retained and become fused to 21 additional amino acids out of the proper reading frame before a stop codon is encountered. The 21K coding region is intact in construct pBr.Ad35A55Ki .
A third construct that has a deletion of E1A., 21K and most of the 55K
sequences was generated as follows. pBr.Ad35.leftITR plX (FIG. 16) was digested with SnaBI and MfeI (isoschizomer of Muni) and the 5' overhang resulting from the Mfel digestion was filled in using Klenow enzyme. The 4.4 kb vector fragment was isolated from gel using the geneclean kit (Bio 101, Inc.) according to the manufacturer's instructions and religated to give construct pBr.Ad35ASM (FIG. 20). In this construct, the Ad35 sequences between nucl. 453 and 2804 are deleted thus 596 nucl. of the 3' end of Elb-55K are retained. A further deletion of 55K sequences was made in construct pBr.Ad350E 1A. AEIB by digestion of pBr.Ad35.leftITR-pIX with SnaBI and BglII, Klenow treatment to fill in the BglII cohesive ends, and religation. FIG. 21 shows a schematic representation of the above mentioned constructs.
To test whether Ad35-based viruses can be generated with these constructs, each of the constructs was cotransfected with NotI digested pWE.Ad35pIX-rITR (see Example 4) onto PER.C6 cells. Hereto, the respective fragments were PCR amplified using primers 35F1 and 35R4 (see, Example 4). This PCR amplification was done since some of the constructs were difficult to isolate in large enough quantities. In this way, equal quality of the different adapter fragments was ensured. For the amplification Pwo DNA
polymerase (Roche) was used according to the manufacturer's instructions but with DMSO (3% final concentration)added to the PCR mixture. Of each template - 50 ng DNA was used. The conditions for the PCR were as follows: 94 C for 2', then 5 cycles of 94 C for 30", 48 C for 45" and 72 C for 4' followed by 25 cycles of 94 C for 30", 60 C for 30" and 72 C for 4' and a final step at 68 C for 8'.
4PCR fragments were generated from pBr.Ad35leftITR-pIX, pBr.Ad35.leftITR-pIXLE1A, pBr.Ad35A21K, pBr.Ad35 55K1, pBr.Ad35ASM and p B r . Ad 3 5 DE 1 AAE 1 B . All fragments were using the PCR purification kit (Qiagen) according to manufacturer's instructions and final concentrations were estimated on EtBr stained agarose gel using the Eagle Eye II Still Video system and EagleSight software (Stratagene) with the SmartLadder molecular weight marker (Eurogentec) as reference.
PER.C6 cells were seeded at a density of 2.5x106 cells in a T25 culturing flask in DMEM
containing 10% fetal calf serum (FCS) and 10mM MgSO4 and cultured in a humidified stove at 37 C, 10% CO2. The next day, 3 mg of each of the PCR fragments was cotransfected with 5 pgr NotI digested pWE.Ad35pIX-rITR using LipofectAmine (GIBCO, Life Technologies Inc.) according to the manufacturer's instructions. Two days after the transfection, all cells were passed to a T80 flask and further cultured. Cultures were then monitored for the appearance of CPE. In line with the outcome of previous experiments described in Examples 4 and 6, pBr.Ad35.leftITR-pIX and pBr.Ad35.leftITR-pIXAE1A showed almost full CPE within one week following transfection. Of the fragments with different E I B deletions only pBr.Ad35A21K showed CPE at the same time as the above two fragments.
Constructs pBr.Ad35A55K1, pBr.Ad35ASM and pBr.Ad35AE1AAE1B did not give CPE at all, also not after harvesting by freeze-thawing and re-infection of the crude lysate onto fresh PER.C6 cells.

From these experiments, it can be concluded that Ad35-EIB-55K, and not EIB-21K, is necessary for generation and propagation of Ad35-based viruses on Ad5 complementing cell lines. Therefore, Ad35-based viruses having a deletion of the ElA
and EiB 21K genes and having the EIB-55K gene or a functional fragment thereof, can 5 be grown on Ad5 complementing cell lines. Alternatively, Ad35-based viruses can be grown on PER.C6 cells that stably express the full E1B region or the E1B-55K
gene or a functional fragment thereof. The Ad35 E1B-55K gene or functional parts thereof maybe expressed from a heterologous promoter, like, but not limited to, the human PGK
promoter, the human cytomegalovirus immediate early promoter (CMV), Rous sarcoma 10 virus promoter, etc. and terminated by a heterologous poly adenylation sequence (pA), like but not limited to the hepatitis B virus poly adenylation sequence (HBVpA), the Simian Virus 40 poly adenylation sequence (SV40pA), etc. As non-limiting examples PER.C6 cells that express the Ad35-EIB region driven by the E1B promoter and HBVpA, PER. C6 cells that express the Ad35-E1B region driven by the human PGK
15 promoter and HBVpA and PER.C6 cells that express a functional fragment of Ad35 E113-55K driven by the human PGK promoter and HBVpA are described below.

Generation ofpIG35BL and pIG35BS
We describe the generation of two expression constructs, pIG.35BS and 20 pIG.35BL, that both carry the Ad35-E1B genes and a neomycin selection marker. The two constructs differ in the length of the fragment containing the E I B
promoter. In 35BL
the promoter fragment is longer and includes the 3' end of the E I A region (103 nucl.
coding sequence and pA). The E1B region is terminated by the HBVpo1yA, the neo' gene is driven by a hPGK promoter/HBVpA cassette.
25 pIG.35BL was made as follows. Construct pRSV.Ad35El (described in Example 5, FIG.
9) was digested with Nru1 and HindIIl and the protruding ends were filled in by Klenow treatment. The 7 kb vector fragment was separated from the smaller fragment on gel and isolated using the geneclean kit (BIO 101, Inc.). After religation of the DNA
and transformation into competent STBL2 cells (Gibco, LTI) correct clones were isolated.
30 pIG.35BL (FIG. 22) contains 273 nucl. upstream of the start site of the EIB-21K coding region.
pIG.35BS was made in the same way as pIG.35BL except that pRSV.Ad35E1 was digested with Nrul and Hpal (both enzymes leave blunt ends), resulting in a shorter fragment upstream of the coding region of E1B-21K: 97 nucleotides.
35 To generate Ad35-E1B expressing cells, PER.C6 cells were seeded in 10 cm dishes at 1x106 cells/dish. Two days later cells were transfected with Seal linearised constructs.
Four dishes were transfected with 1 and four with 2 gg DNA (total of 16 dishes;
Lipofectamine (Gibco, LTI), no carrier DNA used) according to the manufacturer's instructions. The next day, transfected cells received G418-containing medium (0.75 mg/ml). Control transfections using LacZ expression constructs (2 g) were stained after 48 hrs and showed a transfection efficiency of -25%. Four days following addition of selection medium untransfected cells started to die and again three days later clones were becoming visible. A week later, the first clones were picked.
Transfection with 1 .g resulted in less and also initially smaller clones (total -20 clones/dish against >50 clones/dish for the transfection with 2 g DNA). The positive control transfection using 2 gg pcDNA3 (Invitrogen) resulted in - 50 clones.
In total, 120 clones were picked and 107 were succesfully established (55 from pIG35BS
and 52 from pIG35BL).

Generation of pIG35Bneo pIG35Bneo is an Ad35-EIB expression plasmid from which the E I B genes are expressed from a heterologous promoter (hPGK) and that also contains a neomycin resistance expression cassette. To avoid instability of the plasmid due to recombination events on homologous sequences, the RSV promoter drives the neo` gene. To achieve this, construct pRSVhbv.Neo (described in Example 5, FIG. 12) was digested with ScaI
and BamHI and protruding ends were filled in using Klenow enzyme. The 1070 bp fragment containing part of the Ampicilin gene and the RSV promoter was isolated from gel using the geneclean kit (BIO 101, Inc.). Next, pRSVhbvNeo was digested with ScaI
and EcoRl, blunted with Klenow and the 3.2 kb fragment containing the neo gene, HBVpA, vector and part of the Ampicilin gene was isolated as above. The two fragments were then ligated to give pRSVneo4 (FIG. 23). Construct pIG270 (FIG. 15, described in Example 6) was then digested with EcoRI and Ncol and sticky ends were blunted with Klenow enzyme. The vector-containing fragment was isolated from gel as described above and religated to give pIG270delE1A. This construct was digested with AvrII and Xbal and protruding ends were filled in using Klenow enzyme. The 2.9 kb fragment containing the hPGK promoter and Ad35.E1B sequences was isolated from gel as above.
Next, pRSVneo4 was digested with BglII, blunted with Klenow enzyme, dephosphorylated and isolated from gel. The blunted AvrIUXbaI Ad35.E1B
fragment was then ligated with the above prepared pRSVneo4 vector fragment and resulting clones were analysed. One clone that contained both expression cassettes in the same orientation was choosen and named pIG35Bneo (FIG. 24). Detailed analysis of this clone revealed that an extra BgIII site was present probably due to an incomplete Klenow reaction (Bglll site at nucl 2949 in FIG. 24).

Generation ofpIG35.55K
Construct pIG35.55K is similar to pIG35Bneo, however, it lacks the coding region ofAd35.E1B-21K. Hereto, both the E1A and E1B-21K sequences are first deleted from pIG270 as follows:
Construct pIG270 is digested with EcoRI, treated with Klenow enzyme and purified using a PCR purification kit (Qiagen) according to the manufacturer's instructions. The recovered DNA is then digested with Agel and the -5 kb vector fragment was isolated from gel as above. Next, Ad35 EIB-55K sequences are amplified by PCR on pIG270 template DNA using the following primers:
535D21: 5'- TTA GAT CCA TGG ATC CCG CAG ACT C-3' and 635B3: 5'- CCT CAG CCC CAT TTC CAG-3'.
The conditions used for the amplification are as previously described. The PCR
fragment is purified using the PCR purification kit (Qiagen) and digested with Neal.
Following Klenow treatment to fill in the protruding ends, the DNA is further digested with Agel and again column purified. The thus treated PCR fragment is then cloned into the above prepared EcoRUAgeI digested vector fragment to give pIG270.AE 1AA21K. The last steps to obtain pIG35.55K (FIG. 25) are equivalent to the last steps described above for the generation of pIG35Bneo starting with pIG270.AE1AA21K instead of pIG270.AE 1A .
pIG35.55K is then linearized with Scal and used to transfect PER.C6 cells as described above. Clones that are resistent to 0418 selection are picked and analysed for their ability to complement the propagation of El-deleted Ad35 viruses.

Example 8 New packaging cell lines for the generation and propagation of EI-deleted Ad35-based vectors derived from primary human cells.
The complete morphological transformation of primary cells by adenovirus E l genes is the result of the combined activities of the proteins encoded by the E1A and E1B
regions. The roles of the different El proteins in lytic infection and in transformation have been studied extensively (reviewed in Zantema and van der Eb, 1995;
White, 1995, 1996). The adenovirus E1A proteins are essential for transformation of primary cells.
The E1A proteins exert this effect through direct interaction with a number of cellular proteins that are involved in regulation of transcription. These include the pRB family of proteins, p300/CBP and TATA binding protein. In addition to this E1A increases the level of p53 protein in the cells. In the absence of adenovirus E1B activity the rise in p53 levels leads to the induction of apoptosis. Both proteins encoded by the E1B
region counteract the induction of apoptosis although by different mechanisms. E1B-21K seems to counteract apoptosis in a manner similar to Bcl-2 via interaction with the effector proteins downstream in the apoptosis pathway (Han et al., 1996), whereas E1B-functions through direct interaction with p53. Importantly, the molecular mechanism by which the E1B-55K proteins of Ad2 and 5 (subgroup C) and Ad12 (subgroup A) function in the ability to neutralise p53 may differ. Whereas Ad5 EIB-55K binds p53 strongly and the complex localises to the cytoplasm, Adl2 E1B-55K binds p53 weakly and both proteins are localised in the nucleus (Zantema et al., 1985; Grand et al., 1999). Both proteins, however, inhibit the transactivation of other genes by p53 (Yew and Berk, 1992).
In rodent cells, the activity of E 1 A together with either E 1 B-21 K or 55K
is sufficient for full transformation although expression of both EIB proteins together is twice as efficient (Rao et al., 1992; ). In human cells however, the activity of the E1B-55K protein seems to be more important given the observation that E1B-55K is indispensible for the establishment of transformed cells (Gallimore, 1986).
Example 6 hereof describes the generation of pIG270. In this construct the Ad35-El genes are expressed from the hPGK promoter and transcription is terminated by the HBVpA. The hPGK promoter constitutes a Hincll-EcoRI fragment of the promoter sequence described by Singer-Sam et al. (1984). The HBVpA is located in a BamHI-BglII fragment of the Hepatitis B virus genome (Simonsen and Levinson, 1983;
see also Genbank HBV-AF090841). As mentioned before, the promoter and polyadenylation sequences of the E1 expression constructs described in this invention may be derived from other sources whithout departing from the invention. Also, other functional fragments of the hPGK and HBVpA sequences mentioned above may be used.
The functionality of pIG270 was shown by transformation of primary Baby Rat Kidney cells (BRK). Comparison with an equivalent Ad5-E1 expression construct learned that Ad35-E1 genes were less efficient in transforming these cells.
The same has been found for the El genes of Ad12 (Bernards et al., 1982).
It is unclear which El protein(s) determine(s) the difference in transformation efficiency of El sequences observed for adenoviruses from different subgroups.
In the case of Ad12, transfection studies with chimeric E1A/E1B genes suggested that the efficiency of transformation of BRK cells was determined by the E1A proteins (Bemards et al., 1982). The EIB-55K protein is shown infra to contain serotype-specific functions necessary for complementation of El-deleted adenoviruses. If these functions are related to the regulation of mRNA distribution or another late viral function, it is unlikely that these are involved in the transformation efficiency.
Analysis of functional domains in the Ad2 or Ads E1B-55K proteins using insertion mutants have revealed that functions related to viral replication, late protein synthesis and host protein shut-off are not confined to specific domains but are distributed along the protein (Yew et al., 1990). Using the same set of mutants, the domains important for interaction with p53 and E4-Orf6 were found to be more restricted. In addition to one common binding region (amino acids 262 to 326), p53 binding was affected by mutations at as 180 and E4-Orf6 binding was affected by mutations at as 143 (Yew and Berk, 1992; Rubenwolf et al., 1997).
Altogether these results indicate that it is difficult to separate the E1B-55K
functions related to transformation (p53 binding) and late protein synthesis (Orf6 binding).
The invention discloses new El constructs that combine the high efficiency of transformation of one serotype with the serotype-specific complementation function of another serotype. These new constructs are used to transform primary human embryonic retinoblast cells and human anmiocytes.

The generation ofpIG53S, pIG635 and pIG735 Construct pIG535 contains the Ads E1A region and BIB promoter sequences linked to the Ad35 E1B sequences. Hereto, pIG270 (FIG. 15; see example 6) was digested with EcoRI and NcoL The 5.3 kb vector fragment was then isolated from gel using the geneclean kit (BIO Inc. 101) according to the instructions of the manufacturer.
Next, construct pIG.E1A.E1B (FIG. 13; see example 6) was digested with EcoRI
and Xbal and the resulting 890 bp fragment was isolated as above. A third fragment was generated by PCR amplification on pIG.E 1 A.E 1 B using the following primers:
15E1A-F: 5'- GAG ACG CCC GAC ATC ACC TG -3' (SEQ. I.D. NO.,30) and 25E1B R: 5'- CAA GCC TCC ATG OGG TCA GAT GTA AC 3' (SEQ. I.D. NO.31).
3The following PCR program was used: 94 C for 2' followed by 30 cycles of 94 C
for 30", 60 C for 30" and 72 C for 1', and a final step at 72 C for 10' to ensure blunt ends.
The resulting 400 bp PCR fragment was digested with Xbal and NcoL After gel isolation as above, the three fragments were ligated and transformed into STBL-bacteria. One colony containing all three fragments in the correct order was selected and designated pI0535 (FIG. 26).

Construct pIG635 contains the Ad5 E1A and a chimeric Ad5-Ad35 EIB region such that the 21K sequence is essentially from Ad5 and linked to the Ad35 E1B-sequences as far as not overlapping with the 21K sequences. First, part of the Ad5 El sequences are amplified by PCR using pIG.ElA.E1B as template and the following 5 primers:
45AK: 5'- GAG CGA AGA AAC CCA TCT GAG -3' (SEQ. I.D. NO. 32) and 521558 5'- GGT CCA GGC CGG CTC TCG G -3' (SEQ. I.D. NO. 33). Amplification is accomplished with Pwo DNA polymerase (Roche) according to manufacturer's instructions. The 210 bp fragments is then purified from the primer sequences using the 10 PCR purification kit (Qiagen).
A second PCR fragment is amplified from pIG270 DNA as described above but with the following primers:
62155F: 5'- CCG AGA GCC GGC CTG GAC -3' (SEQ. I.D. NO.34) and 735F10: 5'- OCT CTA GAC CTG CAG GTT AGT CAG TTT CTT CTC CAC TG -3' 15 (SEQ. I.D. NO, 35).
The 1.3 kb amplified fragment is purified as above and mixed in a 1:1 molar ratio with the first PCR fragment. The mixture is then first subjected to a PCR
reaction without the addition of primers using Pwo DNA polymerase and the following program:
94 C for 2' and then 5 cycles of 94 C for 30", 60 C for 30", 72 C for 90".
20 Subsequently, primers 5AK and 35F10 are added at 0.6 p.M concentration after which a last PCR amplifies a 1.5 kb fragment. Hereto, temperature was set as follows:
94 C for 2', then 30 cycles of 94 C for 30", 60 C for 30" and 72 C for 90", followed by a final step at 72 C for 10' to ensure blunt ends. The resulting product is purified using the PCR
purification kit (Qiagen) as above and digested with KpnI and Sbf!
(isoschizomer of 25 Sse83871). The digested DNA is then isolated from gel using the geneclean kit (BIO
Inc., 101). Construct pIG.E1A.E1B is digested with KpnI and SbfI and the vector-containing fragment is isolated from gel as above. This fragment is ligated to the above prepared final PCR product and the ligation mixture is transformed into STBL-2 cells (Gibco, LTI) according to manufacturer's instructions. This gives construct pIG635 (Fig.
30 27).
In construct pIG735, the border between Ad5 derived sequences and Ad35 derived sequences is located more 3' than in construct pIG635. First, a BspEI
site is introduced in the Ad5 sequence of construct pIG.ElA.EIB without changing the amino acid sequence. Hereto, Ad5 sequences from pIG.E1A.E1B are amplified using the 35 following PCR primers:

5AK: see above, and Bsp-R: 5'- OCT CTA GAC CTG CAG GOT AGC AAC
AAT TCC GGA TAT TTA CAA G -3' (SEQ. I.D. NO. 36. Amplification is accomplished using Pwo DNA polymerase (Roche) according to the manufacturer's instruction. The following PCR program is used: 94 C for 2' followed by 30 cycles of 94 C for 30", 60 C for 30" and 72 C for 30", and a final step at 72 C for 10' to ensure blunt ends. The resulting 0.6 kb fragment is purified as above and digested with KpnI
and Sbfl and ligated to the above described Kpnl/Sbfl digested pIG.E1A.E1B
vector fragment. Selection of colonies after transformation of STBL-2 bacteria (Life Techn.
Inc.) gives construct pIG.E1055K . pIG. E 1i55K is then digested with Sbfl and to partially with BspEL The 6.4 kb Sbl-partial BspEl digested vector fragment is then isolated from gel using the geneclean lit (BIO 101, Inc.). Next, pIG270 is digested with BspEI and Sbfl and the resulting 915 bp fragment is isolated from gel as above. This fragment is then ligated to the above prepared Sbfllpartial BspEI digested pIG.E1055K
vector fragment and transformed into STBL-2 competent cells. This gives construct pIG735 (FIG. 28). Clones are analysed by restriction enzyme digestion and sequencing to ensure correct ligation of the fragments. Constructs pIG535, pIG635 and pIG735 can be used to generate complementing cell lines from primary human cells as described in Example 6.

Example 9 PER.C6-based complementing cell lines for El-deleted Ad35 viruses.
PER.C6 cells were seeded in 10 cm culture dishes at a density of 3x106 cells/dish in DMEM (Gibco BRL) complemented with FBS (Gibco BRL) up to 10% and l0mM
MgC12 (4.9 M stock solution, Sigma). Two days later, 9 dishes were transfected with I jig Scal linearised pIG35.55K DNA (see example 7) and 9 dishes were transfected with 1.5 jig Scal linearised pIG35.55K DNA. Separate control dishes were transfected with I or 1.5 g Scal linearised pAdApt35.LacZ to monitor transfection efficiency and with 1 or 1.5 jig Scal linearised pcDNA.nlsLacZ. pcDNA.nlsLacZ is a pcDNA3-based plasmid (Invitrogen) with the nlsLacZ gene (Bonnerot et al., 1987) driven by the CMV
promoter.
pcDNA.nlsLacZ also contains a near expression cassette. As a negative control one extra dish was transfected with linearised pAdApt3 S.LacZ, a construct that lacks the neoT
selection gene. All transfections were performed with the LipofectAmine transfection kit (Invitrogen/Life Technologies) according to manufacturers instructions using 5 ml LipofectAmine reagentIgg DNA. Cells were incubated for 4 hrs with the transfection mixture after which the medium was replaced with PER.C6 culture medium. The next day medium was replaced with culture medium containing 0.5 mg/ml G418 (Gibco BRL) except in the two dishes that were transfected with 1 or 1.5 g pAdApt35.LacZ.
These latter dishes were used to monitor LacZ expression two days following transfection. After X-gal staining of these cultures transfection efficiency was estimated at approximately 40% with slightly more blue cells in the dish transfected with 1.5 gg DNA.
Selection medium was refreshed twice weekly in the remaining transfected dishes. Within two weeks following first addition of selection medium most cells in the negative control dish (transfected with 1.5 jig pAdApt35.LacZ) were dead. In the dishes transfected with pcDNA.nlsLacZ cell clones were becoming visible. Since the cells transfected with pIG35.55K seemed to be more resistent to G418, the concentration was raised to 0.75 mg/ml 3 weeks following transfection. Three days and seven days later a total of 196 cell clones were picked from the dishes transfected with pIG35.55K and seeded in separate wells of 96-well plates.

Cells remaining after colony picking of two 10 cm dishes of the transfection with 1 gg pIG35.55K DNA were trypsinised, pooled and expanded to give pool PER55K(1.0) The same was done for two dishes of the 1.5 gg transfection. The PER55K(1.0) cell pool was expanded and seeded in 4 T25 flasks at a density of 3.5x106 cells/flask for transfection to test virus generation. In addition, 3 T25 flasks with parental PER.C6 cells were seeded at the same density. pAdApt35.eGFP (an adapter plasmid containing the green fluorescent protein as marker gene; see example 4) was digested with Pad to liberate the adenoviral sequences from the plasmid backbone. pWE.Ad35.pIX-rITR (see example 4) was digested with Notl to liberate the adenoviral sequences from the cosmid backbone. 2 flasks with PER.C6 cells and 2 flasks with PER55K(1.0) cells were transfected with 2 g digested pAdApt35.eGFP and 6 g digested pWE.Ad35.pIX-rITR each. One flask of each cell line was transfected with 8 g pAdApt35.LacZ to monitor transfection efficiency. The remaining flask with PER55K(1.0) cells served as a negative control and was treated as the others but did not receive the transfection mixture. All transfections were performed with LipofectAmine (Invitrogen/Life Techn.) according to manufacturers instructions using for each transfection a total of 8 gg DNA and 40 l LipofectAmine reagent. The transfection mixture was removed after 4 hrs incubation and fresh culture medium was added. Transfections were done the day after seeding of the cells and again two days later cells in the T25 flasks were transferred to a T80 flask except for the LacZ
control transfections. These were stained with X-gal solution after mild fixation. After five hours incubation with staining solution, the percentage of blue cells was estimated at approximately 90% in both flasks showing that transfection went well for both cell lines.
Four days following the passage to the T80 flasks the transfected PER55K(l.0) cultures showed starting CPE (cytopathogenic effect, indicative of virus replication) with approximately 100 events/flask. The untransfected PER55K(1.0) cells were grown confluent with no evidence of CPE. In the transfected PER.C6 cultures only three CPE
events were visible in the confluent monolayer of cells. Again three days later, the transfected PER55K(1.0) cultures showed full CPE, with all cells rounded and detached in clumbs. In contrast, in the PER.C6 cultures the few events of CPE had not progressed and cells were still in monolayer. This confirms earlier observations that generation of to E1-deleted Ad3 5-based viruses on PER. C6 is very inefficient. Also the untransfected PER55K(1.0) cultures showed, as expected, a confluent monolayer with no CPE.
The cells and medium in the PER55K(l.0) flasks with full CPE were harvested and subjected to two freeze/thaw cycles after which the cell debris was removed by centrifugation at 3000 rpm for 10 minutes in a table centrifuge. One of the resulting crude lysates was used to infect a fresh culture of PER55K(l.0) cells in a T175 flask (1.5 ml/flask).
Cells and medium were harvested at full CPE four days later. This shows that infectious virus had formed in the initial transfections. GFP expression was confirmed by fluorescent microscopy of A549 cells infected with the crude lysate. The crude lysate was then used to analyse complementation of this E1-deleted Ad35.AdApt.eGFP virus in the individual clones as described below.

The above described clones that were picked from the pIG35.55K transfected PER.C6 cells were expanded and were functionally tested for the ability to sustain replication of Ad35.AdApt.eGFP. Hereto, the clones were seeded at two densities in 6-well plates and one day later infected with 15 ml of the above described crude lysate. CPE was monitored the day after. Of the 146 clones tested in this way 19 gave full CPE
at day 2 or 3 and 68 gave full CPE at day 5 or 6. The remaining clones had only partial CPE or showed a few non-progressing events. The latter were indistinguishable from PER.C6 cells that were taken along as a negative control.
3o Based on these results a selection of 24 clones was made that were further screened for the ability to generate recombinant El-deleted viruses following transfection of the pAdApt35.GFP adapter plasmid and the large pWE.Ad35.pIX-rITR cosmid clone.
Hereto, clones were plated in T25 flasks and transfected with 2 g of the adapter and 6 tg of the backbone plasmid using LipofectAmine as described above. Two days following the transfection, cells were transferred to T80 flasks to prevent overconfluency of the cultures. Of the 24 clones 5 gave full CPE three days after passage to T80 and another 13 clones gave progressing to full CPE the day after. The remaining 6 clones showed no CPE or only starting. In comparison: routine generation of E1-deleted Ad5 vectors on PER.C6 cells generally results in full CPE four to six days after transfer to T80 flasks.
This shows that the new clones efficiently complement E1-deleted adenovirus vectors.
One of the clones (clone #16) described above was used to generate and produce multiple batches of E1 and E1/E3 deleted Ad3 5 viruses containing different transgenes.
Hereto, virus in crude lysates resulting from transfections as described above, but using different adapter plasnv.ds, were plaque purified on the new cell line. Single plaques were tested for transgene activity and then amplified for medium scale production in 4-8 triple layer flasks (3x 175 cm/flask). Cells were harvested at full CPE and the virus was released and purified as routinely done for adenoviruses and described in example 1. The extraction step with freon to remove cellular debris was, however, replaced by a centrifugation step.
Thus after incubation with Dnasel, the cell debris was centrifugated in conical 50 ml tubes (Greiner) at 8000 rpm in a table top centrifuge (Beckman Coulter Allegra 21R with fixed angle rotor) for 30 minutes at 4 C. This step is repeated in a fresh 50 ml tube untill the supernatant was clear (usually one time). The amount of virus particles was determined by HPLC (Shabram et al., 1997). Table IV presents the yields after downstream processing of medium scale productions of El- and El/E3-deleted Ad35 viruses on triple layer flasks with PER55K clone #16 cells. The amount of purified virus particles is comparable with the yields of Ad5-based vectors on PER.C6 cells.

We conclude that we have generated multiple cell lines that efficiently complement fully El-deleted Ad35-based vectors. Thus, Ad35 E1B-55K expression in an Ad5 complementing cell line facilitates replication of Ad35 vectors.
Example 10 New complementing cell lines from primary cells Example 8 described the generation of construct pIG535, a hybrid Ad5E1A-Ad35 expression plasmid. pCC536s and pIG536 are also hybrid Ad5-Ad35 El constructs but with the E1A region, EIB promoter and most of the E1B-19K gene derived from Ad5 and most of the E1B-55K gene derived from Ad35. Constructs pCC536s and pIG536 differ only in the heterologous poly adenylation sequence that terminates the EIB
transcript: pIG536 has the HBV pA sequence and pCC536s has a synthetic pA
sequence (SpA). The SpA sequence consists of the upstream sequence element (USE) of the human C2 complement gene (Moreira et al., 1995) and the synthetic pA sequence (SPA) described by Levitt et al., 1989.
The synthetic polyA sequence is build up using the following oligo's:
C2SPA-1: 5'- CCC TGC AGG GAC TTG ACT CAT GCT TGT TTC ACT TTC ACA
5 TGG AAT TTC CCA GTT ATG AAA TTA ATA AAG -3' (SEQ. I.D. NO. 37) C2SPA-2: 5'- GTC TAG ACA CAC AAA AAA CCA ACA CAC TAT TGC AAT GAA
AAT AAA TIT CCT TTA TTA ATT TCA TAA CTG -3' (SEQ. I.D. NO.38) Oligonucleotides were mixed at 10 M concentration in lx annealing buffer (10mM
Tris 10 HCI pH 7.5, 100mM NaCI,1mM EDTA) and, using a PCR machine, the solution was heated to 94 C for 5 minutes and then cooled down to 65 C at 0.5 C / second and after incubation at 65 C for 5 minutes further cooled down to 20 C at 0.05 C /
second.
Subsequently, 10 pl 2mM dNTPs, 0.5 gl IM MgC12 and 3 1 Klenow fragment (New England Biolabs) was added to 87 l of the annealed sample and the mixture was 15 incubated at room temperature for 30 minutes. 1 1 of the annealed and Klenow treated sample was then amplified using the following primers:
C2for 5'- COG GAT CCC CTG CAG GGA CTT GAC -3' (SEQ. I.D. NO. 39) and SPArev: 5'- TTG CGA CTT AAG TCT AGA CAC ACA AAA AAC C -3' (SEQ. I.D. NO. 40) using Pwo 20 DNA polymerase (Roche) according to manufacturers instructions but with addition of DMSO (Sigma) to a final concentration of 3%. The PCR program was set at 94 C
for 2 minutes, followed by 30 cycles of (94 C for 30", 55 C for 30" and 72 C for 20").
Where in this document PCR programs are described' means time in minutes and "
means time in seconds. The amplified DNA was then purified using the QlAquick PCR
25 purification kit (Qiagen) and digested with Xbal and Sbfl. The digested product was then again purified with the PCR purification kit to remove the small digested ends. Construct pIG270 was also digested with Xbal and Sbfl (isoschizomer of Sse83871) and the resulting 5.9 kb vector containing fragment was isolated from gel using the GeneClean II
kit (Bio101, Inc). The treated vector and PCR insert were then ligated to give pCC271 30 (Figure 29). pCC271 thus contains the PGK promoter, the Ad35 El region (nucl. 468 to and including 3400 from Ad35 sequence in example 3 and figure 5) and the synthetic pA
(SpA). The synthetic pA sequence was then also cloned into the construct pIG535 as follows.
pIG535 was digested with EcoRl, Pstl and Scal (All enzymes from New England Biolabs 35 digested in NEB buffer 3) and the 3 kb insert corresponding to chimeric Ads Ad35 El region was purified using the GeneClean II kit (Bio 101, Inc.). Construct pCC271 was' digested with EcoRI and PstI and the 3 kb vector fragment containing the SpA
and PGK
promoter was isolated as above. Both isolated fragments were ligated and transformed into STBL-2 competent cells (Invitrogen/LifeTechnologies) to give pCC535s (Figure 30).
pCC535s contains the same AdS-Ad35 El sequences as pIG535 however, a different pA
sequence.
For the construction of pCC536s, a subclone was made with the new hybrid E1B
sequences. Hereto, Ad5 E1A/E1B2IK sequences were amplified using the primers 5AK 5'- GAG CGA AGA AAC CCA TCT GAG- 3' and 2155R: 5'- GGT CCA GGC CGG CTC TCG G-3' with pIG.BIA.E1B (see example 6 1 o and Figure 13) as template DNA using Pwo DNA polymerase (Roche) according to manufacturers instructions and in addition a final concentration of 3% DMSO.
The program was set at: 94 C for 2' followed by 30 cycles of (94 C for 30", 58 C
for 30"
and 72 C for 30") and ended with 68 C for 8'. This resulted in a 210 bp fragment corresponding to nuci. 2022-2233 of the Ad5 sequence. A second PCR was performed on pCC271 with primers 2155F: 5'- CCG AGA GCC GGC CTG GAC C-3' (SEQ. I.D. NO.41) and 35F10: 5'- OCT CTA GAC CTG CAG GTT AGT CAG TTT CTT CTC CAC TG-3'.
The same PCR program was used but now with an elongation time of 90" . The resulting 1.3 kb fragment corresponds to nucl. 2112 to 3400 of the Ad35 sequence with an Sbfl site at the 3'end. Note that primers 2155F and 2155R are fully complementary allowing assembly of the two fragments as follows:
Both PCR fragments were purified from gel using the Qiagen gel extraction kit.
Aliquots of the purified samples were then mixed in equimolar ratio and used as template for an assembly PCR amplification with primers 5AK and 35F10 with Pwo DNA polymerase as above using the program settings:
94 C for 2', and 5 cycles of (94 C for 30", 60 C for 30" and 72 C for 2') followed by 25 cycles of (94 C for 30", 58 C for 30" and 72 C for 90"). The resulting 1.5 kb fragment was purified from gel using the QlAquick gel extraction kit (Qiagen), ligated to the pCR-Script/Amp cloning vector (Stratagene) and transformed into DH5a competent cells (Invitrogen/Life Technologies) resulting in pCR535BIB (Figure 31). This construct was checked by restriction analysis and sequencing to confirm correct amplification of target sequences.
pCR535E1B was then digested with Notl and protruding ends were made blunt with Klenow fragment. The DNA was then purified using the QIAquick PCR purification kit (Qiagen) and eluted DNA was digested with PstL The 1.5 kb fragment containing the chimeric El sequences from the pCR535E1B vector was purified from gel using the GeneClean II kit (Biol0l, Inc.). This fragment was ligated to vector pCC535s digested with PvuII and PstI, and transformed into STBL-2 competent cells (Invitrogen/Life Technologies) to give pCC2155s (Figure 32). To complete the pCC536s construct Ad5-El sequences were then cloned into the pCC2155s subclone. Hereto, pIG.E1A.EIB
was digested with EcoRl and KpnI and the 1.6 kb fragment corresponding to Ad5 E IA
and Ad5 E I B 21K (nucl. 459 to 2048 of the Ad5 sequence) was isolated from gel using the GeneClean kit. pCC2155s was digested with EcoRl and KpnI and the vector containing fragment was also gel purified. Ligation of both isolated fragments and transformation into DHIOB electrocompetent cells (Invitrogen/Life Technologies) resulted in pCC536s (Figure 33). The hybrid E I B sequences are shown in Figure 38 in more detail.

shows an alignment of protein sequences of E1B-21K in the pCC536s construct with wild type (wt) Ad35 and Ad5 sequences. As can be seen most of the E1B-21K protein in pCC536s is derived from Ad5 except for the C-terminal 6 amino acids that are identical to Ad35 E1B-21K. Figure 38B shows the same alignment for the EIB-55K proteins.
In this case the N-terminal amino acids of pCC536s are identical to Ad5 upto as 65. The remainder is identical to Ad35 E1B-55K. Obviously, different hybrid EIB-55K
constructs can be designed using the general method oulined above whithout departing from the invention.
Construct pIG536 was made by replacing a fragment with the SpA in pCC536s with the corresponding fragment from pIG270 (example 6, Figure 15) containing the HBVpA.
Hereto, pIG270 was digested with BamHI and BgII and the 1.8 kb insert was isolated from gel using the GeneClean II kit (Bio 101, Inc.). pCC536s was digested with the same enzymes and the 4.8 kb vector containing fragment was purified from gel as above.
Ligation of both isolated fragments and transformation into STBL-2 competent cells (Invitrogen/Life Technologies) gave construct pIG536 (Figure 34).

The generated El constructs were tested in primary baby rat kidney (BRK) cells as described in example 6. The results (Table V) confirm earlier observations that Ad5-E1 genes more efficiently transform primary BRK cells than Ad35 E1 genes. The chimeric Ad5-Ad35 El expression constructs, pCC535s and pCC536s, produced more transformed colonies than the full Ad35 E1 constructs, pIG270 and pCC271. Furthermore, the use of a synthetic poly adenylation sequence in pCC535s resulted in slightly more foci compared to the HBVpA variant pIG535.

Human embryonic retinoblast (HER) cells were isolated from the eyes of aborted fetuses of 18 and 21 weeks of age. The eyes were brought in a 6 cm dish with PBS and cleared from outside tissue. An incision was made to reach the inner side and the gray cell layer at the inner back of the eyes containing the retinoblasts, was scraped off.
This layer was transferred to a 14 ml tube in 2m1 of PBS and tissue was allowed to sediment after which the PBS was removed. 2 ml trypsin (0.25%, no EDTA, GibcoBRL) was added and incubated for 5 minutes at 37 C with occasional swirling. Tissue pieces were allowed to sediment and 1 ml trypsin with cells was transferred to a new tube. To this tube 4 ml culture medium (DMEM with 10% FCS) was added and the tube was stored on ice.
The remaining tissue pieces in trypsin were brought in a 6 cm dish and cut into smaller pieces.
These were, after addition of 2 ml fresh trypsin, again incubated in a 14 ml tube at 37 C
with occasionally swirling. Then this mixture was added to the first isolated cells in culture medium and the total was centrifugated at 1000 rpm in a table top centrifuge.
Supernatant was removed and cells were resuspended in 10 ml of culture medium.
The isolated HER cells were plated in two 6 cm dishes and incubated at 37 C/ 10%
C02.
Upon 90% confluency cultures were split 1:3 and further incubated. This procedure was repeated until enough dishes were obtained to be used for transfection and further culturing. Transfections were performed at different passage numbers using the CaPO4 cotransfection kit (Invitrogen/Life Technologies) according to manufacturers instructions.
For each dish (50-70% confluency) 20 g DNA was used. Initial transfections were performed with pIG.ElA.E1B, an Ad5-El expression construct, and with pIG535, the hybrid Ad5-ElA/Ad35-E1B expression construct. 2-3 weeks following transfection transformed foci became visible in the pIG.E1A.E1B transfected dishes. On average 15-20 foci/dish were found in the dishes that were transfected with pIG.ElA.E1B.
Over 30 clones were picked and transferred to 96-well plates. Upon confluency cells were passaged to larger culture plates or flasks and finally viable frozen in ampoules in liqN2 from a T175 flask. All picked clones were established in this way. Transformed foci appeared much later in the dishes that were transfected with pIG535, the first around five weeks following transfection. On average 3-4 clones were found per dish. A
total of 46 clones were picked from 7 weeks to 3 months after transfections of which 14 were viable and could be passaged multiple times. Of these, 2 clones (clone #45 and #75) were grown up to a T175 flask and viable frozen in ampoules in ligN2.
Primary HER cells were also transfected with constructs pCC53 5s and pCC536s.
Transfection of pCC535s let to an average of 2 clones/dish and a total of 50 clones were picked. Of these picked clones 2 could be established. From the transfection with pCC536s, at least one clone could be established.
The above described experiments show that primary HER cells can be transformed with hybrid Ad5-Ad35 El sequences. The efficiency of transformation was lower than obtained with the complete Ad5 E 1 region. We then tested whether the new cell lines could complement recombinant Ad35-based El-deleted vectors. Hereto, the clone #45 that was obtained from the pIG535 transfection was seeded in T25 flasks at a density of 7x106 cells/flask and infected with Ad35.AdApt.eGFP virus (see example 9) at a multiplicity of infection (moi) of 5 and 25 virus particles/cell. Full CPE was seen at days 4 and 5 for the moi 25 and 5 respectively. As a comparison parallel cultures of clone #45 cells that were infected with Ad5.AdApt.eGFP viruses gave full CPE at days 7 and 8 for moi 25 and 5 respectively. The initial infection efficiency was comparable for Ad5 and Ad35 viruses, -80% (moi=5) and -95% (moi=25) of the cells were infected with GFP
virus one day following infection as measured by fluorescence microscopy.
Cells from clone #75 were seeded in a 6-well plate at a density of 2x106 cells/well and infected with Ad35.AdApt.eGFP or AdS.AdApt.eGFP at moi 5 (VP/cell). Again initial infection efficiency was comparable for both viruses. Full CPE was observed at day 4 in case of Ad35.AdApt.eGFP infection whereas Ad5.AdApt.eGFP infected clone #75 cells gave full CPE on day 7. The difference in replication efficiency on Ad35 complementing cells between Ad35 and Ad5 recombinant vectors is even more clear when virus is generated by plasmid transfection. This is exemplified by the following transfection experiment.
Clone #45 cells were seeded in T25 flasks at a density of 3.5x106 cells and transfected three days later using LipofectAmine reagent (Invitrogen/Life Technologies) according to manufacturers instructions and described above. 2 g pAdApt35.eGFP adapter plasmid digested with PacI was cotransfected with 6 tg pWE.Ad35.pIX-rITR or pWE.Ad35.pIX-rITRAE3 backbone cosmid digested with Notl. 2 Rg pAdApt.eGFP (Ad5 adapter plasmid, described in WO 00/70071) digested with PacI was cotransfected with 6 g pWE.Ad5.AflII-rITRsp (Ad5 backbone plasmid, described in WO 00/70071) also digested with Pacl. One T25 was not transfected and served as a negative control. One day later transfection efficiencies were monitored by fluorescent microscopy and estimated at 10-15% in all eGFP transfections. Three days following transfection cells were transferred to T80 flasks and further incubated at 37 C/10%CO2. Again three days later CPE events were becoming visible in the cultures transfected with the pAdApt35.eGFP and the pWE.Ad35pIX-rITR+ or - E3. The transfections with the E3-deleted backbone contained more green fluorescent cells and more CPE events.
The transfection with Ad5 plasmids showed only around 20% green fluorescent cells, of which most were dying, and no CPE events. Two days later this difference had become bigger since cultures transfected with the pAdApt35.eGFP and the pWE.Ad35pIX-rITRAE3 clearly showed 80% CPE and cultures transfected with the pAdApt35.eGFP

and the pWEAd35pIX rITR constructs showed progressing CPE events. The Ads transfected culture did not show any progression. Table VI summarizes these results.
We conclude that the new complementing cell lines described above efficiently sustain replication of E 1 deleted Ad35-based viruses and that the generation and replication of El deleted Ad5-based viruses is less efficient. Apparently, also Ad35-EIB55K
proteins do not form a functional complex with Ad5-E40rf6 proteins. Thus the serotype specificity for complementation is now also shown for recombinant Ad5 vectors on Ad35 packaging cells.

Example 11 Generation of pWE.Ad.pIX-rTi'ROE3 The early region-3 of human adenoviruses contains multiple coding regions for proteins that interfere with the host immune response to adenoviral infection. When adenoviral vectors are used as vaccine carrier such interference is unwanted. Therefore, we constructed an Ad35 backbone cosmid lacking the E3 region.
Hereto, construct pBr.Ad35.PRn (Figure 35; described in example 13 in publication EP 1 054 064 Al) was digested with Stul and MuI and the 17.3 kb vector fragment was purified from low melting point (LMP) gel using agarase enzyme (Roche) according to manufacturers instructions. Next, a PCR fragment was generated on pBr.Ad35.PRn using primers:
35E3for: 5'- AAT GAC TAA TGC AGG TGC GC-3' (SEQ. I.D. NO. 42) and 35E3rev: 5'- CGA CGC GTT GTA GTC OTT GAG CTT CTA G-3'-(SEQ. I.D. NO.43 ). For the amplification Pwo DNA polymerase (Roche) was used according to manufacturers instructions and program set at 94 C for 2', 30. cycles of (94 C for 30", 58 C
for 30"' and 72 C for 1') and a final incubation at 68 C for 8'. The 833 bp PCR
product was purified using the QlAquick PCR purification kit (Qiagen) and digested with Hui and Stul. The digested DNA was purified from gel using the QlAquick gel extraction kit (Qiagen). Both isolated fragments were ligated and transformed into DH5a competent cells (Invitrogen/Life Technologies) to give pBr.Ad35.PRn0E3 (Figure 36). The plasmid was checked by restriction analysis and sequencing of the PCR amplified insert. The E3 deletion was then cloned into the pWEAd35.pIX-r1TR cosmid backbone. Hereto, pWE.Ad35.pDC-rITR (see example 4 and Figure 8) was digested with Pacl and the DNA
was purified by precipitation with isopropanol and washing with 70% EtOH.
Following resuspension in milliQ water, the DNA was digested with Swal and the 22.8 kb vector containing fragment was purified from LMP gel using agarase enzyme as above.

Construct pBr.Ad35.PRnLE3 was digested with Pacl and SwaI in the same manner and the 16.6 kb fragment was also isolated using agarase enzyme. Both isolated fragments were ligated using 0.5-0.6 p,g of each fragment. Ligated fragments were then packaged using 2-phage packaging extracts (Stratagene) according to manufacturers instructions and mixed with STBL-2 cells. Bacteria were plated on LB+Amp plates and resulting colonies were analyzed for the presence of the correct construct. This gave construct pWE.Ad35.pIX-rITRAE3 (Figure 37). The E3 deletion extends from nucl. 27648 to 30320 of the Ad35 sequence (example 3) and thus spans a 2.6 kb region.
Cotransfection of Nod digested pWE.Ad35.pIX-rITRAE3 and pIPsp-1 digested pAdApt35.eGFP onto PER55-clone #16 cells (see example 9) as described above gave rise to GFP expressing Ad3 5-based viruses. Upon isolation of viral DNA from these viruses, PCR amplification of the E3 region showed that the viruses were deleted for 2.6 kb of E3 sequences as expected.

Table I:
Serotype Elution [NaCI] mM VP/ml CCID50 logto VP/CCID50 ratio 1 597 8.66x10 5.00x10 3.2 2 574 1.04x10 3.66x10 0.4 3 131 1.19x10 1.28x10 4.0 4 260 4.84x10 2.50x10 3.3 533 5.40x10 1.12x10 1.7 6 477 1.05x10 2.14x10 1.7 7 328 1.68x10 2.73x10 2.4 9 379 4.99x10 3.75x10 4.1 387 8.32x10 1.12x10 3.9 12 305 3.64x10 1.46x10 4.4 13 231 1012 7.31x10 3.8 443 5.33x10'2 1.25x109 3.6 16 312 1012 5.59x10 3.5 17 478 1.39x 1012 1.45x109 3.0 19 430 8.44x10 8.55x10 4.0 156 1.41x10 1.68x10 3.9 21 437 3.21x10 1.12x10 3.5 22 365 012 5.59x10 3.4 23 132 2.33x10 1.57x10 4.2 24 405 1012 4.27x10 4.1 405 7.24x10 5.59x10 4.1 26 356 1012 1.12x10 4.0 27 342 2.00x10 1.28x10 4.2 28 347 2.77x10 5.00x10 4.7 29 386 2.78x10 2.00x10 4.1 409 1012 5.59x10 3.4 31 303 8.48x10 2.19x10 3.6 33 302 1.02x10 1.12x10 5.0 34 425 1.08x10 1.63x10 0.8 446 3.26x10 1.25x10 1.4 36 325 1012 3.62x10 3.4 37 257 1012 2.8x10 3.3 38 337 X1012 107 4.8 39 241 3.34x 10 1.17x 10 4.5 Continued on next page.

Serotype Elution [NaCI] mM VP/ml CCID50 logic VP/CCID50 # ratio 42 370 o12 1.12x10 4.2 43 284 2.42x10 1.81x10 4.1 44 295 8.45x10 2.00x10 4.6 45 283 5.20x10 2.99x10 4.2 46 282 9.73x10 2.50x10 4.6 47 271 5.69x10 3.42x10 4.2 48 264 1.68x10 9.56x10 3.3 49 332 012 8.55x10 4.4 50 459 1012 2.80x10 3.4 51 450 8.41x10 1.88x10 3.7 Legend to Table I:

All human adenoviruses used in the neutralization experiments were produced on PER.C6 cells (Fallaux et al., 1998) and purified on CsCl as described in example 1. The NaCl concentration at which the different serotypes eluted from the HPLC
column is shown. Virus particles/ml (VP/ml) were calculated from an Ad5 standard. The titer in the experiment (CCID50) was determined on PER.C6 cells as described in Example 1 by titrations performed in parallel with the neutralization experiment. The CCID50 is shown for the 44 viruses used in this study and reflects the dilution of the virus needed to obtain CPE in 50% of the wells after 5 days. The ratio of VP/CCID50 is depicted in 1og10 and is a measurement of the infectivity of the different batches on PER.C6 cells .

Table II. AdApt35.LacZ viruses escape neutralization by human serum.
Human serum dilution Virus no serum lOx 50x 250x 1250x 6250x AdApt5.LacZ 100% 0% 0% 1 % 40% 80%
moi: 5 VP/cell AdApt35.LacZ 100% 100% 100% 100% 100% 100%
250 l crude lysate Table III: The numbers of foci obtained with the different El expression constructs in BRK transformation experiments.
Average # of foci/dish:

Construct 1 gr 5 gr Experiment 1 pIG.E1A.E1B nd 60 pIG.E1A.E1B nd 35 pRSVAd35El 0 3 pIG.Ad35.E1 3 7 Experiment 2 pIG.EIA.E1B 37 nd IG.Ad35.E1 nd 2 Experiment 3 pIG.ElA.ElB nd 140 pIG.Ad35.E 1 nd 20 pIG270 nd 30 Table IV: Yields of El- and El/E3- deleted Ad35 viruses on clone #16 cells produced on triple layer flasks.

Virus Scale(T1751II flasks) Total # of Virus Particles after DSP VP/cell Ad35.AdApt.eGFP 4 7.5x1011 2500 Ad35.AE3.AdApt.empty 8 2x1012 3300 Ad35.DE3.AdApt.LacZ 8 3.8x1011 600 Ad35.EE3.AdApt.MV-F 4 8.8x1011 2900 1o Ad35.DE3.AdApt.MV-H 8 2.6x1012 4250 Table V: Transformation efficiencies on BRK cells with different Ad-El expression constructs.

Construct Transfected DNA ( g) # foci per dish Experiment 1 pIG.E1A.EIB 5 44 pIG270 5 0 pCC271 5 0 pIG535 5 1 pCC535s 5 2.5 Experiment 2 pIG.ElA.E1B 4 15 pCC271 4 0 pCC535s 4 3 pCC536s 4 3 a) o 00 00 N O O O o O
Q -+ N O Q vs 00 0 0 N
U
bA _ ,0 Q c d N O Q .-. 0 0 U W a~i C~7 o Lr) r) o U
p Q N N N O Q O O O O
ct!
a) W) (S kn C>I?
0 Q ~- -i O Q O O O O
(1) co > W M
V') H
o M M M

o v o w w +a o w w +
. y ate), ate), (D a d a) ta) , a) Lr) t U -+ M+ U .. 4- cl M CO) -cod V1 C) References:
Abrahamsen, K., Kong, H-L., Mastrangeli, A., Brough, D., Lizonova, A., Crystal, 5 R.G. and Falck-Pedersen, E. (1997). Construction of an adenoovirus type 7a ElA- vector.
J. Virol. 71, 11, p8946-8951.
Babiss, L.E. and Ginsberg, H.S. (1984). Adenovirus type 5 early region lb gene product is required for efficient shutoff of host protein synthesis. J. Virol.
50, p202-2122 Babiss, L.E., Ginsberg, H.S. and Darnell, J.J. (1985). Adenovirus E1B proteins 10 are required for accumulation of late viral mRNA and for effects on cellular mRNA
translation and transport. Mol. Cell. Biol. 5, p2552-2558.
Bernards,R., Houweling, A. Schrier, P.I., Bos, J.L. and van der Eb, A.j.
(1982).
Characterization of cells transformed by Ad5/Adl 2 hybrid early region 1 plasmids.
Virology 120, p422-432.
15 Bonnerot, C., Rocancourt, D., Briand, P., Grimber, G. and Nicolas, JF.
(1987). A
beta-galactosidase hybrid protein targeted to nuclei as a marker for developmental studies. Proc. Natl. Acad. Sci. USA 84(19), p6795-6799.
Bos, J.L., Polder, L.J., Bernards, R., Schrier, P., van den Elsen, P.J., van der Eb, A.J. and van Ormondt, H. (1981). The 2.2 kb mRNA of the E1B region of human 20 adenovirus type 12 and 5 directs the synthesis of two major tumor antigens from different AUG triplets. Cell 12, p721-732.
Bridge, E. and Ketner, G. (1990). Interaction of adenoviral E4 and Elb products in late gene expression. Virology 174, p345-353.
Bridge, E., Medghalchi, S., Ubol, S., Leesong, M. and Ketner, G. (1993).
25 Adenovirus early region 4 and viral DNA synthesis. Virology 193, p794-801.
Brough, D.E., Lizonova, A., Hsu, C., Kulesa, V.A. and Kovesdi, I. (1996). A
gene transfer vector-cell line system for complete functional complementation of of adenovirus early regions 1 and 4. J. Virol. 70, p6497-6501.
Fallaux, F.J., Kranenburg, 0., Cramer, S.J., Houweling, A., van Ormondt, H., 30 Hoeben, R.C. and van der Eb, A.J. (1996). Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7 (2), p215-222.
Fallaux, F.J., Bout, A., van der Velde, I., van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., van Ormondt, H., van der Eb, A.J., Valerio, D. and 35 Hoeben, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
Gallimore, P.H., Grand, R.J.A. and Byrd, P.J. (1986). Transformation of human embryo retinoblasts with simian virus 40, adenovirus and ras oncogenes.
AntiCancer Res.
6, p499-508.
Gossen, M., and H. Bujard (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89;
5547-5551.
Graham, F.O., Smiley, J., Russell, W. and Nairn, R. (19770. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen.
Virol. 36, to p59-72.
Grand, R.J.A., Parkhill, J., Szestak, T., Rookes, S.M., Roberts, S. and Gallimore, P.H. (1999). Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein. Oncogene 18, p955-965.
Han, J., Sabbatini, P., Perez, D., Rao, L., Modha, D. and White, E. (1996).
The ElB 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev. 10 (4), p461-477.
Jochemsen, A.G., Peltenburg L.T., to Pas, M.F., de Wit, C.M., Bos, J.L. and van der Eb, A.J. (1987). Activation of adenovirus 5 EIA transcription by region E1B in transformed primary rat cells. EMBO J. 6 (11), p3399-3405.
Moreira, A., Wollerton, M., Monks, J. and Proudfoot, NJ. (1995). Upstream sequence elements enhance poly(A) site efficiency of the C2 complement gene and are phylogenetically conserved. EMBO J., 14 (15), p3809-3819.
Leppard, K.N. and Shenk, T. (1989). The adenovirus E I B 55kd protein influences mRNA tranport via an intranuclear effect on RNA metabolism. EMBO J. 8, p2329-2336.
Levitt, N., Briggs, D., Gil, A. and Proudfoot, NJ. (1989). Definition of an efficient synthetic poly(A) site. Genes Dev. 3, p1019-1025.
Pilder, S., Moore, M., Logan, J. and Shenk, T. (1986). The adenovirus E1B 55K
transforming polypeptide modulates transport or cytoplasmic stabilization of viral and 3o host cell mRNAs. Mol. Cell. Biol. 6, p470-476.
Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S. and White, E.
(1992). The adenovirus ElA proteins induce apoptosis, which is inhibited by the ElB 19-kDa and Bcl-2 proteins. Proc. Natl. Acad. Sci. USA 89, p7742-7746.
Rubenwolf, S., Schutt, H., Nevels, M., Wolf, H. and Dobner, T. (1997).
Structural analysis of the adenovirus type 5 EiB 55-kilodalton-E4orf6 protein complex. J.
Virol. 71, p1115-1123.

Singer-Sam, J., Keith, D.H., Tani, K., Simmer, R.L., Shively, L., Lindsay, S., Yoshida, A. and Riggs, A.D. (1984). Sequence of the promoter region of the gene for human X-linked 3-phosphoglycerate kinase. Gene 32 (3), p409-417.
White, E. and Cipriani, R. (1990). Role of adenovirus EIB proteins in transformation: Altered organization of intermediate filaments in transformed cells that express the 19-kilodalton protein. Mol. Cell. Biol. 10, p120-130.
White, E. (1995). Regulation of p53-dependent apoptosis by E1A and E1B. In:
The molecular repertoire of adenoviruses III. Eds. Doerfler, W. and Bohm, P..
Springer-Verlag Berlin Heidelberg 1995, p33-58.
White, E. (1996). Life, death, and the pursuit of apoptosis. Genes Dev. 10 (1), pl-15.
Yew,P.R., Kao, C.C. and Berk, A.J. (1990). Dissection of functional domains in the adenovirus 2 early region 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology 179, p795-805.
Yew, P.R. and Berk, A.J. (1992). Inhibition of p53 transactivation required for transformation by adenovirus early region 1B protein. Nature 357, p82-85.
Simonsen, C.C. and Levinson, A.D. (1983). Analysis of processing and polyadenylation signals of the hepatitis B virus surface antigen gene by using simian virus 40-hepatitis B virus chimeric plasmids. Mol. and Cell. Biol. 3 (12), p2250-2258.
Zantema, A., Fransen, J.A., Davis, O.A., Ramaekers, F.C., Vooijs, G.P., DeLeys, B. and van der Eb, A.J. (1985). Localization of the E1B proteins of adenovirus 5 in transformed cells, as revealed by interaction with monoclonal antibodies.
Virology 142, p44-58.
Zantema, A. and van der Eb, A.J. (1995). Modulation of gene expression by adenovirus transformation. In: The molecular repertoire of adenoviruses III.
Eds.
Doerfler, W. and Bohm, P.Springer-Verlag Berlin Heidelberg 1995, p1-23.

SEQUENCE LISTING
<110> Crucell Holland B.V.
Vogels, Ronald Havenga, Menzo J.E.
Mehtali, Majid <120> Complementing Cell Lines <130> PAT 54585W-1 <140> PCT/NL01/00824 <141> 2001-11-14 <150> US 09=/713,678 <151> 2000-11-15 <160> 50 <170> Patentln Ver. 2.1 <210> 1 <211> 14 <212> DNA
<213> adenoviridae <220>
<221> misc feature <222> (1) ._(14) <223> /note="5'end"
<400> 1 ccaataatat acct 14 <210> 2 <211> 21 <212> DNA
<213> adenoviridae <220>
<221> misc feature <222> (1)._(21) <223> /note="3'end"
<400> 2 aggtatatta ttgatgatgg g 21 <210> 3 <211> 18 <212> DNA
<213> adenoviridae <220>
<221> mist feature <222> (1).._(18) <223> /note="Terminal sequence"
<400> 3 catcatcaat aatatacc 18 <210> 4 <211> 47 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligo ExSalPacF

<220>
<221> misc feature <222> (1) _(47) <400> 4 tcgatggcaa acagctatta tgggtattat gggttcgaat taattaa 47 <210> 5 <211> 47 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligo ExSalPacR

<220>
<221> misc feature <222> (1) ._ (47) <400> 5 tcgattaatt aattcgaacc cataataccc ataatagctg tttgcca 47 <210> 6 <211> 42 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer PCLIPMSF

<220>
<221> misc feature <222> (1)._(42) <400> 6 ccccaattgg tcgaccatca tcaataatat accttatttt gg 42 <210> 7 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer pCLIPBSRGI

<220>
<221> misc feature <222> (1) _(22) <400> 7 gcgaaaattg tcacttcctg tg 22 <210> 8 <211> 37 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligo Ecolinker+

<220>
<221> misc feature <222> (1).^(37) <400> 8 aattcggcgc gccgtcgacg atatcgatag cggccgc 37 <210> 9 <211> 37 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligo Ecolinker-<220>
<221> misc feature <222> (1) ._(37) <400> 9 aattgcggcc gctatcgata tcgtcgacgg cgcgccg 37 <210> 10 <211> 49 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence:
oligonucleotide HindXba+

<220>
<221> misc feature <222> (1) ._(49) <400> 10 agctctagag gatccgttaa cgctagcgaa ttcaccggta ccaagctta 49 <210> 11 <211> 49 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence:
oligonucleotide HindXba-<220>
<221> misc feature <222> (1) (49) <400> 11 ctagtaagct tggtaccggt gaattcgcta gcgttaacgg atcctctag 49 <210> 12 <211> 44 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 35F1 <220>
<221> misc feature <222> (1) ._(44) <400> 12 cggaattctt aattaatcga catcatcaat aatatacctt atag 44 <210> 13 <211> 33 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 35R2 <220>
<221> misc feature <222> (1) ._ (33) <400> 13 ggtggtccta ggctgacacc tacgtaaaaa cag 33 <210> 14 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 335F3 <220>
<221> misc feature <222> (1) ._(30) <400> 14 tggtggagat ctggtgagta ttgggaaaac 30 <210> 15 <211> 37 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 435R4 <220>
<221> misc feature <222> (1) (37) <400> 15 cggaattctt aattaaggga aatgcaaatc tgtgagg 37 <210> 16 <211> 34 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 535F5 <220>
<221> misc feature <222> (1) ._(34) <400> 16 cggaattcgc ggccgcggtg agtattggga aaac 34 <210> 17 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 635R6 <220>
<221> misc feature <222> (1) .. (22) <400> 17 cgccagatcg tctacagaac ag 22 <210> 18 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 735F7 <220>
<221> misc feature <222> (1) ._(23) <400> 18 gaatgctggc ttcagttgta atc 23 <210> 19 <211> 42 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 835R8 <220>
<221> misc feature <222> (1)._(42) <400> 19 cggaattcgc ggccgcattt aaatcatcat caataatata cc 42 <210> 20 <211> 33 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 135F11 <220>
<221> misc feature <222> (1) .. (33) <400> 20 ggggtaccga attctcgcta gggtatttat acc 33 <210> 21 <211> 38 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 235F10 <220>
<221> misc feature <222> (1) .. (38) <400> 21 gctctagacc tgcaggttag tcagtttctt ctccactg 38 <210> 22 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 3HBV-F
<220>
<221> misc feature <222> (1)._(27) <400> 22 ggctctagag atccttcgcg ggacgtc 27 <210> 23 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 4HBV-R

<220>
<221> misc feature <222> (1) ._ (26) <400> 23 ggcgaattca ctgccttcca ccaagc 26 <210> 24 <211> 17 <212> DNA
<213> Artificial Sequence' <220>
<223> Description of Artificial Sequence:
oligonucleotide 1BB1 <220>
<221> misc feature <222> (1) ._(17) <400> 24 gtgcctaggc cacgggg 17 <210> 25 <211> 13 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence:
oligonucleotide 2BB2 <220>
<221> misc feature <222> (1) _ (13) <400> 25 gtggcctagg cac 13 <210> 26 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 3270F
<220>
<221> misc feature <222> (1) ._(20) <400> 26 cacctctgcc taatcatctc 20 <210> 27 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 4270R
<220>
<221> misc feature <222> (1) ._(27) <400> 27 gctctagaaa ttccactgcc ttccacc 27 <210> 28 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223>.Description of Artificial Sequence: primer 135D21/

<220>
<221> misc feature <222> (1) .. (25) <400> 28 ttagatccat ggatcccgca gactc 25 <210> 29 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <220>
<221> misc feature <222> (1)..(18) <400> 29 cctcagcccc atttccag 18 <210> 30 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 15E1A-F
<220>
<221> misc feature <222> (1)._(20) <400> 30 gagacgcccg acatcacctg 20 <210> 31 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 25E1B-R
<220>
<221> misc feature <222> (1) ..(26) <400> 31 caagcctcca tggggtcaga tgtaac 26 <210> 32 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <220>
<221> misc feature <222> (1) .. (21) <400> 32 gagcgaagaa acccatctga g 21 <210> 33 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <220>
<221> misc feature <222> (1)._(19) <400> 33 ggtccaggcc ggctctcgg 19 <210> 34 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 62155F
<220>
<221> misc_feature <222> (1) (18) <400> 34 ccgagagccg gcctggac 18 <210> 35 <211> 38 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <220>
<221> misc feature <222> (1) ._ (38) <400> 35 gctctagacc tgcaggttag tcagtttctt ctccactg 38 <210> 36 <211> 43 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer Bsp-R
<220>
<221> misc feature <222> (1) _(43) <400> 36 gctctagacc tgcagggtag caacaattcc ggatatttac aag 43 <210> 37 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence:
oligonucleotide C2SPA-1 <220>
<221> mist feature <222> (1) .^(69) <400> 37 ccctgcaggg acttgactca tgcttgtttc actttcacat ggaatttccc agttatgaaa 60 ttaataaag 69 <210> 38 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence:
oligonucleotide C2SPA-2 <220>
<221> misc feature <222> (1) ._(69) <400> 38 gtctagacac acaaaaaacc aacacactat tgcaatgaaa ataaatttcc tttattaatt 60 tcataactg 69 <210> 39 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer C2for <220>
<221> misc feature <222> (1) ._ (24) <400> 39 cgggatcccc tgcagggact tgac 24 <210> 40 <211> 31 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer SPArev <220>
<221> misc feature <222> (1)._(31) <400> 40 ttgcgactta agtctagaca cacaaaaaac c 31 <210> 41 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 2155F
<220>
<221> misc feature <222> (1) ._(19) <400> 41 ccgagagccg gcctggacc 19 <210> 42 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 35E3for <220>
<221> mist feature <222> (1) .. (20) <400> 42 aatgactaat gcaggtgcgc 20 <210> 43 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer 35E3rev <220>
<221> misc feature <222> (1) ._ (28) <400> 43 cgacgcgttg tagtcgttga gcttctag 28 <210> 44 <211> 34794 <212> DNA
<213> adenoviridae <220>
<221> misc feature <222> (1) ._(34794) <223> /note="Nucleic acid sequence of Ad 35"
<400> 44 catcatcaat aatatacctt atagatggaa tggtgccaat atgtaaatga ggtgatttta 60 aaaagtgtgg gccgtgtggt gattggctgt ggggttaacg gttaaaaggg gcggcgcggc 120 cgtgggaaaa tgacgtttta tgggggtgga gtttttttgc aagttgtcgc gggaaatgtt 180 acgcataaaa aggcttcttt tctcacggaa ctacttagtt ttcccacggt atttaacagg 240 aaatgaggta gttttgaccg gatgcaagtg aaaattgctg attttcgcgc gaaaactgaa 300 tgaggaagtg tttttctgaa taatgtggta tttatggcag ggtggagtat ttgttcaggg 360 ccaggtagac tttgacccat tacgtggagg tttcgattac cgtgtttttt acctgaattt 420 ccgcgtaccg tgtcaaagtc ttctgttttt acgtaggtgt cagctgatcg ctagggtatt 480 tatacctcag ggtttgtgtc aagaggccac tcttgagtgc cagcgagaag agttttctcc 540 tctgcgccgg cagtttaata ataaaaaaat gagagatttg cgatttctgc ctcaggaaat 600 aatctctgct gagactggaa atgaaatatt ggagcttgtg gtgcacgccc tgatgggaga 660 cgatccggag ccacctgtgc agctttttga gcctcctacg cttcaggaac tgtatgattt 720 agaggtagag ggatcggagg attctaatga ggaagctgtg aatggctttt ttaccgattc 780 tatgctttta gctgctaatg aaggattaga attagatccg cctttggaca ctttcaatac 840 tccaggggtg attgtggaaa gcggtacagg tgtaagaaaa ttacctgatt tgagttccgt 900 ggactgtgat ttgcactgct atgaagacgg gtttcctccg agtgatgagg aggaccatga 960 aaaggagcag tccatgcaga ctgcagcggg tgagggagtg aaggctgcca atgttggttt 1020 tcagttggat tgcccggagc ttcctggaca tggctgtaag tcttgtgaat ttcacaggaa 1080 aaatactgga gtaaaggaac tgttatgttc gctttgttat atgagaacgc actgccactt 1140 tatttacagt aagtgtgttt aagttaaaat t.taaaggaat atgctgtttt tcacatgtat 1200 attgagtgtg agttttgtgc ttcttattat aggtcctgtg tctgatgctg atgaatcacc 1260 atctcctgat tctactacct cacctcctga tattcaagca cctgttcctg tggacgtgcg 1320 caagcccatt cctgtgaagc ttaagcctgg gaaacgtcca gcagtggaga aacttgagga 1380 cttgttacag ggtggggacg gacctttgga cttgagtaca cggaaacgtc caagacaata 1440 agtgttccat atccgtgttt acttaaggtg acgtcaatat ttgtgtgaga gtgcaatgta 1500 ataaaaatat gttaactgtt cactggtttt tattgctttt tgggcgggga ctcaggtata 1560 taagtagaag cagacctgtg tggttagctc ataggagctg gctttcatcc atggaggttt 1620 gggccatttt ggaagacctt aggaagacta ggcaactgtt agagagcgct tcggacggag 1680 tctccggttt ttggagattc tggttcgcta gtgaattagc tagggtagtt tttaggataa 1740 aacaggacta taaacaagaa tttgaaaagt tgttggtaga ttgcccagga ctttttgaag 1800 ctcttaattt gggccatcag gttcacttta aagaaaaagt tttatcagtt ttagactttt 1860 caaccccagg tagaactgct gctgctgtgg cttttcttac ttttatatta gataaatgga 1920 tcccgcagac tcatttcagc aggggatacg ttttggattt catagccaca gcattgtgga 1980 gaacatggaa ggttcgcaag atgaggacaa tcttaggtta ctggccagtg cagcctttgg 2040 gtgtagcggg aatcctgagg catccaccgg tcatgccagc ggttctggag gaggaacagc 2100 aagaggacaa cccgagagcc ggcctggacc ctccagtgga ggaggcggag tagctgactt 2160 gtctcctgaa ctgcaacggg tgcttactgg atctacgtcc actggacggg ataggggcgt 2220 taagagggag agggcatcca gtggtactga tgctagatct gagttggctt taagtttaat 2280 gagtcgcaga cgtcctgaaa ccatttggtg gcatgaggtt cagaaagagg gaagggatga 2340 agtttctgta ttgcaggaga aatattcact ggaacaggtg aaaacatgtt ggttggagcc 2400 agaggatgat tgggcggtgg ccattaaaaa ttatgccaag atagctttga ggcctgataa 2460 acagtataag atcagtagac ggattaatat ccggaatgct tgttacatat ctggaaatgg 2520 ggctgaggtg gtaatagata ctcaagacaa gacagttatt agatgctgca tgatggatat 2580 gtggcctgga gtagtcggta tggaagcagt cacttttgta aatgttaagt ttaggggaga 2640 tggttataat ggaatagtgt ttatggccaa taccaaactt atattgcatg gttgtagctt 2700 ttttggtttc aacaatacct gtgtagatgc ctggggacag gttagtgtac gggggtgtag 2760 tttctatgcg tgttggattg ccacagctgg cagaaccaag agtcaattgt ctctgaagaa 2820 atgcatattc caaagatgta acctgggcat tctgaatgaa ggcgaagcaa gggtccgtca 2880 ctgcgcttct acagatactg gatgttttat tttaattaag ggaaatgcca gcgtaaagca 2940 taacatgatt tgtggtgctt ccgatgagag gccttatcaa atgctcactt gtgctggtgg 3000 gcattgtaat atgctggcta ctgtgcatat tgtttcccat caacgcaaaa aatggcctgt 3060 ttttgatcac aatgtgttga ccaagtgcac catgcatgca ggtgggcgta gaggaatgtt 3120 tatgccttac cagtgtaaca tgaatcatgt gaaagtgttg ttggaaccag atgccttttc 3180 cagaatgagc ctaacaggaa tctttgacat gaacacgcaa atctggaaga tcctgaggta 3240 tgatgatacg agatcgaggg tgcgcgcatg cgaatgcgga ggcaagcatg ccaggttcca 3300 gccggtgtgt gtagatgtga ccgaagatct cagaccggat catttggtta ttgcccgcac 3360 tggagcagag ttcggatcca gtggagaaga aactgactaa ggtgagtatt gggaaaactt 3420 tggggtggga ttttcagatg gacagattga gtaaaaattt gttttttctg tcttgcagct 3480 gacatgagtg gaaatgcttc ttttaagggg ggagtcttca gcccttatct gacagggcgt 3540 ctcccatcct gggcaggagt tcgtcagaat gttatgggat ctactgtgga tggaagaccc 3600 gttcaacccg ccaattcttc aacgctgacc tatgctactt taagttcttc acctttggac 3660 gcagctgcag ccgctgccgc cgcctctgtc gccgctaaca ctgtgcttgg aatgggttac 3720 tatggaagca tcgtggctaa ttccacttcc tctaataacc cttctacact gactcaggac 3780 aagttacttg tccttttggc ccagctggag gctttgaccc aacgtctggg tgaactttct 3840 cagcaggtgg ccgagttgcg agtacaaact gagtctgctg tcggcacggc aaagtctaaa 3900 taaaaaaaat tccagaatca atgaataaat aaacgagctt gttgttgatt taaaatcaag 3960 tgtttttatt tcatttttcg cgcacggtat gccctggacc accgatctcg atcattgaga 4020 actcggtgga ttttttccag aatcctatag aggtgggatt gaatgtttag atacatgggc 4080 attaggccgt ctttggggtg gagatagctc cattgaaggg attcatgctc cggggtagtg 4140 ttgtaaatca cccagtcata acaaggtcgc agtgcatggt gttgcacaat atcttttaga 4200 agtaggctga ttgccacaga taagcccttg gtgtaggtgt ttacaaaccg gttgagctgg 4260 gaggggtgca ttcgaggtga aattatgtgc attttggatt ggatttttaa gttggcaata 4320 ttgccgccaa gatcccgtct tgggttcatg ttatgaagga ctaccaagac ggtgtatccg 4380 gtacatttag gaaatttatc gtgcagcttg gatggaaaag cgtggaaaaa tttggagaca 4440 cccttgtgtc ctccgagatt ttccatgcac tcatccatga taatagcaat ggggccgtgg 4500 gcagcggcgc gggcaaacac gttccgtggg tctgacacat catagttatg ttcctgagtt 4560 aaatcatcat aagccatttt aatgaatttg gggcggagcg taccagattg gggtatgaat 4620 gttccttcgg gccccggagc atagttcccc tcacagattt gcatttccca agctttcagt 4680 tctgagggtg gaatcatgtc cacctggggg gctatgaaga acaccgtttc gggggcgggg 4740 gtgattagtt gggatgatag caagtttctg agcaattgag atttgccaca tccggtgggg 4800 ccataaataa ttccgattac aggttgcagg tggtagttta gggaacggca actgccgtct 4860 tctcgaagca agggggccac ctcgttcatc atttccctta catgcatatt ttcccgcacc 4920 aaatccatta ggaggcgctc tcctcctagt gatagaagtt cttgtagtga ggaaaagttt 4980 ttcagcggtt ttagaccgtc agccatgggc attttggaaa gagtttgctg caaaagttct 5040 agtctgttcc acagttcagt gatgtgttct atggcatctc gatccagcag acctcctcgt 5100 ttcgcgggtt tggacggctc ctggagtagg gtatgagacg atgggcgtcc agcgctgcca 5160 gggttcggtc cttccagggt ctcagtgttc gagtcagggt tgtttccgtc acagtgaagg 5220 ggtgtgcgcc tgcttgggcg cttgccaggg tgcgcttcag actcattctg ctggtggaga 5280 acttctgtcg cttggcgccc tgtatgtcgg ccaagtagca gtttaccatg agttcgtagt 5340 tgagcgcctc ggctgcgtgg cctttggcgc ggagcttacc tttggaagtt ttcttgcata 5400 ccgggcagta taggcatttc agcgcataca gcttgggcgc aaggaaaatg gattctgggg 5460 agtatgcatc cgcgccgcag gaggcgcaaa cagtttcaca ttccaccagc caggttaaat 5520 ccggttcatt ggggtcaaaa acaagttttc cgccatattt tttgatgcgt ttcttacctt 5580 tggtctccat aagttcgtgt cctcgttgag tgacaaacag gctgtccgta tctccgtaga 5640 ctgattttac aggcctcttc tccagtggag tgcctcggtc ttcttcgtac aggaactctg 5700 accactctga tacaaaggcg cgcgtccagg ccagcacaaa ggaggctatg tgggaggggt 5760 agcgatcgtt gtcaaccagg gggtccacct tttccaaagt atgcaaacac atgtcaccct 5820 cttcaacatc caggaatgtg attggcttgt aggtgtattt cacgtgacct ggggtccccg 5880 ctgggggggt ataaaagggg gcggttcttt gctcttcctc actgtcttcc ggatcgctgt 5940 ccaggaacgt cagctgttgg ggtaggtatt ccctctcgaa ggcgggcatg acctctgcac 6000 tcaggttgtc attttttaag aacgaggagg atttgatatt gacagtgccg gttgagatgc 6060 ctttcatgag gttttcgtcc atttggtcag aaaacacaat ttttttattg tcaagtttgg 6120 tggcaaatga tccatacagg gcgttggata aaagtttggc aatggatcgc atggtttggt 6180 tcttttcctt gtccgcgcgc tctttggcgg cgatgttgag ttggacatac tcgcgtgcca 6240 ggcacttcca ttcggggaag atagttgtta attcatctgg cacgattctc acttgccacc 6300 ctcgattatg caaggtaatt aaatccacac tggtggccac ctcgcctcga aggggttcat 6360 tggtccaaca gagcctacct cctttcctag aacagaaagg gggaagtggg tctagcataa 6420 gttcatcggg agggtctgca tccatggtaa agattcccgg aagtaaatcc ttatcaaaat 6480 agctgatggg agtggggtca tctaaggcca tttgccattc tcgagctgcc agtgcgcgct 6540 catatgggtt aaggggactg ccccagggca tgggatgggt gagagcagag gcatacatgc 6600 cacagatgtc atagacgtag atgggatcct caaagatgcc tatgtaggtt ggatagcatc 6660 gcccccctct gatacttgct cgcacatagt catatagttc atgtgatggc gctagcagcc 6720 ccggacccaa gttggtgcga ttgggttttt ctgttctgta gacgatctgg cgaaagatgg 6780 cgtgagaatt ggaagagatg gtgggtcttt gaaaaatgtt gaaatgggca tgaggtagac 6840 ctacagagtc tctgacaaag tgggcataag attcttgaag cttggttacc agttcggcgg 6900 tgacaagtac gtctagggcg cagtagtcaa gtgtttcttg aatgatgtca taacctggtt 6960 ggtttttctt ttcccacagt tcgcggttga gaaggtattc ttccagatcc ttccagtact 7020 cttctagcgg aaacccgtct ttgtctgcac ggtaagatcc tagcatgtag aactgattaa 7080 ctgccttgta agggcagcag cccttctcta cgggtagaga gtatgcttga gcagcttttc 7140 gtagcgaagc gtgagtaagg gcaaaggtgt ctctgaccat gactttgaga aattggtatt 7200 tgaagtccat gtcgtcacag gctccctgtt cccagagttg gaagtctacc cgtttcttgt 7260 aggcggggtt gggcaaagcg aaagtaacat cattgaagag aatcttaccg gctctgggca 7320 taaaattgcg agtgatgcgg aaaggctgtg gtacttccgc tcgattgttg atcacctggg 7380 cagctaggac gatttcgtcg aaaccgttga tgttgtgtcc tacgatgtat aattctatga 7440 aacgcggcgt gcctctgacg tgaggtagct taccgagctc atcaaaggtt aggtctgtgg 7500 ggtcagataa ggcgtagtgt tcgagagccc attcgtgcag gtgaggattt gcatgtagga 7560 atgatgacca aagatctacc gccagtgctg tttgtaactg gtcccgatac tgacgaaaat 7620 gccggccaat tgccattttt tctggagtga cacagtagaa ggttctgggg tcttgttgcc 7680 atcgatccca cttgagttta atggctagat cgtgggccat gttgacgaga cgctcttctc 7740=
ctgagagttt catgaccagc atgaaaggaa ctagttgttt gccaaaggat cccatccagg 7800 tgtaagtttc cacatcgtag gtcaggaaga gtctttctgt gcgaggatga gagccgatcg 7860 ggaagaactg gatttcctgc caccagttgg aggattggct gttgatgtga tggaagtaga 7920 agtttctgcg gcgcgccgag cattcgtgtt tgtgcttgta cagacggccg cagtagtcgc 7980 agcgttgcac gggttgtatc tcgtgaatga gctgtacctg gcttcccttg acgagaaatt 8040 tcagtgggaa gccgaggcct ggcgattgta tctcgtgctc ttctatattc gctgtatcgg 8100 cctgttcatc ttctgtttcg atggtggtca tgctgacgag cccccgcggg aggcaagtcc 8160 agacctcggc gcgggagggg cggagctgaa ggacgagagc gcgcaggctg gagctgtcca 8220 gagtcctgag acgctgcgga ctcaggttag taggtaggga cagaagatta acttgcatga 8280 tcttttccag ggcgtgcggg aggttcagat ggtacttgat ttccacaggt tcgtttgtag 8340 agacgtcaat ggcttgcagg gttccgtgtc ctttgggcgc cactaccgta cctttgtttt 8400 ttctttttat cggtggtggc tctcttgctt cttgcatgct cagaagcggt gacggggacg 8460 cgcgccgggc ggcagctgtt gttccggacc cgggggcatg gctggtagtg gcacgtcggc 8520 gccgcgcacg ggcaggttct ggtattgcgc tctgagaaga cttgcgtgcg ccaccacgcg 8580 tcgattgacg tcttgtatct gacgtctctg ggtgaaagct accggccccg tgagcttgaa 8640 cctgaaagag agttcaacag aatcaatttc ggtatcgtta acggcagctt gtctcagtat 8700 ttcttgtacg tcaccagagt tgtcctggta ggcgatctcc gccatgaact gctcgatttc 8760 ttcctcctga agatctccgc gacccgctct ttcgacggtg gccgcgaggt cattggagat 8820 acggcccatg agttgggaga atgcattcat gcccgcctcg ttccagacgc ggctgtaaac 8880 cacggccccc tcggagtctc ttgcgcgcat caccacctga gcgaggttaa gctccacgtg 8940 tctggtgaag accgcatagt tgcataggcg ctgaaaaagg tagttgagtg tggtggcaat 9000 gtgttcggcg acgaagaaat acatgatcca tcgtctcagc ggcatttcgc taacatcgcc 9060 cagagcttcc aagcgctcca tggcctcgta gaagtccacg gcaaaattaa aaaactggga 9120 gtttcgcgcg gacacggtca attcctcctc gagaagacgg atgagttcgg ctatggtggc 9180 ccgtacttcg cgttcgaagg ctcccgggat ctcttcttcc tcttctatct cttcttccac 9240 taacatctct tcttcgtctt caggcggggg cggagggggc acgcggcgac gtcgacggcg 9300 cacgggcaaa cggtcgatga atcgttcaat gacctctccg cggcggcggc gcatggtttc 9360 agtgacggcg cggccgttct cgcgcggtcg cagagtaaaa acaccgccgc gcatctcctt 9420 aaagtggtga ctgggaggtt ctccgtttgg gagggagagg gcgctgatta tacattttat 9480 taattggccc gtagggactg cgcgcagaga tctgatcgtg tcaagatcca cgggatctga 9540 aaacctttcg acgaaagcgt ctaaccagtc acagtcacaa ggtaggctga gtacggcctc 9600 ttgtgggcgg gggtggttat gtgttcggtc tgggtcttct gtttcttctt catctcggga 9660 aggtgagacg atgctgctgg tgatgaaatt aaagtaggca gttctaagac ggcggatggt 9720 ggcgaggagc accaggtctt tgggtccggc ttgctggata cgcaggcgat tggccattcc 9780 ccaagcatta tcctgacatc tagcaagatc tttgtagtag tcttgcatga gccgttctac 9840 gggcacttct tcctcacccg ttctgccatg catacgtgtg agtccaaatc cgcgcattgg 9900 ttgtaccagt gccaagtcag ctacgactct ttcggcgagg atggcttgct gtacttgggt 9960 aagggtggct tgaaagtcat caaaatccac aaagcggtgg taagcccctg tattaatggt 10020 gtaagcacag ttggccatga ctgaccagtt aactgtctgg tgaccagggc gcacgagctc 10080 ggtgtattta aggcgcgaat aggcgcgggt gtcaaagatg taatcgttgc aggtgcgcac 10140 cagatactgg taccctataa gaaaatgcgg cggtggttgg cggtagagag gccatcgttc 10200 tgtagctgga gcgccagggg cgaggtcttc caacataagg cggtgatagc cgtagatgta 10260 cctggacatc caggtgattc ctgcggcggt agtagaagcc cgaggaaact cgcgtacgcg 10320 gttccaaatg ttgcgtagcg gcatgaagta gttcattgta ggcacggttt gaccagtgag 10380 gcgcgcgcag tcattgatgc tctatagaca cggagaaaat gaaagcgttc agcgactcga 10440 ctccgtagcc tggaggaacg tgaacgggtt gggtcgcggt gtaccccggt tcgagacttg 10500 tactcgagcc ggccggagcc gcggctaacg tggtattggc actcccgtct cgacccagcc 10560 tacaaaaatc caggatacgg aatcgagtcg ttttgctggt ttccgaatgg cagggaagtg 10620 agtcctattt tttttttttt tttgccgctc agatgcatcc cgtgctgcga cagatgcgcc 10680 cccaacaaca gcccccctcg cagcagcagc agcagcaacc acaaaaggct gtccctgcaa 10740 ctactgcaac tgccgccgtg agcggtgcgg gacagcccgc ctatgatctg gacttggaag 10800 agggcgaagg actggcacgt ctaggtgcgc cttcgcccga gcggcatccg cgagttcaac 10860 tgaaaaaaga ttctcgcgag gcgtatgtgc cccaacagaa cctatttaga gacagaagcg 10920 gcgaggagcc ggaggagatg cgagcttccc gctttaacgc gggtcgtgag ctgcgtcacg 10980 gtttggaccg aagacgagtg ttgcgagacg aggatttcga agttgatgaa gtgacaggga 11040 tcagtcctgc cagggcacac gtggctgcag ccaaccttgt atcggcttac gagcagacag 11100 taaaggaaga gcgtaacttc caaaagtctt ttaataatca tgtgcgaacc ctgattgccc 11160 gcgaagaagt tacccttggt ttgatgcatt tgtgggattt gatggaagct atcattcaga 11220 accctactag caaacctctg accgcccagc tgtttctggt ggtgcaacac agcagagaca 11280 atgaggcttt cagagaggcg ctgctgaaca tcaccgaacc cgaggggaga tggttgtatg 11340 atcttatcaa cattctacag agtatcatag tgcaggagcg gagcctgggc ctggccgaga 11400 aggtagctgc catcaattac tcggttttga gcttgggaaa atattacgct cgcaaaatct 11460 acaagactcc atacgttccc atagacaagg aggtgaagat agatgggttc tacatgcgca 11520 tgacgctcaa ggtcttgacc ctgagcgatg atcttggggt gtatcgcaat gacagaatgc 11580 atcgcgcggt tagcgccagc aggaggcgcg agttaagcga cagggaactg atgcacagtt 11640 tgcaaagagc tctgactgga gctggaaccg agggtgagaa ttacttcgac atgggagctg 11700 acttgcagtg gcagcctagt cgcagggctc tgagcgccgc gacggcagga tgtgagcttc 11760 cttacataga agaggcggat gaaggcgagg aggaagaggg cgagtacttg gaagactgat 11820 ggcacaaccc gtgttttttg ctagatggaa cagcaagcac cggatcccgc aatgcgggcg 11880 gcgctgcaga gccagccgtc cggcattaac tcctcggacg attggaccca ggccatgcaa 11940 cgtatcatgg cgttgacgac tcgcaacccc gaagccttta gacagcaacc ccaggccaac 12000 cgtctatcgg ccatcatgga agctgtagtg ccttcccgat ctaatcccac tcatgagaag 12060 gtcctggcca tcgtgaacgc gttggtggag aacaaagcta ttcgtccata tgaggccgga 12120 ctggtataca acgctctctt agaacgcgtg gctcgctaca acagtagcaa tgtgcaaacc 12180 aatttggacc gtatgataac agatgtacgc gaagccgtgt ctcagcgcga aaggttccag 12240 cgtgatgcca acctgggttc gctggtggcg ttaaatgctt tcttgagtac tcagcctgct 12300 aatgtgccgc gtggtcaaca ggattatact aactttttaa gtgctttgag actgatggta 12360 tcagaagtac ctcagagcga agtgtatcag tccggtcctg attacttctt tcagactagc 12420 agacagggct tgcagacggt aaatctgagc caagctttta aaaaccttaa aggtttgtgg 12480 ggagtgcatg ccccggtagg agaaagagca accgtgtcta gcttgttaac tccgaactcc 12540 cgcctgttat tactgttggt agctcctttc accgacagcg gtagcatcga ccgtaattcc 12600 tatttgggtt acctactaaa cctgtatcgc gaagccatag ggcaaagtca ggtggacgag 12660 cagacctatc aagaaattac ccaagtcagt cgcgctttgg gacaggaaga cactggcagt 12720 ttggaagcca ctctgaactt cttgcttacc aatcggtctc aaaagatccc tcctcaatat 12780 gctcttactg cggaggagga gaggatcctt agatatgtgc agcagagcgt gggattgttt 12840 ctgatgcaag agggggcaac tccgactgca gcactggaca tgacagcgcg aaatatggag 12900 cccagcatgt atgccagtaa ccgacctttc attaacaaac tgctggacta cttgcacaga 12960 gctgccgcta tgaactctga ttatttcacc aatgccatct taaacccgca ctggctgccc 13020 ccacctggtt tctacacggg cgaatatgac atgcccgacc ctaatgacgg atttctgtgg 13080 gacgacgtgg acagcgatgt tttttcacct ctttctgatc atcgcacgtg gaaaaaggaa 13140 ggcggtgata gaatgcattc ttctgcatcg ctgtccgggg tcatgggtgc taccgcggct 13200 gagcccgagt ctgcaagtcc ttttcctagt ctaccctttt ctctacacag tgtacgtagc 13260 agcgaagtgg gtagaataag tcgcccgagt ttaatgggcg aagaggagta cctaaacgat 13320 tccttgctca gaccggcaag agaaaaaaat ttcccaaaca atggaataga aagtttggtg 13380 gataaaatga gtagatggaa gacttatgct caggatcaca gagacgagcc tgggatcatg 13440 gggactacaa gtagagcgag ccgtagacgc cagcgccatg acagacagag gggtcttgtg 13500 tgggacgatg aggattcggc cgatgatagc agcgtgttgg acttgggtgg gagaggaagg 13560 ggcaacccgt ttgctcattt gcgccctcgc ttgggtggta tgttgtgaaa aaaaataaaa 13620 aagaaaaact cagcaaggcc atggcgacga gcgtacgttc gttcttcttt attatctgtg 13680 tctagtataa tgaggcgagt cgtgctaggc ggagcggtgg tgtatccgga gggtcctcct 13740 ccttcgtacg agagcgtgat gcagcagcag caggcgacgg cggtgatgca atccccactg 13800 gaggctccct ttgtgcctcc gcgatacctg gcacctacgg agggcagaaa cagcattcgt 13860 tactcggaac tggcacctca gtacgatacc accaggttgt atctggtgga caacaagtcg 13920 gcggacattg cttctctgaa ctatcagaat gaccacagca acttcttgac cacggtggtg 13980 cagaacaatg actttacccc tacggaagcc agcacccaga ccattaactt tgatgaacga 14040 tcgcggtggg gcggtcagct aaagaccatc atgcatacta acatgccaaa cgtgaacgag 14100 tatatgttta gtaacaagtt caaagcgcgt gtgatggtgt ccagaaaacc tcccgacggt 14160 gctgcagttg gggatactta tgatcacaag caggatattt tggaatatga gtggttcgag 14220 tttactttgc cagaaggcaa cttttcagtt actatgacta ttgatttgat gaacaatgcc 14280 atcatagata attacttgaa agtgggtaga cagaatggag tgcttgaaag tgacattggt 14340 gttaagttcg acaccaggaa cttcaagctg ggatgggatc ccgaaaccaa gttgatcatg 14400 cctggagtgt atacgtatga agccttccat cctgacattg tcttactgcc tggctgcgga 14460 gtggatttta ccgagagtcg tttgagcaac cttcttggta tcagaaaaaa acagccattt 14520 caagagggtt ttaagatttt gtatgaagat ttagaaggtg gtaatattcc ggccctcttg 14580 gatgtagatg cctatgagaa cagtaagaaa gaacaaaaag ccaaaataga agctgctaca 14640 gctgctgcag aagctaaggc aaacatagtt gccagcgact ctacaagggt tgctaacgct 14700 ggagaggtca gaggagacaa ttttgcgcca acacctgttc cgactgcaga atcattattg 14760 gccgatgtgt ctgaaggaac ggacgtgaaa ctcactattc aacctgtaga aaaagatagt 14820 aagaatagaa gctataatgt gttggaagac aaaatcaaca cagcctatcg cagttggtat 14880 ctttcgtaca attatggcga tcccgaaaaa ggagtgcgtt cctggacatt gctcaccacc 14940 tcagatgtca cctgcggagc agagcaggtt tactggttgc ttccagacat gatgaaggat 15000 cctgtcactt tccgctccac tagacaagtc agtaactacc ctgtggtggg tgcagagctt 15060 atgcccgtct tctcaaagag cttctacaac gaacaagctg tgtactccca gcagctccgc 15120 cagtccacct cgcttacgca cgtcttcaac cgctttcctg agaaccagat tttaatccgt 15180 ccgccggcgc ccaccattac caccgtcagt gaaaacgttc ctgctctcac agatcacggg 15240 accctgccgt tgcgcagcag tatccgggga gtccaacgtg tgaccgttac tgacgccaga 15300 cgccgcacct gtccctacgt gtacaaggca ctgggcatag tcgcaccgcg cgtcctttca 15360 agccgcactt tctaaaaaaa aaaaatgtcc attcttatct cgcccagtaa taacaccggt 15420 tggggtctgc gcgctccaag caagatgtac ggaggcgcac gcaaacgttc tacccaacat 15480 cccgtgcgtg ttcgcggaca ttttcgcgct ccatggggtg ccctcaaggg ccgcactcgc 15540 gttcgaacca ccgtcgatga tgtaatcgat caggtggttg ccgacgcccg taattatact 15600 cctactgcgc ctacatctac tgtggatgca gttattgaca gtgtagtggc tgacgctcgc 15660 aactatgctc gacgtaagag ccggcgaagg cgcattgcca gacgccaccg agctaccact 15720 gccatgcgag ccgcaagagc tctgctacga agagctagac gcgtggggcg aagagccatg 15780 cttagggcgg ccagacgtgc agcttcgggc gccagcgccg gcaggtcccg caggcaagca 15840 gccgctgtcg cagcggcgac tattgccgac atggcccaat cgcgaagagg caatgtatac 15900 tgggtgcgtg acgctgccac cggtcaacgt gtacccgtgc gcacccgtcc ccctcgcact 15960 tagaagatac tgagcagtct ccgatgttgt gtcccagcgg cgaggatgtc caagcgcaaa 16020 tacaaggaag aaatgctgca ggttatcgca cctgaagtct acggccaacc gttgaaggat 16080 gaaaaaaaac cccgcaaaat caagcgggtt aaaaaggaca aaaaagaaga ggaagatggc 16140 gatgatgggc tggcggagtt tgtgcgcgag tttgccccac ggcgacgcgt gcaatggcgt 16200 gggcgcaaag ttcgacatgt gttgagacct ggaacttcgg tggtctttac acccggcgag 16260 cgttcaagcg ctacttttaa gcgttcctat gatgaggtgt acggggatga tgatattctt 16320 gagcaggcgg ctgaccgatt aggcgagttt gcttatggca agcgtagtag aataacttcc 16380 aaggatgaga cagtgtcaat acccttggat catggaaatc ccacccctag tcttaaaccg 16440 gtcactttgc agcaagtgtt acccgtaact ccgcgaacag gtgttaaacg cgaaggtgaa 16500 gatttgtatc ccactatgca actgatggta cccaaacgcc agaagttgga ggacgttttg 16560 gagaaagtaa aagtggatcc agatattcaa cctgaggtta aagtgagacc cattaagcag 16620 gtagcgcctg gtctgggggt acaaactgta gacattaaga ttcccactga aagtatggaa 16680 gtgcaaactg aacccgcaaa gcctactgcc acctccactg aagtgcaaac ggatccatgg 16740 atgcccatgc ctattacaac tgacgccgcc ggtcccactc gaagatcccg acgaaagtac 16800 ggtccagcaa gtctgttgat gcccaattat gttgtacacc catctattat tcctactcct 16860 ggttaccgag gcactcgcta ctatcgcagc cgaaacagta cctcccgccg tcgccgcaag 16920 acacctgcaa atcgcagtcg tcgccgtaga cgcacaagca aaccgactcc cggcgccctg 16980 gtgcggcaag tgtaccgcaa tggtagtgcg gaacctttga cactgccgcg tgcgcgttac 17040 catccgagta tcatcactta atcaatgttg ccgctgcctc cttgcagata tggccctcac 17100 ttgtcgcctt cgcgttccca tcactggtta ccgaggaaga aactcgcgcc gtagaagagg 17160 gatgttggga cgcggaatgc gacgctacag gcgacggcgt gctatccgca agcaattgcg 17220 gggtggtttt ttaccagcct taattccaat tatcgctgct gcaattggcg cgataccagg 17280 catagcttcc gtggcggttc aggcctcgca acgacattga cattggaaaa aaaacgtata 17340 aataaaaaaa aatacaatgg actctgacac tcctggtcct gtgactatgt tttcttagag 17400 atggaagaca tcaatttttc atccttggct ccgcgacacg gcacgaagcc gtacatgggc 17460 acctggagcg acatcggcac gagccaactg aacgggggcg ccttcaattg gagcagtatc 17520 tggagcgggc ttaaaaattt tggctcaacc ataaaaacat acgggaacaa agcttggaac 17580 agcagtacag gacaggcgct tagaaataaa cttaaagacc agaacttcca acaaaaagta 17640 gtcgatggga tagcttccgg catcaatgga gtggtagatt tggctaacca ggctgtgcag 17700 aaaaagataa acagtcgttt ggacccgccg ccagcaaccc caggtgaaat gcaagtggag 17760 gaagaaattc ctccgccaga aaaacgaggc gacaagcgtc cgcgtcccga tttggaagag 17820 acgctggtga cgcgcgtaga tgaaccgcct tcttatgagg aagcaacgaa gcttggaatg 17880 cccaccacta gaccgatagc cccaatggcc accggggtga tgaaaccttc tcagttgcat 17940 cgacccgtca ccttggattt gccccctccc cctgctgcta ctgctgtacc cgcttctaag 18000 cctgtcgctg ccccgaaacc agtcgccgta gccaggtcac gtcccggggg cgctcctcgt 18060 ccaaatgcgc actggcaaaa tactctgaac agcatcgtgg gtctaggcgt gcaaagtgta 18120 aaacgccgtc gctgctttta attaaatatg gagtagcgct taacttgcct atctgtgtat 18180 atgtgtcatt acacgccgtc acagcagcag aggaaaaaag gaagaggtcg tgcgtcgacg 18240 ctgagttact ttcaagatgg ccaccccatc gatgctgccc caatgggcat acatgcacat 18300 cgccggacag gatgcttcgg agtacctgag tccgggtctg gtgcagttcg cccgcgccac 18360 agacacctac ttcaatctgg gaaataagtt tagaaatccc accgtagcgc cgacccacga 18420 tgtgaccacc gaccgtagcc agcggctcat gttgcgcttc gtgcccgttg accgggagga 18480 caatacatac tcttacaaag tgcggtacac cctggccgtg ggcgacaaca gagtgctgga 18540 tatggccagc acgttctttg acattagggg cgtgttggac agaggtccca gtttcaaacc 18600 ctattctggt acggcttaca actctctggc tcctaaaggc gctccaaatg catctcaatg 18660 gattgcaaaa ggcgtaccaa ctgcagcagc cgcaggcaat ggtgaagaag aacatgaaac 18720 agaggagaaa actgctactt acacttttgc caatgctcct gtaaaagccg aggctcaaat 18780 tacaaaagag ggcttaccaa taggtttgga gatttcagct gaaaacgaat ctaaacccat 18840 ctatgcagat aaactttatc agccagaacc tcaagtggga gatgaaactt ggactgacct 18900 agacggaaaa accgaagagt atggaggcag ggctctaaag cctactacta acatgaaacc 18960 ctgttacggg tcctatgcga agcctactaa tttaaaaggt ggtcaggcaa aaccgaaaaa 19020 ctcggaaccg tcgagtgaaa aaattgaata tgatattgac atggaatttt ttgataactc 19080 atcgcaaaga acaaacttca gtcctaaaat tgtcatgtat gcagaaaatg taggtttgga 19140 aacgccagac actcatgtag tgtacaaacc tggaacagaa gacacaagtt ccgaagctaa 19200 tttgggacaa cagtctatgc ccaacagacc caactacatt ggcttcagag ataactttat 19260 tggactcatg tactataaca gtactggtaa catgggggtg ctggctggtc aagcgtctca 19320 gttaaatgca gtggttgact tgcaggacag aaacacagaa ctttcttacc aactcttgct 19380 tgactctctg ggcgacagaa ccagatactt tagcatgtgg aatcaggctg tggacagtta 19440 tgatcctgat gtacgtgtta ttgaaaatca tggtgtggaa gatgaacttc ccaactattg 19500 ttttccactg gacggcatag gtgttccaac aaccagttac aaatcaatag ttccaaatgg 19560 agaagataat aataattgga aagaacctga agtaaatgga acaagtgaga tcggacaggg 19620 taatttgttt gccatggaaa ttaaccttca agccaatcta tggcgaagtt tcctttattc 19680 caatgtggct ctgtatctcc cagactcgta caaatacacc ccgtccaatg tcactcttcc 19740 agaaaacaaa aacacctacg actacatgaa cgggcgggtg gtgccgccat ctctagtaga 19800 cacctatgtg aacattggtg ccaggtggtc tctggatgcc atggacaatg tcaacccatt 19860 caaccaccac cgtaacgctg gcttgcgtta ccgatctatg cttctgggta acggacgtta 19920 tgtgcctttc cacatacaag tgcctcaaaa attcttcgct gttaaaaacc tgctgcttct 19980 cccaggctcc tacacttatg agtggaactt taggaaggat gtgaacatgg ttctacagag 20040 ttccctcggt aacgacctgc gggtagatgg cgccagcatc agtttcacga gcatcaacct 20100 ctatgctact tttttcccca tggctcacaa caccgcttcc acccttgaag ccatgctgcg 20160 gaatgacacc aatgatcagt cattcaacga ctacctatct gcagctaaca tgctctaccc 20220 cattcctgcc aatgcaacca atattcccat ttccattcct tctcgcaact gggcggcttt 20280 cagaggctgg tcatttacca gactgaaaac caaagaaact ccctctttgg ggtctggatt 20340 tgacccctac tttgtctatt ctggttctat tccctacctg gatggtacct tctacctgaa 20400 ccacactttt aagaaggttt ccatcatgtt tgactcttca gtgagctggc ctggaaatga 20460 caggttacta tctcctaacg aatttgaaat aaagcgcact gtggatggcg aaggctacaa 20520 cgtagcccaa tgcaacatga ccaaagactg gttcttggta cagatgctcg ccaactacaa 20580 catcggctat cagggcttct acattccaga aggatacaaa gatcgcatgt attcattttt 20640 cagaaacttc cagcccatga gcaggcaggt ggttgatgag gtcaattaca aagacttcaa 20700 ggccgtcgcc ataccctacc aacacaacaa ctctggcttt gtgggttaca tggctccgac 20760 catgcgccaa ggtcaaccct atcccgctaa ctatccctat ccactcattg gaacaactgc 20820 cgtaaatagt gttacgcaga aaaagttctt gtgtgacaga accatgtggc gcataccgtt 20880 ctcgagcaac ttcatgtcta tgggggccct tacagacttg ggacagaata tgctctatgc 20940 caactcagct catgctctgg acatgacctt tgaggtggat cccatggatg agcccaccct 21000 gctttatctt ctcttcgaag ttttcgacgt ggtcagagtg catcagccac accgcggcat 21060 catcgaggca gtctacctgc gtacaccgtt ctcggccggt aacgctacca cgtaagaagc 21120 ttcttgcttc ttgcaaatag cagctgcaac catggcctgc ggatcccaaa acggctccag 21180 cgagcaagag ctcagagcca ttgtccaaga cctgggttgc ggaccctatt ttttgggaac 21240 ctacgataag cgcttcccgg ggttcatggc ccccgataag ctcgcctgtg ccattgtaaa 21300 tacggccgga cgtgagacgg ggggagagca ctggttggct ttcggttgga acccacgttc 21360 taacacctgc tacctttttg atccttttgg attctcggat gatcgtctca aacagattta 21420 ccagtttgaa tatgagggtc tcctgcgccg cagcgctctt gctaccaagg accgctgtat 21480 tacgctggaa aaatctaccc agaccgtgca gggcccccgt tctgccgcct gcggactttt 21540 ctgctgcatg ttccttcacg cctttgtgca ctggcctgac cgtcccatgg acggaaaccc 21600 caccatgaaa ttgctaacag gagtgccaaa caacatgctt cattctccta aagtccagcc 21660 caccctgtgt gacaatcaaa aagcactcta ccattttctt aatacccatt cgccttattt 21720 tcgctctcat cgtacacaca tcgaaagggc cactgcgttc gaccgtatgg atgttcaata 21780 atgactcatg taaacaacgt gttcaataaa catcacttta tttttttaca tgtatcaagg 21840 ctctggatta cttatttatt-tacaagtcga atgggttctg acgagaatca gaatgacccg 21900 caggcagtga tacgttgcgg aactgatact tgggttgcca cttgaattcg ggaatcacca 21960 acttgggaac cggtatatcg ggcaggatgt cactccacag ctttctggtc agctgcaaag 22020 ctccaagcag gtcaggagcc gaaatcttga aatcacaatt aggaccagtg ctctgagcgc 22080 gagagttgcg gtacaccgga ttgcagcact gaaacaccat cagcgacgga tgtctcacgc 22140 ttgccagcac ggtgggatct gcaatcatgc ccacatccag atcttcagca ttggcaatgc 22200 tgaacggggt catcttgcag gtctgcctac ccatggcggg cacccaatta ggcttgtggt 22260 tgcaatcgca gtgcaggggg atcagtatca tcttggcctg atcctgtctg attcctggat 22320 acacggctct catgaaagca tcatattgct tgaaagcctg ctgggcttta ctaccctcgg 22380 tataaaacat cccgcaggac ctgctcgaaa actggttagc tgcacagccg gcatcattca 22440 cacagcagcg ggcgtcattg ttggctattt gcaccacact tctgccccag cggttttggg 22500 tgattttggt tcgctcggga ttctccttta aggctcgttg tccgttctcg ctggccacat 22560 ccatctcgat aatctgctcc ttctgaatca taatattgcc atgcaggcac ttcagcttgc 22620 cctcataatc attgcagcca tgaggccaca acgcacagcc tgtacattcc caattatggt 22680 gggcgatctg agaaaaagaa tgtatcattc cctgcagaaa tcttcccatc atcgtgctca 22740 gtgtcttgtg actagtgaaa gttaactgga tgcctcggtg ctcttcgttt acgtactggt 22800 gacagatgcg cttgtattgt tcgtgttgct caggcattag tttaaaacag gttctaagtt 22860 cgttatccag cctgtacttc tccatcagca gacacatcac ttccatgcct ttctcccaag 22920 cagacaccag gggcaagcta atcggattct taacagtgca ggcagcagct cctttagcca 22980 gagggtcatc tttagcgatc ttctcaatgc ttcttttgcc atccttctca acgatgcgca 23040 cgggcgggta gctgaaaccc actgctacaa gttgcgcctc ttctctttct tcttcgctgt 23100 cttgactgat gtcttgcatg gggatatgtt tggtcttcct tggcttcttt ttggggggta 23160 tcggaggagg aggactgtcg ctccgttccg gagacaggga ggattgtgac gtttcgctca 23220 ccattaccaa ctgactgtcg gtagaagaac ctgaccccac acggcgacag gtgtttttct 23280 tcgggggcag aggtggaggc gattgcgaag ggctgcggtc cgacctggaa ggcggatgac 23340 tggcagaacc ccttccgcgt tcgggggtgt gctccctgtg gcggtcgctt aactgatttc 23400 cttcgcggct ggccattgtg ttctcctagg cagagaaaca acagacatgg aaactcagcc 23460 attgctgtca acatcgccac gagtgccatc acatctcgtc ctcagcgacg aggaaaagga 23520 gcagagctta agcattccac cgcccagtcc tgccaccacc tctaccctag aagataagga 23580 ggtcgacgca tctcatgaca tgcagaataa aaaagcgaaa gagtctgaga cagacatcga 23640 gcaagacccg ggctatgtga caccggtgga acacgaggaa gagttgaaac gctttctaga 23700 gagagaggat gaaaactgcc caaaacagcg agcagataac tatcaccaag atgctggaaa 23760 tagggatcag aacaccgact acctcatagg gcttgacggg gaagacgcgc tccttaaaca 23820 tctagcaaga cagtcgctca tagtcaagga tgcattattg gacagaactg aagtgcccat 23880 cagtgtggaa gagctcagct gcgcctacga gcttaacctt ttttcacctc gtactccccc 23940 caaacgtcag ccaaacggca cctgcgagcc aaatcctcgc ttaaactttt atccagcttt 24000 tgctgtgcca gaagtactgg ctacctatca catctttttt aaaaatcaaa aaattccagt 24060 ctcctgccgc gctaatcgca cccgcgccga tgccctactc aatctgggac ctggttcacg 24120 cttacctgat atagcttcct tggaagaggt tccaaagatc ttcgagggtc tgggcaataa 24180 tgagactcgg gccgcaaatg ctctgcaaaa gggagaaaat ggcatggatg agcatcacag 24240 cgttctggtg gaattggaag gcgataatgc cagactcgca gtactcaagc gaagcgtcga 24300 ggtcacacac ttcgcatatc ccgctgtcaa cctgccccct aaagtcatga cggcggtcat 24360 ggaccagtta ctcattaagc gcgcaagtcc cctttcagaa gacatgcatg acccagatgc 24420 ctgtgatgag ggtaaaccag tggtcagtga tgagcagcta acccgatggc tgggcaccga 24480 ctctccccgg gatttggaag agcgtcgcaa gcttatgatg gccgtggtgc tggttaccgt 24540 agaactagag tgtctccgac gtttctttac cgattcagaa accttgcgca aactcgaaga 24600 gaatctgcac tacactttta gacacggctt tgtgcggcag gcatgcaaga tatctaacgt 24660 ggaactcacc aacctggttt cctacatggg tattctgcat gagaatcgcc taggacaaag 24720 cgtgctgcac agcaccctta agggggaagc ccgccgtgat tacatccgcg attgtgtcta 24780 tctctacctg tgccacacgt ggcaaaccgg catgggtgta tggcagcaat gtttagaaga 24840 acagaacttg aaagagcttg acaagctctt acagaaatct cttaaggttc tgtggacagg 24900 gttcgacgag cgcaccgtcg cttccgacct ggcagacctc atcttcccag agcgtctcag 24960 ggttactttg cgaaacggat tgcctgactt tatgagccag agcaccctta acaattttcg 25020 ctctttcatc ctggaacgct ccggtatcct gcccgccacc tgctgcgcac tgccctccga 25080 ctttgtgcct ctcacctacc gcgagtgccc cccgccgcta tggagtcact gctacctgtt 25140 ccgtctggcc aactatctct cctaccactc ggatgtgatc gaggatgtga gcggagacgg 25200 cttgctggag tgccactgcc gctgcaatct gtgcacgccc caccggtccc tagcttgcaa 25260 cccccagttg atgagcgaaa cccagataat aggcaccttt gaattgcaag gccccagcag 25320 ccaaggcgat gggtcttctc ctgggcaaag tttaaaactg accccgggac tgtggacctc 25380 cgcctacttg cgcaagtttg ctccggaaga ttaccacccc tatgaaatca agttctatga 25440 ggaccaatca cagcctccaa aggccgaact ttcggcttgc gtcatcaccc agggggcaat 25500 tctggcccaa ttgcaagcca tccaaaaatc ccgccaagaa tttctactga aaaagggtaa 25560 gggggtctac cttgaccccc agaccggcga ggaactcaac acaaggttcc ctcaggatgt 25620 cccaacgacg agaaaacaag aagttgaagg tgcagccgcc gcccccagaa gatatggagg 25680 aagattggga cagtcaggca gaggaggcgg aggaggacag tctggaggac agtctggagg 25740 aagacagttt ggaggaggaa aacgaggagg cagaggaggt ggaagaagta accgccgaca 25800 aacagttatc ctcggctgcg gagacaagca acagcgctac catctccgct ccgagtcgag 25860 gaacccggcg gcgtcccagc agtagatggg acgagaccgg acgcttcccg aacccaacca 25920 gcgcttccaa gaccggtaag aaggatcggc agggatacaa gtcctggcgg gggcataaga 25980 atgccatcat ctcctgcttg catgagtgcg ggggcaacat atccttcacg cggcgctact 26040 tgctattcca ccatggggtg aactttccgc gcaatgtttt gcattactac cgtcacctcc 26100 acagccccta ctatagccag caaatcccga cagtctcgac agataaagac agcggcggcg 26160 acctccaaca gaaaaccagc agcggcagtt agaaaataca caacaagtgc agcaacagga 26220 ggattaaaga ttacagccaa cgagccagcg caaacccgag agttaagaaa tcggatcttt 26280 ccaaccctgt atgccatctt ccagcagagt cggggtcaag agcaggaact gaaaataaaa 26340 aaccgatctc tgcgttcgct caccagaagt tgtttgtatc acaagagcga agatcaactt 26400 cagcgcactc tcgaggacgc cgaggctctc ttcaacaagt actgcgcgct gactcttaaa 26460 gagtaggcag cgaccgcgct tattcaaaaa aggcgggaat tacatcatcc tcgacatgag 26520 taaagaaatt cccacgcctt acatgtggag ttatcaaccc caaatgggat tggcagcagg 26580 cgcctcccag gactactcca cccgcatgaa ttggctcagc gccgggcctt ctatgatttc 26640 tcgagttaat gatatacgcg cctaccgaaa ccaaatactt ttggaacagt cagctcttac 26700 caccacgccc cgccaacacc ttaatcccag aaattggccc gccgccctag tgtaccagga 26760 aagtcccgct cccaccactg tattacttcc tcgagacgcc caggccgaag tccaaatgac 26820 taatgcaggt gcgcagttag ctggcggctc caccctatgt cgtcacaggc ctcggcataa 26880 tataaaacgc ctgatgatca gaggccgagg tatccagctc aacgacgagt cggtgagctc 26940 tccgcttggt ctacgaccag acggaatctt tcagattgcc ggctgcggga gatcttcctt 27000 cacccctcgt caggctgttc tgactttgga aagttcgtct tcgcaacccc gctcgggcgg 27060 aatcgggacc gttcaatttg tagaggagtt tactccctct gtctacttca accccttctc 27120 cggatctcct gggcactacc cggacgagtt cataccgaac ttcgacgcga ttagcgagtc 27180 agtggacggc tacgattgat gtctggtgac gcggctgagc tatctcggct gcgacatcta 27240 gaccactgcc gccgctttcg ctgctttgcc cgggaactta ttgagttcat ctacttcgaa 27300 ctccccaagg atcaccctca aggtccggcc cacggagtgc ggattactat cgaaggcaaa 27360 atagactctc gcctgcaacg aattttctcc cagcggcccg tgctgatcga gcgagaccag 27420 ggaaacacca cggtttccat ctactgcatt tgtaatcacc ccggattgca tgaaagcctt 27480 tgctgtctta tgtgtactga gtttaataaa aactgaatta agactctcct acggactgcc 27540 gcttcttcaa cccggatttt acaaccagaa gaacaaaact tttcctgtcg tccaggactc 27600 tgttaacttc acctttccta ctcacaaact agaagctcaa cgactacacc gcttttccag 27660 aagcattttc cctactaata ctactttcaa aaccggaggt gagctccacg gtctccctac 27720 agaaaaccct tgggtggaag cgggccttgt agtactagga attcttgcgg gtgggcttgt 27780 gattattctt tgctacctat acacaccttg cttcactttc ctagtggtgt tgtggtattg 27840 gtttaaaaaa tggggcccat actagtcttg cttgttttac tttcgctttt ggaaccgggt 27900 tctgccaatt acgatccatg tctagacttt gacccagaaa actgcacact tacttttgca 27960 cccgacacaa gccgcatctg tggagttctt attaagtgcg gatgggaatg caggtccgtt 28020 gaaattacac acaataacaa aacctggaac aataccttat ccaccacatg ggagccagga 28080 gttcccgagt ggtacactgt ctctgtccga ggtcctgacg gttccatccg cattagtaac 28140 aacactttca ttttttctga aatgtgcgat ctggccatgt tcatgagcaa acagtattct 28200 ctatggcctc ctagcaagga caacatcgta acgttctcca ttgcttattg cttgtgcgct 28260 tgccttctta ctgctttact gtgcgtatgc atacacctgc ttgtaaccac tcgcatcaaa 28320 aacgccaata acaaagaaaa aatgccttaa cctctttctg tttacagaca tggcttctct 28380 tacatctctc atatttgtca gcattgtcac tgccgctcac ggacaaacag tcgtctctat 28440 cccactagga cataattaca ctctcatagg acccccaatc acttcagagg tcatctggac 28500 caaactggga agcgttgatt actttgatat aatctgtaac aaaacaaaac caataatagt 28560 aacttgcaac atacaaaatc ttacattgat taatgttagc aaagtttaca gcggttacta 28620 ttatggttat gacagataca gtagtcaata tagaaattac ttggttcgtg ttacccagtt 28680 gaaaaccacg aaaatgccaa atatggcaaa gattcgatcc gatgacaatt ctctagaaac 28740 ttttacatct cccaccacac ccgacgaaaa aaacatccca gattcaatga ttgcaattgt 28800 tgcagcggtg gcagtggtga tggcactaat aataatatgc atgcttttat atgcttgtcg 28860 ctacaaaaag tttcatccta aaaaacaaga tctcctacta aggcttaaca tttaatttct 28920 ttttatacag ccatggtttc cactaccaca ttccttatgc ttactagtct cgcaactctg 28980 acttctgctc gctcacacct cactgtaact ataggctcaa actgcacact aaaaggacct 29040 caaggtggtc atgtcttttg gtggagaata tatgacaatg gatggtttac aaaaccatgt 29100 gaccaacctg gtagattttt ctgcaacggc agagacctaa ccattatcaa cgtgacagca 29160 aatgacaaag gcttctatta tggaaccgac tataaaagta gtttagatta taacattatt 29220 gtactgccat ctaccactcc agcaccccgc acaactactt tctctagcag cagtgtcgct 29280 aacaatacaa tttccaatcc aacctttgcc gcgcttttaa aacgcactgt gaataattct 29340 acaacttcac atacaacaat ttccacttca acaatcagca tcatcgctgc agtgacaatt 29400 ggaatatcta ttcttgtttt taccataacc tactacgcct gctgctatag aaaagacaaa 29460 cataaaggtg atccattact tagatttgat atttaatttg ttcttttttt ttatttacag 29520 tatggtgaac accaatcatg gtacctagaa atttcttctt caccatactc atctgtgctt 29580 ttaatgtttg cgctactttc acagcagtag ccacagcaac cccagactgt ataggagcat 29640 ttgcttccta tgcacttttt gcttttgtta cttgcatctg cgtatgtagc atagtctgcc 29700 tggttattaa ttttttccaa cttctagact ggatccttgt gcgaattgcc tacctgcgcc 29760 accatcccga ataccgcaac caaaatatcg cggcacttct tagactcatc taaaaccatg 29820 caggctatac taccaatatt tttgcttcta ttgcttccct acgctgtctc aaccccagct 29880 gcctatagta ctccaccaga acaccttaga aaatgcaaat tccaacaacc gtggtcattt 29940 cttgcttgct atcgagaaaa atcagaaatc cccccaaatt taataatgat tgctggaata 30000 attaatataa tctgttgcac cataatttca tttttgatat accccctatt tgattttggc 30060 tggaatgctc ccaatgcaca tgatcatcca caagacccag aggaacacat tcccccacaa 30120 aacatgcaac atccaatagc gctaatagat tacgaaagtg aaccacaacc cccactactc 30180 cctgctatta gttacttcaa cctaaccggc ggagatgact gaaacactca ccacctccaa 30240 ttccgccgag gatctgctcg atatggacgg ccgcgtctca gaacaacgac ttgcccaact 30300 acgcatccgc cagcagcagg aacgcgtggc caaagagctc agagatgtca tccaaattca 30360 ccaatgcaaa aaaggcatat tctgtttggt aaaacaagcc aagatatcct acgagatcac 30420 cgctactgac catcgcctct cttacgaact tggcccccaa cgacaaaaat ttacctgcat 30480 ggtgggaatc aaccccatag ttatcaccca acaaagtgga gatactaagg gttgcattca 30540 ctgctcctgc gattccatcg agtgcaccta caccctgctg aagaccctat gcggcctaag 30600 agacctgcta ccaatgaatt aaaaaaaaat gattaataaa aaatcactta cttgaaatca 30660 gcaataaggt ctctgttgaa attttctccc agcagcacct cacttccctc ttcccaactc 30720 tggtattcta aaccccgttc agcggcatac tttctccata ctttaaaggg gatgtcaaat 30780 tttagctcct ctcctgtacc cacaatcttc atgtctttct tcccagatga ccaagagagt 30840 ccggctcagt gactccttca accctgtcta cccctatgaa gatgaaagca cctcccaaca 30900 cccctttata aacccagggt ttatttcccc aaatggcttc acacaaagcc cagacggagt 30960 tcttacttta aaatgtttaa ccccactaac aaccacaggc ggatctctac agctaaaagt 31020 gggaggggga cttacagtgg atgacactga tggtacctta caagaaaaca tacgtgctac 31080 agcacccatt actaaaaata atcactctgt agaactatcc attggaaatg gattagaaac 31140 tcaaaacaat aaactatgtg ccaaattggg aaatgggtta aaatttaaca acggtgacat 31200 ttgtataaag gatagtatta acaccttatg gactggaata aaccctccac ctaactgtca 31260 aattgtggaa aacactaata caaatgatgg caaacttact ttagtattag taaaaaatgg 31320 agggcttgtt aatggctacg tgtctctagt tggtgtatca gacactgtga accaaatgtt 31380 cacacaaaag acagcaaaca tccaattaag attatatttt gactcttctg gaaatctatt 31440 aactgaggaa tcagacttaa aaattccact taaaaataaa tcttctacag cgaccagtga 31500 aactgtagcc agcagcaaag cctttatgcc aagtactaca gcttatccct tcaacaccac 31560 tactagggat agtgaaaact acattcatgg aatatgttac tacatgacta gttatgatag 31620 aagtctattt cccttgaaca tttctataat gctaaacagc cgtatgattt cttccaatgt 31680 tgcctatgcc atacaatttg aatggaatct aaatgcaagt gaatctccag aaagcaacat 31740 agctacgctg accacatccc cctttttctt ttcttacatt acagaagacg acaactaaaa 31800 taaagtttaa gtgtttttat ttaaaatcac aaaattcgag tagttatttt gcctccacct 31860 tcccatttga cagaatacac caatctctcc ccacgcacag ctttaaacat ttggatacca 31920 ttagagatag acattgtttt agattccaca ttccaaacag tttcagagcg agccaatctg 31980 gggtcagtga tagataaaaa tccatcgcga tagtctttta aagcgctttc acagtccaac 32040 tgctgcggat gcgactccgg agtttggatc acggtcatct ggaagaagaa cgatgggaat 32100 cataatccga aaacggtatc ggacgattgt gtctcatcaa acccacaagc agccgctgtc 32160 tgcgtcgctc cgtgcgactg ctgtttatgg gatcagggtc cacagtttcc tgaagcatga 32220 ttttaatagc ccttaacatc aactttctgg tgcgatgcgc gcagcaacgc attctgattt 32280 cactcaaatc tttgcagtag gtacaacaca ttattacaat attgtttaat aaaccataat 32340 taaaagcgct ccagccaaaa ctcatatctg atataatcgc ccctgcatga ccatcatacc 32400 aaagtttaat ataaattaaa tgacgttccc tcaaaaacac actacccaca tacatgatct 32460 cttttggcat gtgcatatta acaatctgtc tgtaccatgg acaacgttgg ttaatcatgc 32520 aacccaatat aaccttccgg aaccacactg ccaacaccgc tcccccagcc atgcattgaa 32580 gtgaaccctg ctgattacaa tgacaatgaa gaacccaatt ctctcgaccg tgaatcactt 32640 gagaatgaaa aatatctata gtggcacaac atagacataa atgcatgcat cttctcataa 32700 tttttaactc ctcaggattt agaaacatat cccagggaat aggaagctct tgcagaacag 32760 taaagctggc agaacaagga agaccacgaa cacaacttac actatgcata gtcatagtat 32820 cacaatctgg caacagcggg tggtcttcag tcatagaagc tcgggtttca ttttcctcac 32880 aacgtggtaa ctgggctctg gtgtaagggt gatgtctggc gcatgatgtc gagcgtgcgc 32940 gcaaccttgt cataatggag ttgcttcctg acattctcgt attttgtata gcaaaacgcg 33000 gccctggcag aacacactct tcttcgcctt ctatcctgcc gcttagcgtg ttccgtgtga 33060 tagttcaagt acagccacac tcttaagttg gtcaaaagaa tgctggcttc agttgtaatc 33120 aaaactccat cgcatctaat tgttctgagg aaatcatcca cggtagcata tgcaaatccc 33180 aaccaagcaa tgcaactgga ttgcgtttca agcaggagag gagagggaag agacggaaga 33240 accatgttaa tttttattcc aaacgatctc gcagtacttc aaattgtaga tcgcgcagat 33300 ggcatctctc gcccccactg tgttggtgaa aaagcacagc taaatcaaaa gaaatgcgat 33360 tttcaaggtg ctcaacggtg gcttccaaca aagcctccac gcgcacatcc aagaacaaaa 33420 gaataccaaa agaaggagca ttttctaact cctcaatcat catattacat tcctgcacca 33480 ttcccagata attttcagct ttccagcctt gaattattcg tgtcagttct tgtggtaaat 33540 ccaatccaca cattacaaac aggtcccgga gggcgccctc caccaccatt cttaaacaca 33600 ccctcataat gacaaaatat cttgctcctg tgtcacctgt agcgaattga gaatggcaac 33660 atcaattgac atgcccttgg ctctaagttc ttctttaagt tctagttgta aaaactctct 33720 catattatca ccaaactgct tagccagaag ccccccggga acaagagcag gggacgctac 33780 agtgcagtac aagcgcagac ctccccaatt ggctccagca aaaacaagat tggaataagc 33840 atattgggaa ccaccagtaa tatcatcgaa gttgctggaa atataatcag gcagagtttc 33900 ttgtagaaat tgaataaaag aaaaatttgc caaaaaaaca ttcaaaacct ctgggatgca 33960 aatgcaatag gttaccgcgc tgcgctccaa cattgttagt tttgaattag tctgcaaaaa 34020 taaaaaaaaa acaagcgtca tatcatagta gcctgacgaa caggtggata aatcagtctt 34080 tccatcacaa gacaagccac agggtctcca gctcgaccct cgtaaaacct gtcatcgtga 34140 ttaaacaaca gcaccgaaag ttcctcgcgg tgaccagcat gaataagtct tgatgaagca 34200 tacaatccag acatgttagc atcagttaag gagaaaaaac agccaacata gcctttgggt 34260 ataattatgc ttaatcgtaa gtatagcaaa gccacccctc gcggatacaa agtaaaaggc 34320 acaggagaat aaaaaatata attatttctc tgctgctgtt taggcaacgt cgcccccggt 34380 ccctctaaat acacatacaa agcctcatca gccatggctt accagagaaa gtacagcggg 34440 cacacaaacc acaagctcta aagtcactct ccaacctstc cacaatatat atacacaagc 34500 cctaaactga cgtaatggga ctaaagtgta aaaaatcccg ccaaacccaa cacacacccc 34560 gaaactgcgt caccagggaa aagtacagtt tcacttccgc aatcccaaca agcgtcactt 34620 cctctttctc acggtacgtc acatcccatt aacttacaac gtcattttcc cacggccgcg 34680 ccgccccttt taaccgttaa ccccacagcc aatcaccaca cggcccacac tttttaaaat 34740 cacctcattt acatattgtc accattccat ctataaggta tattattgat gatg 34794 <210> 45 <211> 180 <212> PRT
<213> adenoviridae <220>
<221> SITE
<222> (1)..(180) <223> /note="pCC536s E1B-21K sequence"
<400> 45 Met Glu Ala Trp Glu Cys Leu Glu Asp Phe Ser Ala Val Arg Asn Leu Leu Glu Gln Ser Ser Asn Ser Thr Ser Trp Phe Trp Arg Phe Leu Trp Gly Ser Ser Gln Ala Lys Leu Val Cys Arg Ile Lys Glu Asp Tyr Lys Trp Glu Phe Glu Glu Leu Leu Lys Ser Cys Gly Glu Leu Phe Asp Ser Leu Asn Leu Gly His Gln Ala Leu Phe Gln Glu Lys Val Ile Lys Thr Leu Asp Phe Ser Thr Pro Gly Arg Ala Ala Ala Ala Val Ala Phe Leu Ser Phe Ile Lys Asp Lys Trp Ser Glu Glu Thr His Leu Ser Gly Gly Tyr Leu Leu Asp Phe Leu Ala Met His Leu Trp Arg Ala Val Val Arg His Lys Asn Arg Leu Leu Leu Leu Ser Ser Val Arg Pro Ala Ile Ile Pro Thr Glu Glu Gln Gln Gln Gln Gln Glu Glu Ala Arg Arg Arg Arg Gln Glu Gln Ser Pro Trp Asn Pro Arg Ala Gly Leu Asp Pro Pro Val Glu Glu Ala Glu <210> 46 <211> 176 <212> PRT
<213> adenoviridae <220>
<221> SITE
<222> (1) .. (176) <223> /note="Ad5. E1B-21K sequence"
<400> 46 Met Glu Ala Trp Glu Cys Leu Glu Asp Phe Ser Ala Val Arg Asn Leu Leu Glu Gln Ser Ser Asn Ser Thr Ser Trp Phe Trp Arg Phe Leu Trp Gly Ser Ser Gln Ala Lys Leu Val Cys Arg Ile Lys Glu Asp Tyr Lys Trp Glu Phe Glu Glu Leu Leu Lys Ser Cys Gly Glu Leu Phe Asp Ser Leu Asn Leu Gly His Gln Ala Leu Phe Gln Glu Lys Val Ile Lys Thr Leu Asp Phe Ser Thr Pro Gly Arg Ala Ala Ala Ala Val Ala Phe Leu Ser Phe Ile Lys Asp Lys Trp Ser Glu Glu Thr His Leu Ser Gly Gly Tyr Leu Leu Asp Phe Leu Ala Met His Leu Trp Arg Ala Val Val Arg His Lys Asn Arg Leu Leu Leu Leu Ser Ser Val Arg Pro Ala Ile Ile Pro Thr Glu Glu Gln Gln Gln Gln Gln Glu Glu Ala Arg Arg Arg Arg Gln Glu Gln Ser Pro Trp Asn Pro Arg Ala Gly Leu Asp Pro Arg Glu <210> 47 <211> 180 <212> PRT
<213> adenoviridae <220>
<221> SITE
<222> (1)..(180) <223> /note=1'Ad35.E1B-21K sequence"
<400> 47 Met Glu Val Trp Ala Ile Leu Glu Asp Leu Arg Lys Thr Arg Gln Leu Leu Glu Ser Ala Ser Asp Gly Val Ser Gly Phe Trp Arg Phe Trp Phe Ala Ser Glu Leu Ala Arg Val Val Phe Arg Ile Lys Gln Asp Tyr Lys Gln Glu Phe Glu Lys Leu Leu Val Asp Cys Pro Gly Leu Phe Glu Ala Leu Asn Leu Gly His Gln Val His Phe Lys Glu Lys Val Leu Ser Val Leu Asp Phe Ser Thr Pro Gly Arg Thr Ala Ala Ala Val Ala Phe Leu Thr Phe Ile Leu Asp Lys Trp Ile Pro Gln Thr His Phe Ser Arg Gly Tyr Val Leu Asp Phe Ile Ala Thr Ala Leu Trp Arg Thr Trp Lys Val Arg Lys Met Arg Thr Ile Leu Gly Tyr Trp Pro Val Gln Pro Leu Gly Val Ala Gly Ile Leu Arg His Pro Pro Val Met Pro Ala Val Leu Glu Glu Glu Gln Gln Glu Asp Asn Pro Arg Ala Gly Leu Asp Pro Pro Val Glu Glu Ala Glu <210> 48 <211> 494 <212> PRT
<213> adenoviridae <220>
<221> SITE
<222> (1) .. (494) <223> /note="pCC536s E1B-55K sequence"
<400> 48 Met Glu Arg Arg Asn Pro Ser Glu Arg Gly Val Pro Ala Gly Phe Ser Gly His Ala Ser Val Glu Ser Gly Cys Glu Thr Gln Glu Ser Pro Ala Thr Val Val Phe Arg Pro Pro Gly Asp Asn Thr Asp Gly Gly Ala Ala Ala Ala Ala Gly Gly Ser Gln Ala Ala Ala Ala Gly Ala Glu Pro Met Glu Pro Glu Ser Arg Pro Gly Pro Ser Ser Gly Gly Gly Gly Val Ala Asp Leu Ser Pro Glu Leu Gln Arg Val Leu Thr Gly Ser Thr Ser Thr Gly Arg Asp Arg Gly Val Lys Arg Glu Arg Ala Ser Ser Gly Thr Asp Ala Arg Ser Glu Leu Ala Leu Ser Leu Met Ser Arg Arg Arg Pro Glu Thr Ile Trp Trp His Glu Val Gln Lys Glu Gly Arg Asp Glu Val Ser Val Leu Gln Glu Lys Tyr Ser Leu Glu Gln Val LysThr Cys Trp Leu Glu Pro Glu Asp Asp Trp Ala Val Ala Ile Lys Asn Tyr Ala Lys Ile Ala Leu Arg Pro Asp Lys Gln Tyr Lys Ile Ser Arg Arg Ile Asn Ile Arg Asn Ala Cys Tyr Ile Ser Gly Asn Gly Ala Glu Val Val Ile Asp Thr Gln Asp Lys Thr Val Ile Arg Cys Cys Met Met Asp Met Trp Pro Gly Val Val Gly Met Glu Ala Val Thr Phe Val Asn Val Lys Phe Arg Gly Asp Gly Tyr Asn Gly Ile Val Phe Met Ala Asn Thr Lys Leu Ile Leu His Gly Cys Ser Phe Phe Gly Phe Asn Asn Thr Cys Val Asp Ala Trp Gly Gln Val Ser Val Arg Gly Cys Ser Phe Tyr Ala Cys Trp Ile Ala Thr Ala Gly Arg Thr Lys Ser Gln Leu Ser Leu Lys Lys Cys Ile Phe Gln Arg Cys Asn Leu Gly Ile Leu Asn Glu Gly Glu Ala Arg Val Arg His Cys Ala Ser Thr Asp Thr Gly Cys Phe Ile Leu Ile Lys Gly Asn Ala Ser Val Lys His Asn Met Ile Cys Gly Ala Ser Asp Glu Arg Pro Tyr Gln Met Leu Thr Cys Ala Gly Gly His Cys Asn Met Leu Ala Thr Val His Ile Val Ser His Gln Arg Lys Lys Trp Pro Val Phe Asp His Asn Val Leu Thr Lys Cys Thr Met His Ala Gly Gly Arg Arg Gly Met Phe Met Pro Tyr Gln Cys Asn Met Asn His Val Lys Val Leu Leu Glu Pro Asp Ala Phe Ser Arg Met Ser Leu Thr Gly Ile Phe Asp Met Asn Thr Gln Ile Trp Lys Ile Leu Arg Tyr Asp Asp Thr Arg Ser Arg Val Arg Ala Cys Glu Cys Gly Gly Lys His Ala Arg Phe Gln Pro Val Cys Val Asp Val Thr Glu Asp Leu Arg Pro Asp His Leu Val Ile Ala Arg Thr Gly Ala Glu Phe Gly Ser Ser Gly Glu Glu Thr Asp <210> 49 <211> 494 <212> PRT
<213> adenoviridae <220>
<221> SITE
<222> (1) .. (494) <223> /note="Ad35. E1B-55K sequence"
<400> 49 Met Asp Pro Ala Asp Ser Phe Gln Gln Gly Ile Arg Phe Gly Phe His Ser His Ser Ile Val Glu Asn Met Glu Gly Ser Gln Asp Glu Asp Asn Leu Arg Leu Leu Ala Ser Ala Ala Phe Gly Cys Ser Gly Asn Pro Glu Ala Ser Thr Gly His Ala Ser Gly Ser Gly Gly Gly Thr Ala Arg Gly Gln Pro Glu Ser Arg Pro Gly Pro Ser Ser Gly Gly Gly Gly Val Ala Asp Leu Ser Pro Glu Leu Gln Arg Val Leu Thr Gly Ser Thr Ser Thr Gly Arg Asp Arg Gly Val Lys Arg Glu Arg Ala Ser Ser Gly Thr Asp 100 . 105 110 Ala Arg Ser Glu Leu Ala Leu Ser Leu Met Ser Arg Arg Arg Pro Glu Thr Ile Trp Trp His Glu Val Gln Lys Glu Gly Arg Asp Glu Val Ser Val Leu Gln Glu Lys Tyr Ser Leu Glu Gln Val Lys Thr Cys Trp Leu Glu Pro Glu Asp Asp Trp Ala Val Ala Ile Lys Asn Tyr Ala Lys Ile Ala Leu Arg Pro Asp Lys Gln Tyr Lys Ile Ser Arg Arg Ile Asn Ile Arg Asn Ala Cys Tyr Ile Ser Gly Asn Gly Ala Glu Val Val Ile Asp Thr Gln Asp Lys Thr Val Ile Arg Cys Cys Met Met Asp Met Trp Pro Gly Val Val Gly Met Glu Ala Val Thr Phe Val Asn Val Lys Phe Arg Gly Asp Gly Tyr Asn Gly Ile Val Phe Met Ala Asn Thr Lys Leu Ile Leu His Gly Cys Ser Phe Phe Gly Phe Asn Asn Thr Cys Val Asp Ala Trp Gly Gln Val Ser Val Arg Gly Cys Ser Phe Tyr Ala Cys Trp Ile Ala Thr Ala Gly Arg Thr Lys Ser Gln Leu Ser Leu Lys Lys Cys Ile Phe Gln Arg Cys Asn Leu Gly Ile Leu Asn Glu Gly Glu Ala Arg Val Arg His Cys Ala Ser Thr Asp Thr Gly Cys Phe Ile Leu Ile Lys Gly Asn Ala Ser Val Lys His Asn Met Ile Cys Gly Ala Ser Asp Glu Arg Pro Tyr Gln Met Leu Thr Cys Ala Gly Gly His Cys Asn Met Leu Ala Thr Val His Ile Val Ser His Gln Arg Lys Lys Trp Pro Val Phe Asp His Asn Val Leu Thr Lys Cys Thr Met His Ala Gly Gly Arg Arg Gly Met Phe Met Pro Tyr Gln Cys Asn Met Asn His Val Lys Val Leu Leu Glu Pro Asp Ala Phe Ser Arg Met Ser Leu Thr Gly Ile Phe Asp Met Asn Thr Gln Ile Trp Lys Ile Leu Arg Tyr Asp Asp Thr Arg Ser Arg Val Arg Ala Cys Glu Cys Gly Gly Lys His Ala Arg Phe Gln Pro Val Cys Val Asp Val Thr Glu Asp Leu Arg Pro Asp His Leu Val Ile Ala Arg Thr Gly Ala Glu Phe Gly Ser Ser Gly Glu Glu Thr Asp <210> 50 <211> 496 <212> PRT
<213> adenoviridae <220>
<221> SITE
<222> (1) .. (496) <223> /note="AdS. E1B-55K sequence"
<400> 50 Met Glu Arg Arg Asn Pro Ser Glu Arg Gly Val Pro Ala Gly Phe Ser Gly His Ala Ser Val Glu Ser Gly Cys Glu Thr Gln Glu Ser Pro Ala Thr Val Val Phe Arg Pro Pro Gly Asp Asn Thr Asp Gly Gly Ala Ala Ala Ala Ala Gly Gly Ser Gln Ala Ala Ala Ala Gly Ala Glu Pro Met Glu Pro Glu Ser Arg Pro Gly Pro Ser Gly Met Asn Val Val Gln Val Ala Glu Leu Tyr Pro Glu Leu Arg Arg Ile Leu Thr Ile Thr Glu Asp Gly Gln Gly Leu Lys Gly Val Lys Arg Glu Arg Gly Ala Cys Glu Ala Thr Glu Glu Ala Arg Asn Leu Ala Phe Ser Leu Met Thr Arg His Arg Pro Glu Cys Ile Thr Phe Gln Gln Ile Lys Asp Asn Cys Ala Asn Glu Leu Asp Leu Leu Ala Gln Lys Tyr Ser Ile Glu Gln Leu Thr Thr Tyr Trp Leu Gln Pro Gly Asp Asp Phe Glu Glu Ala Ile Arg Val Tyr Ala Lys Val Ala Leu Arg Pro Asp Cys Lys Tyr Lys Ile Ser Lys Leu Val Asn Ile Arg Asn Cys Cys Tyr Ile Ser Gly Asn Gly Ala Glu Val Glu Ile Asp Thr Glu Asp Arg Val Ala Phe Arg Cys Ser Met Ile Asn Met Trp Pro Gly Val Leu Gly Met Asp Gly Val Val Ile Met Asn Val Arg Phe Thr Gly Pro Asn Phe Ser Gly Thr Val Phe Leu Ala Asn Thr Asn Leu Ile Leu His Gly Val Ser Phe Tyr Gly Phe Asn Asn Thr Cys Val Glu Ala Trp Thr Asp Val Arg Val Arg Gly Cys Ala Phe Tyr Cys Cys Trp Lys Gly Val Val Cys Arg Pro Lys Ser Arg Ala Ser Ile Lys Lys Cys Leu Phe Glu Arg Cys Thr Leu Gly Ile Leu Ser Glu Gly Asn Ser Arg Val Arg His Asn Val Ala Ser Asp Cys Gly Cys Phe Met Leu Val Lys Ser Val Ala Val Ile Lys His Asn Met Val Cys Gly Asn Cys Glu Asp Arg Ala Ser Gln Met Leu Thr Cys Ser Asp Gly Asn Cys His Leu Leu Lys Thr Ile His Val Ala Ser His Ser Arg Lys Ala Trp Pro Val Phe Glu His Asn Ile Leu Thr Arg Cys Ser Leu His Leu Gly Asn Arg Arg Gly Val Phe Leu Pro Tyr Gln Cys Asn Leu Ser His Thr Lys Ile Leu Leu Glu Pro Glu Ser Met Ser Lys Val Asn Leu Asn Gly Val Phe Asp Met Thr Met Lys Ile Trp Lys Val Leu Arg Tyr Asp Glu Thr Arg Thr Arg Cys Arg Pro Cys Glu Cys Gly Gly Lys His Ile Arg Asn Gln Pro Val Met Leu Asp Val Thr Glu Glu Leu Arg Pro Asp His Leu Val Leu Ala Cys Thr Arg Ala Glu Phe Gly Ser Ser Asp Glu Asp Thr Asp

Claims (18)

CLAIMS:
1. A packaging cell line for complementing recombinant adenovirus based on a serotype from subgroup B, wherein said cell line is a human cell line that has been transformed by E1 coding sequences of an adenovirus wherein the sequence coding for E1B-55K
protein is from subgroup B.
2. The packaging cell line of claim 1, wherein said serotype from subgroup B
is adenovirus type 35.
3. The packaging cell line of claim 1 or 2, wherein said E1 coding sequences are either operatively linked on one DNA molecule or located on two separate DNA
molecules, said adenovirus E1 coding sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins.
4. The packaging cell line of any one of claims 1-3, wherein the human cell line is a primary retinoblast, primary embryonic kidney cell or primary amniocyte cell line.
5. The packaging cell line of any one of claims 1-4, wherein all E1 coding sequences are from serotype 35.
6. The packaging cell line of any one of claims 1-4, wherein said cell line has been transformed by a chimeric adenovirus E1 construct comprising E1A coding sequences and at least part of E1B-21K coding sequences from an adenovirus of subgroup C, and further comprising E1B-55K coding sequences from an adenovirus of subgroup B.
7. The packaging cell line of any one of claims 1-4, wherein said cell line has been transformed by adenovirus E1 sequences located on two separate DNA molecules wherein the first DNA molecule comprises E1A coding sequences and at least part of E1B-21K
coding sequences from an adenovirus of subgroup C and wherein the second DNA molecule comprises E1B-55K coding sequences from an adenovirus of subgroup B.
8. The packaging cell line of claim 6 or 7, wherein the E1B-55K coding sequences from an adenovirus of subgroup B are from an adenovirus serotype 35.
9. The packaging cell line of any one of claims 1-4, wherein said cell line is PER.C6 cells, whose ECACC deposit number is 96022940, which further comprise an Ad35-E1 region integrated into their genome, and wherein said Ad35-E1 region is present in a functional expression cassette.
10. The packaging cell line of any one of claims 1-9, further comprising a DNA
sequence encoding at least E4-orf6 of an adenovirus of subgroup B.
11. The packaging cell line of claim 10, wherein the adenovirus of subgroup B
is adenovirus serotype 35.
12. A cell line wherein said cell line is PER.C6 cells, whose ECACC deposit number is 96022940, which cells further comprise Ad35-E1B coding sequence integrated into their genome.
13. The cell line of claim 12, further comprising a DNA sequence encoding at least E4-orf6 of an adenovirus of subgroup B.
14. The cell line of claim 13, wherein the adenovirus of subgroup B is adenovirus serotype 35.
15. A method for complementing a recombinant adenovirus based on a serotype of subgroup B, said method comprising providing a packaging cell line according to any one of claims 1-11, or a cell line according to any one of claims 12-14, with said recombinant adenovirus and culturing said cell line to allow for complementation.
16. A method according to claim 15, further comprising harvesting complemented recombinant adenovirus.
17. A method according to claim 15 or 16, wherein said recombinant adenovirus based on a serotype of subgroup B is adenovirus serotype 35.
18. Use of a packaging cell line according to any one of claims 1-11, or the cell line of any one of claims 12-14, for the complementation of a recombinant adenovirus.
CA2428739A 2000-11-15 2001-11-14 Complementing cell lines Expired - Fee Related CA2428739C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/713,678 US6492169B1 (en) 1999-05-18 2000-11-15 Complementing cell lines
US09/713,678 2000-11-15
PCT/NL2001/000824 WO2002040665A2 (en) 2000-11-15 2001-11-14 Complementing cell lines

Publications (2)

Publication Number Publication Date
CA2428739A1 CA2428739A1 (en) 2002-05-23
CA2428739C true CA2428739C (en) 2010-11-16

Family

ID=24867049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2428739A Expired - Fee Related CA2428739C (en) 2000-11-15 2001-11-14 Complementing cell lines

Country Status (13)

Country Link
US (8) US6492169B1 (en)
EP (1) EP1349926B1 (en)
JP (1) JP4402881B2 (en)
AT (1) ATE332965T1 (en)
AU (2) AU2002218569B2 (en)
CA (1) CA2428739C (en)
CY (1) CY1105232T1 (en)
DE (1) DE60121471T2 (en)
DK (1) DK1349926T3 (en)
ES (1) ES2267864T3 (en)
NZ (1) NZ525997A (en)
PT (1) PT1349926E (en)
WO (1) WO2002040665A2 (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE445705T1 (en) * 1995-06-15 2009-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUSES FOR GENE THERAPY
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
NZ524743A (en) * 2000-09-20 2004-07-30 Crucell Holland B Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein
DE60138403D1 (en) * 2000-09-26 2009-05-28 Crucell Holland Bv ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST
CN100547069C (en) * 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 The production of virus, viral isolates and vaccine
IL164802A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
EA010828B1 (en) * 2002-04-25 2008-12-30 Круселл Холланд Б.В. Recombinant adenovirus vectors and methods for the production thereof and use
US20060073123A1 (en) * 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
JP4237449B2 (en) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 Adenovirus vector
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
EP1573012B1 (en) 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2519207A1 (en) * 2003-03-28 2004-11-11 Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
WO2004099396A1 (en) * 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
DK1626992T3 (en) * 2003-05-23 2010-09-20 Crucell Holland Bv Production of recombinant IgM in PER.C6 cells
EP1646717A4 (en) * 2003-07-18 2006-12-20 Onyx Pharma Inc Subgroup b adenoviral vectors for treating disease
DE602004031681D1 (en) 2003-07-21 2011-04-14 Transgene Sa Multifunctional cytokines
CN1863918B (en) * 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 Packaging cells for recombinant adenovirus
JP2007522814A (en) * 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー Virus purification method
JP5600375B2 (en) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Influenza virus vaccine
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
EP1799836B1 (en) 2004-10-13 2010-12-22 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
SG159554A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
ES2536745T3 (en) 2004-12-08 2015-05-28 Medimmune, Llc Methods of production of influenza vaccine compositions
AU2012216357B2 (en) * 2005-04-11 2014-01-30 Purdue Research Foundation Vaccine against pandemic strains of influenza viruses
ES2317517T5 (en) * 2005-04-11 2016-01-21 Crucell Holland B.V. Virus purification using ultrafiltration
JP2008541730A (en) * 2005-05-23 2008-11-27 ヴァクシン インコーポレイテッド A rapid method for the production of recombinant adenoviral vectors free of high titers and replication competent adenoviruses.
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
EP2842572A1 (en) 2005-11-01 2015-03-04 Novartis Vaccines and Diagnostics GmbH Cell-derived viral vaccines with low levels of residual cell dna
DE102005054628A1 (en) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Process for the preparation of permanent human cell lines
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
ES2528951T3 (en) 2006-06-02 2015-02-13 International Aids Vaccine Initiative Consensus sequences, antigens and transgenes of HIV-1 of clade A
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
RU2482189C2 (en) 2007-01-30 2013-05-20 Трансген С.А. Papillomavirus e2 polypeptides used for vaccination
DE602008004476D1 (en) * 2007-03-09 2011-02-24 Vectorlogics Inc CELLS FOR ADENOVIRUS VECTOR AND PROTEIN PRODUCTION
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EP2342321B1 (en) 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
CN102203242B (en) * 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 Method for the production of adenoviral vectors
US20110312525A1 (en) 2009-01-20 2011-12-22 Bruce Acres Soluble icam-1 as biomarker for prediction of therapeutic response
MX2011010061A (en) 2009-03-24 2011-11-18 Transgene Sa Biomarker for monitoring patients.
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
CN102483405B (en) 2009-07-10 2015-12-02 特朗斯吉有限公司 For selecting biomarker and the correlation technique of patient
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
JP5465331B2 (en) 2009-10-15 2014-04-09 クルセル ホランド ベー ヴェー Method for purifying adenovirus from high cell density cultures
EA028623B1 (en) 2009-10-15 2017-12-29 Янссен Вэксинс Энд Превеншн Б.В. Method for the purification of adenovirus particles
ES2813347T3 (en) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Recombinant High Titer Influenza Viruses with Enhanced Replication in Vero Cells
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN102762721B (en) 2010-02-15 2015-03-11 克鲁塞尔荷兰公司 Method for the production of Ad26 adenoviral vectors
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2563909A1 (en) 2010-04-26 2013-03-06 Novartis AG Improved production of virus replicon particles in packaging cells
AU2011307655B2 (en) * 2010-08-16 2015-12-17 Cevec Pharmaceuticals Gmbh Permanent human amniocyte cell lines for producing influenza viruses
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
EP4098325A1 (en) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
US9058175B2 (en) * 2011-06-07 2015-06-16 The Mathworks, Inc. Parameter promotion in a block diagram modeling environment
BR112014008694A2 (en) 2011-10-11 2017-06-20 Novartis Ag recombinant polycistronic nucleic acid molecules
EP2766385A2 (en) 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
ES2582504T3 (en) 2012-03-12 2016-09-13 Crucell Holland B.V. Lots of recombinant adenovirus with altered ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
KR102050616B1 (en) 2012-03-22 2019-12-03 얀센 백신스 앤드 프리벤션 비.브이. Vaccine against rsv
US9442702B1 (en) 2012-04-30 2016-09-13 The Mathworks, Inc. Overriding an interface in a graphical block diagram modeling environment
WO2013174910A1 (en) 2012-05-24 2013-11-28 Crucell Holland B.V. Adenoviral vectors for transduction of vascular tissue
CN109134640A (en) 2012-10-23 2019-01-04 爱默蕾大学 GM-CSF and IL-4 conjugates, composition and relative method
CN105051198A (en) 2012-11-16 2015-11-11 貝丝以色列女执事医疗中心 Recombinant adenoviruses and use thereof
MY181066A (en) 2013-04-25 2020-12-17 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
KR102313153B1 (en) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble pre-fusion rsv f polypeptides
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
SI3283634T1 (en) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6913032B2 (en) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド Common neoantigen
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
TWI750122B (en) 2015-06-09 2021-12-21 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
KR20180026734A (en) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble fusion-pre-RSV F polypeptide
EA039065B1 (en) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Vaccine against rsv
EA036412B1 (en) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Method for protecting an adenovirus from plastic-induced degradation and use of 2-hydroxypropyl--cyclodextrin for protecting the adenovirus
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
MY193584A (en) 2016-04-05 2022-10-19 Janssen Vaccines & Prevention Bv Vaccine against rsv
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
ES2836598T3 (en) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Stabilized prefusion RSV F proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US20200096521A1 (en) 2017-02-12 2020-03-26 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
JP2020519663A (en) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
MX2020002876A (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv.
KR20200117981A (en) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 Zika vaccine and immunogenic composition, and methods of using the same
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
TW201930340A (en) 2017-12-18 2019-08-01 美商尼恩醫療公司 Neoantigens and uses thereof
CN108342362A (en) * 2018-01-31 2018-07-31 武汉枢密脑科学技术有限公司 A kind of stable cell lines MDCK and its construction method for expanding recombination hepatitis infectiosa canis virus CAV2
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN113474840A (en) 2018-12-21 2021-10-01 百欧恩泰美国公司 Methods and systems for predicting HLA class II specific epitopes and characterizing CD4+ T cells
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (en) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) Improved influenza virus replication for vaccine development
SG11202110975XA (en) 2019-05-08 2021-10-28 Takeda Vaccines Inc Inactivated virus compositions and zika vaccine formulations
KR20220008875A (en) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. Co-administration of seasonal influenza vaccine and adenovirus-based respiratory syncytial virus vaccine
EA202193119A1 (en) 2019-05-15 2022-02-18 Янссен Вэксинс Энд Превеншн Б.В. PREVENTIVE TREATMENT OF RESPIRATORY SYNCYTHIAL VIRUS INFECTION WITH ADENOVIRUS VACCINE
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
KR20230142704A (en) 2020-12-14 2023-10-11 바이오엔테크 유에스 인크. Tissue-specific antigens for cancer immunotherapy
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US20230399625A1 (en) * 2022-06-09 2023-12-14 CHO Plus, Inc. Cell hybrids as host cells for high efficiency production of gene therapy vectors and viral vaccines
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (en) 1986-08-13 1990-06-01 Transgene Sa EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2000048A1 (en) * 1988-10-03 1990-04-03 Edward F. Plow Peptides and antibodies that inhibit integrin-ligand bindin g
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
DE69033181T2 (en) 1989-10-20 1999-10-21 Dartmouth College IGA RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES
ES2133139T3 (en) 1989-10-20 1999-09-01 Medarex Inc BISPECIFIC ANTIBODIES HETERO WITH DOUBLE EFFECTIVE FUNCTIONS.
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2681786A1 (en) 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
ES2312164T3 (en) 1992-09-25 2009-02-16 Aventis Pharma S.A. ADENOVIRUS VECTORS FOR THE TRANSFER OF STRANGE GENES IN CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN THE BRAIN.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE307212T1 (en) 1992-11-18 2005-11-15 Arch Dev Corp ADENOVIRUS-DIRECTED GENE TRANSFER TO THE HEART AND VASCULAR SMOOTH MUSCLE
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
PT698109E (en) 1993-05-10 2002-12-31 Univ Michigan TRANSFER OF GENES INTO PANCREATIC EPITHELIAL CELLS
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1995006745A1 (en) 1993-09-03 1995-03-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vector for gene therapy of the liver
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
IT1271461B (en) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE.
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE69520496T2 (en) 1994-05-13 2001-07-12 Chiron Corp METHOD AND COMPOSITIONS AS VEHICLES FOR TARGETED INTRODUCTION OF GENES
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5570975A (en) 1994-06-27 1996-11-05 Reinert, Sr.; Gary L. Metal foundation push-it and installation apparatus and method
FR2721943B1 (en) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP0779923A2 (en) 1994-09-09 1997-06-25 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
FR2724846B1 (en) 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa METHOD OF TREATING CANCER BY REGULATING THE ACTIVITY OF RAS PROTEINS
FR2725726B1 (en) * 1994-10-17 1997-01-03 Centre Nat Rech Scient VIRAL VECTORS AND USE IN GENE THERAPY
WO1996013597A2 (en) 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996014837A1 (en) 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
AU3993495A (en) 1994-11-29 1996-06-19 Takara Shuzo Co., Ltd. Process for producing transformed cell
FR2727867B1 (en) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
AUPN107195A0 (en) 1995-02-10 1995-03-09 Withers, Graham Rex Metal matrix forming method and apparatus
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU5703796A (en) 1995-05-10 1996-11-29 Introgene B.V. Improved retroviral vectors, especially suitable for gene th erapy
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE445705T1 (en) * 1995-06-15 2009-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUSES FOR GENE THERAPY
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5871727A (en) * 1995-12-08 1999-02-16 Uab Research Foundation Targeted adenovirus vectors
WO1997038723A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
AU4344197A (en) 1996-09-13 1998-04-02 Albert Einstein College Of Medicine Of Yeshiva University Car, a novel coxsackievirus and adenovirus receptor
IL128958A0 (en) 1996-09-25 2000-02-17 Novartis Ag And The Scripps Re Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
EP0977854A2 (en) 1997-04-25 2000-02-09 Collateral Therapeutics Truncated vegf-related proteins
AU743051B2 (en) 1997-05-08 2002-01-17 Genetic Therapy, Inc. Gene transfer with adenoviruses having modified fiber proteins
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
DE19754103A1 (en) * 1997-12-08 1999-06-10 Hepavec Ag Fuer Gentherapie New packaging cell line for E1-deleted adenovirus
WO1999032647A1 (en) * 1997-12-23 1999-07-01 Introgene B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
DE19807265C2 (en) 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviral transfer vector for the gene transport of a DNA sequence
WO1999047180A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IT1299201B1 (en) 1998-05-08 2000-02-29 San Raffaele Centro Fond GENETICALLY MODIFIED FIBROBLASTS AND THEIR USE
EP0959136A1 (en) 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
WO2000024730A1 (en) 1998-10-28 2000-05-04 The University Of British Columbia Organic vanadium(iii) complexes and their use
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1020529B1 (en) 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
DE60039683D1 (en) 1999-03-04 2008-09-11 Crucell Holland Bv USE OF AN ADENOVIRUS VECTOR FOR THE TRANSDUCTION OF SYNOVIAL CELLS
DE19918023A1 (en) * 1999-03-16 2000-09-21 Guenter Cichon Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
ATE364707T1 (en) 1999-05-17 2007-07-15 Crucell Holland Bv RECOMBINANT HUMAN ADENOVIRUS SEROTYPE 35
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
JP3886806B2 (en) 1999-10-28 2007-02-28 機能性木質新素材技術研究組合 Creosote oil emulsion and its production method
AU9434801A (en) 2000-08-10 2002-02-18 Crucell Holland Bv Gene delivery vectors with cell type specificity for primary human chondrocytes
NZ524743A (en) 2000-09-20 2004-07-30 Crucell Holland B Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein
EP1191104A1 (en) 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
DE60138403D1 (en) 2000-09-26 2009-05-28 Crucell Holland Bv ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EA010828B1 (en) 2002-04-25 2008-12-30 Круселл Холланд Б.В. Recombinant adenovirus vectors and methods for the production thereof and use
IL164802A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
CN1863918B (en) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 Packaging cells for recombinant adenovirus
EP1799836B1 (en) 2004-10-13 2010-12-22 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
SG159554A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors

Also Published As

Publication number Publication date
EP1349926A2 (en) 2003-10-08
US20030185801A1 (en) 2003-10-02
DE60121471T2 (en) 2007-02-08
US20030119192A1 (en) 2003-06-26
ES2267864T3 (en) 2007-03-16
JP4402881B2 (en) 2010-01-20
EP1349926B1 (en) 2006-07-12
WO2002040665A2 (en) 2002-05-23
CY1105232T1 (en) 2010-03-03
US7250293B2 (en) 2007-07-31
CA2428739A1 (en) 2002-05-23
WO2002040665A3 (en) 2002-10-17
DK1349926T3 (en) 2006-10-30
AU1856902A (en) 2002-05-27
US20050277194A1 (en) 2005-12-15
US6974695B2 (en) 2005-12-13
NZ525997A (en) 2005-10-28
US6492169B1 (en) 2002-12-10
US20030171336A1 (en) 2003-09-11
US6869794B2 (en) 2005-03-22
ATE332965T1 (en) 2006-08-15
JP2004513657A (en) 2004-05-13
US20130156736A1 (en) 2013-06-20
PT1349926E (en) 2006-12-29
AU2002218569B2 (en) 2007-04-05
US9228205B2 (en) 2016-01-05
US7344883B2 (en) 2008-03-18
US20080199433A1 (en) 2008-08-21
DE60121471D1 (en) 2006-08-24
US20150010952A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
CA2428739C (en) Complementing cell lines
CA2372655C (en) Recombinant adenovirus having low pre-existing neutralizing activity
US7820440B2 (en) Means and methods for producing adenovirus vectors
AU2002218569A1 (en) Complementing cell lines
AU3445899A (en) Generation of packaging system for human recombinant adenoviral vectors
US20050232900A1 (en) Serotype of adenovirus and uses thereof
Class et al. Patent application title: COMPLEMENTING CELL LINES Inventors: Ronald Vogels (Linschoten, NL) Menzo Jans Emco Havenga (Alphen A/d Rijn, NL) Majid Mehtall (Plobsheim, FR)
CA2488058C (en) Adenovirus vector
AU766771B2 (en) Packaging systems for human recombinant adenoviruses to be used in gene therapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131114